var title_f26_4_26688="Nasal polyps in nostril";
var content_f26_4_26688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal polyps in nostril",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nasal polyps appear as fixed, glistening, gray or white, mucoid masses in the nasal cavities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenis Scadding, MD and Peter Andrews, BSc, FRCS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26688=[""].join("\n");
var outline_f26_4_26688=null;
var title_f26_4_26689="Contents: Pediatric endocrinology";
var content_f26_4_26689=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric endocrinology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric endocrinology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adrenal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40071\">",
"           Adrenal hyperandrogenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/46/28391\">",
"           Adrenal steroid biosynthesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27238\">",
"           Causes and clinical manifestations of central adrenal insufficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23369\">",
"           Causes and clinical manifestations of primary adrenal insufficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/55/26489\">",
"           Causes and pathophysiology of Cushing's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15878\">",
"           Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/54/17255\">",
"           Diagnosis of adrenal insufficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24726\">",
"           Diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11034\">",
"           Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/6/19560\">",
"           Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/1/9240\">",
"           Metabolism of adrenal steroids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9896\">",
"           Pathogenesis of autoimmune adrenal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/14/38121\">",
"           Pheochromocytoma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/22/31078\">",
"           Treatment of adrenal insufficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/0/31754\">",
"           Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/51/35641\">",
"           Uncommon causes of congenital adrenal hyperplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/7/12408\">",
"           Unusual causes of adrenal insufficiency",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diabetes mellitus and hypoglycemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/43/31414\">",
"           Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29641\">",
"           Blood glucose self-monitoring in management of adults with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16983\">",
"           Cerebral edema in children with diabetic ketoacidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/33/14874\">",
"           Classification of diabetes mellitus and genetic diabetic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41480\">",
"           Clinical features and diagnosis of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34249\">",
"           Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/29/40410\">",
"           Complications and screening in children and adolescents with type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/54/38758\">",
"           Diagnosis of diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40889\">",
"           Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4506\">",
"           Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11993\">",
"           Estimation of blood glucose control in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28567\">",
"           Insulin resistance: Definition and clinical spectrum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36329\">",
"           Management of type 2 diabetes mellitus in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/42/23210\">",
"           Pathogenesis of type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36346\">",
"           Pathogenesis of type 2 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/21/32087\">",
"           Prediction of type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/5/13401\">",
"           Prevention of type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/6/21606\">",
"           Self-management education for the child with diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1142\">",
"           Special situations in children and adolescents with type 1 diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32954\">",
"           The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7626\">",
"           Treatment and complications of diabetic ketoacidosis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of divalent ions and bone",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4538\">",
"           Bone problems in childhood cancer patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/50/36646\">",
"           Clinical manifestations of hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9562\">",
"           Drugs that affect bone metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28248\">",
"           Etiology and treatment of calcipenic rickets in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/24/35209\">",
"           Etiology of hypocalcemia in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21209\">",
"           Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/23/26999\">",
"           Neonatal hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34906\">",
"           Normal skeletal development and regulation of bone formation and resorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/21/26967\">",
"           Overview of rickets in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23685\">",
"           Relation between total and ionized serum calcium concentration",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Disorders of glucose homeostasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/0/8201\">",
"           Approach to hypoglycemia in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/40/16010\">",
"           Etiology of hypoglycemia in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44809\">",
"           Infant of a diabetic mother",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/9/40090\">",
"           Management of type 1 diabetes mellitus in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/49/3866\">",
"           Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/0/12295\">",
"           Treatment and complications of persistent hyperinsulinemic hypoglycemia of infancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Growth disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/18/10537\">",
"           Causes of short stature",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/5/82\">",
"           Diagnosis of growth hormone deficiency in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18376\">",
"           Diagnostic approach to short stature",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7286\">",
"           Endocrine surveillance in childhood cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31607\">",
"           Growth failure after childhood cancer: Role of growth hormone deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39223\">",
"           Growth failure after childhood cancer: Role of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39270\">",
"           Growth hormone insensitivity syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/58/23463\">",
"           Growth hormone treatment during the transition period",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3672\">",
"           Growth hormone treatment for children born small for gestational age",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18248\">",
"           Growth hormone treatment for idiopathic short stature",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/9/13464\">",
"           Pituitary gigantism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/53/10073\">",
"           The child with tall stature or abnormally rapid growth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/0/14345\">",
"           Treatment of growth hormone deficiency in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gynecologic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/8/11402\">",
"           Diagnosis and treatment of endometriosis in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17529\">",
"           Management of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21033\">",
"           Ovarian cysts and neoplasms in infants, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/25/31125\">",
"           Primary dysmenorrhea in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypogonadism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33449\">",
"           Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22616\">",
"           Clinical manifestations and pathogenesis of disorders of the androgen receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17096\">",
"           Diagnosis and treatment of disorders of the androgen receptor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7286\">",
"           Endocrine surveillance in childhood cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14329\">",
"           Management of Turner syndrome (gonadal dysgenesis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7401\">",
"           Pubertal development and gonadal function in survivors of childhood cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypothalamic and pituitary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/16/38151\">",
"           ACTH deficiency in survivors of childhood cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30776\">",
"           Causes and clinical manifestations of acromegaly",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/35/21048\">",
"           Clinical manifestations and causes of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24520\">",
"           Craniopharyngioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7286\">",
"           Endocrine surveillance in childhood cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/55/31607\">",
"           Growth failure after childhood cancer: Role of growth hormone deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/30/25059\">",
"           Hypothalamic-pituitary axis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/46/7913\">",
"           Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/9/13464\">",
"           Pituitary gigantism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/31/505\">",
"           Treatment of central diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6691\">",
"           Urine output in diabetes insipidus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal endocrinology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/48/44809\">",
"           Infant of a diabetic mother",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/21/20823\">",
"           Large for gestational age newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37816\">",
"           Neonatal hyperglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/23/26999\">",
"           Neonatal hypocalcemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17673\">",
"           Neonatal hypoglycemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15081\">",
"           Treatment and prognosis of congenital hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/47/24312\">",
"           Diagnosis of polyuria and diabetes insipidus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28567\">",
"           Insulin resistance: Definition and clinical spectrum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/44/17098\">",
"           Undescended testes (cryptorchidism) in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31800\">",
"           Male reproductive physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40246\">",
"           Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Puberty and adrenarche",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/13/39130\">",
"           Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19546\">",
"           Definition, etiology, and evaluation of precocious puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/9/34970\">",
"           Definition, pathogenesis, and etiology of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22424\">",
"           Diagnosis and treatment of delayed puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7286\">",
"           Endocrine surveillance in childhood cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/2/2089\">",
"           Etiology, diagnosis, and treatment of primary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/56/34697\">",
"           Etiology, diagnosis, and treatment of secondary amenorrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/48/23302\">",
"           Normal adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/25/1434\">",
"           Normal puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27685\">",
"           Physiology of the normal menstrual cycle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21481\">",
"           Premature adrenarche",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7401\">",
"           Pubertal development and gonadal function in survivors of childhood cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24297\">",
"           Treatment of polycystic ovary syndrome in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4889\">",
"           Treatment of precocious puberty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexuality",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42201\">",
"           Contraception: Overview of issues specific to adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/5/19546\">",
"           Definition, etiology, and evaluation of precocious puberty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/32/31236\">",
"           Diagnosis and management of gestational hyperandrogenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/9/6294\">",
"           Epidemiology and pathogenesis of gynecomastia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/16/28935\">",
"           Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/59/24506\">",
"           Evaluation of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/3/31800\">",
"           Male reproductive physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35577\">",
"           Management of the infant with ambiguous genitalia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41220\">",
"           Normal sexual differentiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30423\">",
"           Steroid 5-alpha-reductase 2 deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/0/12\">",
"           Steroid hormone metabolism in polycystic ovary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4889\">",
"           Treatment of precocious puberty",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thyroid disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21865\">",
"           Acquired hypothyroidism in childhood and adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2682\">",
"           Clinical features and detection of congenital hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/29/7641\">",
"           Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24280\">",
"           Congenital and acquired goiter in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7286\">",
"           Endocrine surveillance in childhood cancer survivors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/6/97\">",
"           Evaluation and management of neonatal Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/19/39223\">",
"           Growth failure after childhood cancer: Role of hypothyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/59/39864\">",
"           Iodine deficiency disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/33/3608\">",
"           Laboratory assessment of thyroid function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43830\">",
"           Overview of thyroiditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/30/40425\">",
"           Pathogenesis of Graves' disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27833\">",
"           Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/49/1818\">",
"           Radiation-induced thyroid cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/37/1626\">",
"           Reduced sensitivity to thyroid hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16518\">",
"           Resistance to thyrotropin and thyrotropin-releasing hormone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/4/10312\">",
"           Suppurative thyroiditis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/16/25864\">",
"           Thyroglossal duct cysts and ectopic thyroid",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23191\">",
"           Thyroid nodules and cancer in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/47/40696\">",
"           Thyroid physiology and screening in preterm infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25400\">",
"           Treatment and prognosis of Graves' disease in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/46/15081\">",
"           Treatment and prognosis of congenital hypothyroidism",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-892A712F7E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f26_4_26689=[""].join("\n");
var outline_f26_4_26689=null;
var title_f26_4_26690="Aortic atherosclerosis on MRI";
var content_f26_4_26690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Aortic atherosclerosis on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aortic atherosclerosis (arrow) visualized by MRI (T2 weighted images with fat suppression).",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Pierre Maldjian.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26690=[""].join("\n");
var outline_f26_4_26690=null;
var title_f26_4_26691="Melanocytic lesions";
var content_f26_4_26691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Dermoscopic structures seen in melanocytic lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dermoscopic structures seen in melanocytic lesions.",
"    <br>",
"     (A) Pigment network.",
"     <br>",
"      (B) Negative network.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26691=[""].join("\n");
var outline_f26_4_26691=null;
var title_f26_4_26692="Isradipine: Patient drug information";
var content_f26_4_26692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isradipine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"     see \"Isradipine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"     see \"Isradipine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10095388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DynaCirc CR&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702339",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isradipine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10778 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26692=[""].join("\n");
var outline_f26_4_26692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10095388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020093\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020095\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020094\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020099\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020100\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020102\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020097\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020098\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020103\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020104\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=related_link\">",
"      Isradipine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=related_link\">",
"      Isradipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_4_26693="Delancey levels pelvic support 2";
var content_f26_4_26693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    DeLancey levels of vaginal support",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 393px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGJAhYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq17f2diqte3VvbKxwDNIEB+mTVmvM/iPp1hqvj3wrb6rZW97beXcN5VxGHXOBg4NAHcf8JFon/QY07/wKT/Gj/hItE/6DGnf+BSf41zsHg/wmWkX/hGNFBRc/wDHmn+FSnwX4UeAuvhrRclc/wDHmn+FAG7/AMJFon/QY07/AMCk/wAaP+Ei0X/oMad/4FJ/jXIt4O8Lr4feQeG9GLgYz9kT1+lUj4T8Mf24M+HdH2eQDt+yJjPr0oA7v/hIdF/6C+nf+BKf40f8JDov/QY07/wJT/GvMn8M+GRFFnw9pH3mYkWidB+FWfDvhDw8+rQFfDWly+dETLm3TbGoPBC46mgD0T/hItE/6DGm/wDgUn+NH/CRaJ/0GNN/8Ck/xqh/wgvhT/oW9I/8BE/wo/4QXwp/0Lekf+Aif4UAX/8AhItE/wCgxpv/AIFJ/jR/wkWif9BjTf8AwKT/ABqh/wAIL4U/6FvSP/ARP8KP+EF8Kf8AQt6R/wCAif4UAX/+Ei0T/oMab/4FJ/jR/wAJFon/AEGNN/8AApP8aof8IL4U/wChb0j/AMBE/wAKr3ngTwyY/wBz4c0QHvus0P5cUAa//CRaJ/0GNO/8Ck/xo/4SLRP+gxp3/gUn+Ncrb+E/C5Fu8vhrRQzkxsBZpjI/CrK+DPCpv2Q+GdGwF7Waf4UAdD/wkWif9BjTv/ApP8aP+Ei0T/oMad/4FJ/jWFH4K8IPah18M6MAX24+xoO/0qtr/g3wra6e7r4a0YN2Is0/woA6b/hItE/6DGnf+BSf41bsr+zv1ZrG7t7kLwxhkV8fXBrmYfA3hVbWIv4a0UkqM5s0/wAKyPAFhp2nfEHxZBpVpbWcIjtz5VvGEXoecDvQB6NRXD/HH/kkHi7/ALB0v8q87vviG+k/Afw43gnUtOvNVtrLT4L/AMiZJn06IxKryugD7dpAXLKQCeQcYoA98or55m8deLdG8OSeIJ/FGla5pWk6vB9u/ssx3Rexl+Uo8ogjQuh2kGML947scVWvPHnj220Dwbc6jqUOnW/iKS5u5dRufKtorOM828BkMEioCuG3OhLbsbhjIAPoSTU7CPU4tNkvbVdRljMsdq0qiV0HBYJnJA9cVbr568GahqWqfGLwPda3qOnanftoF4kl7p27yJ9s7qGTKr2A5AwTyOCK1P2lrnSLS58ETXepRwX8Wv2cjQSXxRRbhnLSmEttwCADIVyOmccUAe40VHbTw3VvFcW0sc0EqCSOSNgyupGQwI4II5zUlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADWbGB3PSlA/Oo0P7989gMVLQAUUUGgAophJpu73oAWRvKO8/c/i9vepBzyOlQ7sgg8g9qooZLOUIr5ic/Jv6fTPagDUpB94j8ajjmDcMrI3oR/WmyzCOYZ6FSR+FAEoILfSnVDaSpNAjowYHv71NQAUUUUAFFFFABXnfjtinxA8LsO0Nx/IV6JXn/jZPM8f+HF7m2usfkKAOhsnDXXtJHmpbJi6shOOCMVlafMR9lc9mKGtJT5F8R2Y8UAVrgkaHeL3jyax75yl7HIOjWxH481usm9ry37SocVyeq3bfYYJMYKbo2574oAzrifakceQDsHGfU11vgM+dd6lLt+WJlgQ/RRn9a8n1fV83cYjcKojTP13Yr2PwBGIvD4kYr+9keQn6mgDpqKyZ9ds42dIS9w68ERjI/PpVOTxBOf9VaKo/6aSD+lAHRUVzg126YDENuD3+YkU+PX5M/vIYz/ALj/AONAHQUyYbonHtWZFrtuSBOksXuRuA/EVpQyxzxh4nV0PQqcigDj5rlHWURsAUlRwR9ecVsRyFtVXnqhzXG6teRWt7dwb13/ACAADjlq6nT2JvpXbG1E6+5oA0ETZFaRD+KQtVTxN++ktrUHl3GfpWhDG8l8jN9yJNvXuaoxD7Z4hkk5McA69s0AXb+TylwP4UwPrXG+DYRD8UfFgAwz21q7e5w1dVg3l9tz8incf6Vzvhwg/FjxYB2tLQfo1AHd0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFAPWio5DsKt26GgCSiiigAooyPWjIoAKKaWFIXoAfSZFR7qTdQBIW9KQuaj3U0tQBFcTeXMp/vDFTxSbgDmszV2KxIw7OKuWh3IKALganA5pqinUARvxUTNU0gqBgc0AJmmSos0bJIu5D1FOxSgGgCvb+fC3lyHzYv4X/iHsfX61POPNhdOMkHGfWlwaUAg0AULdJTClzYkBmHzxH7rn+hq/aXsdwTGQY51+9G/BH+NUrWQWWpNbyHENwS8J/2u6/1rQurSG5A81MkdGHBH0NAE9FVFiuYABHIJk/uycH86UXqK224V4W/2x8v/AH10oAtUUiMrqGUhlPcHNLQAVw3icBviZ4WB6GC5H6LXc1wfiyURfEzwmzdDFcj9BQBOUNvcXVuM/I25fwrUuWEttDcr1AGfwqLxFD5F3DfJna2Fel0ptwntXxjOU9waAHyP5d5BJnKtxn2Ncbr8Yji1O2wV8qTzVz3HtXUTBvsMqjJkt8jb6jsa4rx7dFYLa9zhbiIpkf3l6j+VAHkmonU9Y8VwaRoqq8syMsjnpCAQQx9q910i0k0nRILGe6e62csTwCx68en1rivg/Zx/2NqGsMgF1dzlC2Odi8AV25BJ5PXmgB7XDEfKAB/KoyzdT3pBnNLlUUluhGc9cCgBQpYEnpTT7GuNvfiJo9rrcmnMw8yNcne2OfT6+1dRpt7HqFqtxD9xqALyTOh4Y/jzT4piJhIjvDKOjxtj8x0P41Bjik60AcT4ps9Q0nWINQuZBc6W0yvPMeGQLyAQPeuz0jXbe40a3uJ5PLa9kMyoepjX/Hip2gjvrWe0uVDwTIUZT715v8N7K91XxDPpt0weGzYwA/3Ilbp+JoA93iuxFo/2txtaRd20+p6CmIostOxz5svzNnrzUbst5qQiHFpZgFj2LdhU0G6+uy748qM9KAJrRBaWbSv99uTXH+E8n4qeLGbq1tan9Grr3Iu7jH/LCLk+9cj4Vk834reLmH3RbWoH5NQB39FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSModSrDg8UtFAFe3kKu0Eh+deQT/EvrT5mxUOoRsYxNEP3sR3D3HcUGVZoUkQ5VhmgBRJzT99Uy2DUiNxQBYLU0mmZozQA7dSZNNzRQAtGaSigDL158WygdS6itKw/wBUKx9dfdPaxDu+4/hW1Yj90tAF0cCiignFACN0phWhmpN1ADCvNKtDGmbuaAJcCjFR76A9ADL20ivLdoZwSp5BBwVPYg9jVGO+m0wrDqZLwZ2pdgcewf0PvWnu4qKTDBlYBlIwQRkEe9AFtWV1DKQQeQR3pTyOa54WFxYsX0eYRpnLWs2TGf8AdPVf1HtUsXiCKKQQ6pFJYS+svMbfRxx+eKANGTT4GYsgeFz1aJiufypnkXsf+qu1kHpKn9RVtJUdQysCp5BHQ04EHoRQBRE99H/rLNJMd45B/I1wvi12vPiH4YXyZonW3uWG9cc4HFek1w3ibn4m+FR/0xuP5LQBuQFdT0mS3Y/vFHH1rDt5ng2TAHfA2yQd9vr+Fa1yjaXqQkjGIZDnjpmotViEN2l5HhoJhhhj86AJbzalxDcDmCceXIPr0Nc7caIL621DQ7z5Y2PnWkx52NW7axlUewnbMUqloWJ7en1FV5QXiErkrd2R+bnG4ds+1AHH+BbGPSrO505SyfvWby3/AIWPXHseorbZWVsMMY4zWde2T2V/b3YkDW92SG3NyjZzsB9O4/LvWzGJEYx3QDx/wzL6f7QoAqgkHjrR/Krs9g6qGTlT0I6VWdJB94H8qAMmbQdKuJ/OuLGCR+5Za0IIo4IRHCqpGvRVHAp+1vQ/lS7W67SaAGg//qoqVYZHPA/Spo4I0BeaRVUdSf8ADvQBGS0FnLMqlmRSwHqayfBelTeF9IllMW7W9XmMgjPVc+vsK2JbpklzLGFiA3QwEjzZD2dhngegq34UsHt0n1W/czX9wx2KzZ2AnoKANdYTb2qWUWGlbmRvVj1NWinkxpaW/wDrG+83pTo0NuuT891J29KZNKtmm0MHuZD1PrQA26IjRbS35dutcr4VUJ8VfFijta2n8mrqbeJrWJp5zuuJOFHp9K5bwqmz4q+LATkm1tCfyagDv6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArJiH2a6ltv8Almw8yP8AqK1j0rM1ddsKXC/fgYNn/Z7/AKUAQyHDGpI2pkoBII6HmkXigC2DkUtRoakoAKKKKACiiigDntUy2t2y9ghP610drxGv0rnNZ/d61ZP2ZWX+tb9s+UBFAF8VFIeaA3FIRmgCMnPrSqpqRUp4UUARBTRsqU47U0mgCFhimGnu3NRlhQAuaDUUk8cX+sdUz0yetVZL8FtsMUkh9cYX86ALxIqOURzRtHKiSRtwVYZBrCuZNRmk5u4rWH0hTc5/Fsj9Kpy2EM423VzfXC45DXDKD+AIFAGi2gQRPv0u5utNf0gfKH6qeKAPEVoflay1SIeuYJT/AOy/rWSND0tmBMExI6E3EhI/WrVroGmhsxG9h9o7yVR9fvUAaCa5cxnF7ouqQEDkogmX/wAczXnvjzxHnx34UuNL88S26XDSRz27oHXAyuSBj616DJpN+kLLpmvXluSMATqs4X3ywJ/WvH/jHqupeEdd8JXur3LX2DMjTQoeQQOWT0+mKAPbNPvrTxJoyywOCrjI55U1Ss3YiawvBtPTnsexryjw54sisb0ahorCS2nw1zZIw6/34/f26GvWIbqz8RWcN5ps6GfHynpu9VYdj7UARxxNLG9rM2yaFsq/9w9iPY1V1KZriB/3X+lRfJPHjO4evv61PM80qrNbj/S4OHQ/xr3U1WtporsyS2sjKqKdp/jQ909x+ooAyYYft9u2m3jk29xgxyrwyEHI/EetQadqbxXC22u21zZyxyGGK8K/u5sdm7A/z7VbGnTRHe5mFuGLHA+dCf4h7fp7VNqWjzywRTwzy3N1Ah8rzHwkoPO1x6fyoA34hg7rWZNrdR2P0qTMedlzENx6MDgGuc0+8shPHaySJZ6k0YdrSQ/MM+h6N+Fa6iVQOZPwIIoAsT28TRMY4tr4+Uk/KawXGrMcRx2qDOCRlj+taslzImVaQ4PZoj/jVSW+2qQjuXPZY8UAQyaTNOn+lXlxtPOEIRT7YqaC30+xupBGPnCjCq2cD8azJtSvSkX7raX4USS4LfQDBrK07TL/AFO7GoPNPBb72VluI9nmpjoqjnHXk80AbM062119t+zQ+Uo3CTePmHsT+pNauh6m85S4a3Kxu5EW5Nq7c9VHXHuayIvC8N3qVvPIj+TEu1QDtQ+mFHX61vtq2mWc8llbPFNeQJucnlIh23Ed/agDbmk+ywtMQZJn4VVGST2AqrY2oR3u7w+ZcD+EdE9h703RpHu7Mzzyu28/LIy7CR6KOwrQVFEYLgRwJyF/qaAIZZo7e3mv9QdY4YlLEt0VRXn/AMN9Tl1b4leL7uRQkbw2vlJ/EEw2N3uetcv8afH0jQDTtKBcGQBVHR2HVm/2R6dzVX9mKWSfxH4ylncvK5gZ2JyWOG5J/wAKAPoOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAD0qtcoJIXQ9GUirJ6GoXoAyLV/NsIH/wBnBqVOaq2w8me8tv7sm9R/stzU8TfNQBZWpRUa1JQAUUUUAFFFFAHPeLFMaWdwDjy7hc/Q8VtWTZiGKzfFMfn6LdqvLKm9fqOal8P3IubGGUHh0DfpQBtKKkUCogwFI0oFAE5YAVE0oqrPdKiMzuqooyWJwBXMz+KDdu0Ph21/tGQHDXDHZbRn3f8Ai+goA60yE9KxNQ8UaTZy+TJexyT5x5MGZXz9EyR+NczqNsr2z3Pi3Vzcwjk20R8m3X2wOW/GuVu/GdxHCYPCuhrbwdFleLGfcL/jQB6IfEEkwLQ6dcpGP+WlyViX8s5/Sks9etbx2iivLWWZR8yQyhiK8Wn0zxP4jmP9p3bCMnI82T5R9EWu48F+E7XQiZxI892y7TK/AUeijsKAO43xbg+xWcdGYZIokuC3GTVYHjEY3nODt7fWrMcJagCu+5qr3t3aabbmfUbmK2h/vyNtB9h61tJbAdRXkXxT0XUZtfW5ucjTCgSGXGUiPcN6EnvQBvXPxH0C3lCRfarjJ++kW1f/AB7FWIfiXoKEGQXUY9THu/kTXntl4LNwQxlDg90Oa6rSfh7BgF42J96AO707xx4dulXZqtvGT/DMTGf/AB7Fcd8V9MPifxH4Xh0w2t5+6uXCmT5ZBgDAI7/iPrWg/wAPrIKMxH8KzdF8N2+g/FLw+9uhTzba4B9Oo7UAeE61pmp+H9XkGl2kiR2rbpFLESW57q64yo7hsFT6967LwX4xuo7rzNPuP9LfaXtJxhZvdH9fbr6Fule3fFLwF/wlVvFqGjXA0/xNZKfst2OjjvFIP4kPv0r5w1u0vpT5kelrBqNlJs1bTdux42/vxeoI5B6EUAe/Wvim1vmjknm+x3uPLYTHarn+6zdM+h/MCqfiWZtJZdSsfty4P+mQW8e/K9iyd/8AeFcn4C8Ixa5okV/fancyMxPkMsmMR9lY/wAX0PSt6CC88I4mjkuNRsIjlreT5/L9dh6r9OlAHXeGdf07U7ESQz+ZF93cTux7N3H0NbkKBEJt33x9sHcB/Wud0kaJ4iiku9LCRz9ZVUeXKjejrWlBplzahBBIcA5PvQBcubWyuwBdxRMQCAxAyueDg9R+BrF/4RWS0tVh0HWprQK5ceb+/wCD/DyQcfjWw806oRcQrIPbrURa0f7yPGcdxQBTFj4gOolhf2hscYEX2Y7wcdd+717YqNdE12SzeG91siRnyJbS3WEhf7vJb86k8uAsGDPHzjrwasAkPxcp+JoAii0FIZoLqX/SL2JPLSeRtzgD8gD7gZq432aIpNdsGmXnJbP6VBHtIAkui3+6Kf5dqoPyM59xQBBqWovnfaRNIw6Mx2qKtaTaWyxefJFFLI/z7Yk2pn1JPWpILZ5NrhEiI4Bbk1S8Sa7pHh2zWXW72GJScKsrfNIfRUHJoA055LmZhcQSRMsZzjOVAHXn6V518V/HKQ2n2a2uvJtHX55UPzy+qoPTtupmrXOu+LcJZTLpehcFU8v55PqO49uleS+M/B11pPii3EuoSakLiJ5xLcnAi292HQIvYdzQBkw2V94r1R45TJb6bDhrqcHHlJ2jXvuPevZ/gDLayeKvFKWGxbaGK2iSNcfIAG4OO/159a5L4X+F7rx1boLbz7LwrbyYe6wUe9P8Sx98E9X/AAFes+CrC00v4keJLHTreK2tYLK0VI41wBw9AHodFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHoagepz0NQNQBjX6mLWIJf4JozGfqORQjYena98tvDN/zymU/geDUX/LSgDQjbIFTVTierSHIoAdRRRQAY5zSMcClqKZsDFAFa5w8UinoVI/Suf8CzEaREjH7jOg/BjWtqEm23cg4IUn9K5bwNKF0aFs53M7ZPuxoA7p5sAn0rnr7xJF5jQ6bFJf3A7RcRr/vOeB+Gaj1aa3mhxcsfKXkrv2qfrXF6z470rT0MFowndeBFbgY/McCgDfubV75jN4huFuEHItIztt0/3u7/APAuPaqUviQ3SNbaCIXji+Q3H/LGM+igfePsMCvJte8Qanr0xS4laK1Y4W2izz9e7Gut8GaXPp9g/n5RpiGEX9wY/nQBvpbxCQT3bte3XXzZ+cH/AGV6L+AqSa4LDB5FCwsadPJaWMJmu5AqDj1JPoAOSaAKguzFKikYLnCjua3LCFrqRftAZkH8OSB+nWs7RLSS9vH1O8gMC48u2gf7yp3Zh2J9PTFdbZxDjAxQBctIUjQJGioo7KMCtCGLA6VwXjrxZd6KU0/RbcSahIu5ppFykS+uO59q5XTLfxdq7iS71jUlQnOEYIPyxQB7c5jhjLzOkaAZLOwUfmayNQ1iwKKLXUNLlyfnR7qP5l7gc9frXB+KNAW1+H2syXclxc3DIiu88hbcCwyPaumg+H3hH/RR/wAI7peWX5sxcnge9AEMieGoyt3b3GjwuWwCk6J82e+1q0dL8TaNLDGU1PT1D527rqME469Wpj/DjwaiSTf8I3pQIXJzF1xWEPhx4LbQrG9n0HS4zEyuXMZxgnnvQB1o8T6KbiaE6rp+6FBJIftMeFBz7+1YF7f2V/8AEjws9heW1yv2e4OYZVfg7cHg1DP8MvBlo091B4fsGMseRvQleT6ZrKsfCmi6B8WNAutGsILN5rOaKQQrtB247ZoA9hrzz4r+BG8R2y6voRW38S2SfuZOguUzkwufQkcHsa9DooA8F+GWvpqljcWXkTWDszq8WNrRTDh09iDz71JD4huPBl5DpvjaZ7nTZ2K2ut7MbcnhJ8d/9rHNa3xT8FX1lq0vjDwnC0twVB1HT4hhrkL0lj/6aD0/iHvUHh3WtO8aaE1rqMUNxFOu0o4ysvqCOzDuOoNAE2q+GIblxq3hzUjZXzjdHOnzxye4IPI9untUtr4p8RaQI11vSxqSA4a4s28pwPUqcq35iuIu/CXivwBM134BvjdaMxLyaTP+9RfYDqPwrY0T4xWEirbeKtLn0qYHDEKWiB+uMj8aAO/t/Gug3YxPdS2j90uoSv6jI/WtIX2kuqkahp5B9Zdv865pb/w54igAsp9OvlPQCUbh+FEvh7TjGI5IQidgOMfmKAOmDaXJ/wAvViQOhW5Q0jT6NE3z3tgvrm4WuNfwXoEpzLCzY6fvOP0FXI/Cen3ICra+YF7FhjHvQBtXXiXw3YqTJqlgoHfLOP0FZrePdLkjP9mQXV+3IBii8tWPsTz+lTjw1YCHb9ihYDsygAVn6lreh+H4/wDTb+wt2A+WJWDP9Ao5oAgF/wCLNcYrDbw6Hbk/eRvNmYf7xGBTLzSfD3hq3/tbxHJD5yci5vD5jlv9nOSx+lc1rHxK1bU5BZeEdIlV3GBdXi4/FIxyfxxVjw34Ema8TXvHF6+o6gnzok5ykf0XpQBZ0u/8QeJb6PVpA+h+F7Zt0MTqPtF8egLjHyr7dTWBc6VdfEv4gXOkQv5eiWmz+1JkzwByLcMP4j1bHT61f1fxDqnjTxE3hvwWCZozi61EjMNivrkcGTH3V7fy9j8G+GdP8JaFBpelx4jT5pJG5eVz952Pck0Aamn2dvp1jBZ2UKQ20CCOONBgKoGABXGeHBj4s+LPe0tP5NXd1w3h4Y+K/ivnraWh/wDQqAO5ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEboagep26Gq79aAMvxB/yCJ/w/nUQGcfSpdf8A+QZKP7xUfrUQIDAUASA4NW4WyBVN6lgftQBdopFOaWgAPSqVy+OpqzI4ArA1q+S3ikkkkCRIpZ3Y8ADvQBneKtSWx0a8unPCIVQDqzHgAe9cNpU2oW1hbW8t+sYVeVgiAPPPJOeaz9U1aXXL2O7lJFrGT9kgP8I/vt/tH9KZdXi2NnJcygttHQdSfSgDSvLeO5fdLvnb+9MxfH0B4FUR4ZtZtxYMpbqRXCTa1qd1cs7XMiKTxEhwFFWbG+1aOZWtbq5Z8/dJ3L+IxQB6PpPh6ysWDwxAyYxvblvzrejhVRk1l6JqLXmkwXEyqkjD5gDxkVYMkkpwrDHsaAJLq4VeFOAOpqHSbc3Uxu5h7Rj0X1+tLPCEj+cZJ6io9YmltPDN7JZ5Eqx4Qr1BPGaAJ9W8V6NoknlXdyXnHPkwrvb8fSpdH+IejXjiK3gvjOxwqGLGT9e1eV6R4Xu7ybMqsu45bPUn3Nei2Phi306x83cPtEYEgUdcAgn+VAHdXFtDcQfbZbKBr+OIlAxzg/3d3pWjFHKNEinit0NzIqHYvRScZ/DrVXTbdDEJI3LI4DKCelXdIvjJPPauRiNuPoe1AGB8UzjwVqYyAPLTI994rehybi2HogJ/IVyfxTnKeF9TQAsrlFz6fMK622GbmL/rkn8qAJNbBXT5fn25Rhn0461VvbaNfDItpzkSIkeVHUkir2ugm1KKcE8Co9WB26fFt3bplz+AzQBLfqBAikc8LXG3bb/iD4VcZ+aK6/8AZa63WpP4V64/nxXM6vEIfiJ4SjH8NvcfyWgDvqKKKACvN/Gnw6kub2bWPCN2um6pK4kuLdlBt7wjuw/gf/bXB9c16RRQB43aeKXs7hLDxNZ3OlahnA87lX91ccMPfg+1aupaLpWuRbrqBJGI4mi+V/x9fxr0XU9Os9UtGttRtYbmBuqSqGH156H3rhtU+HMkA3+FNauNLYHP2edftEB9uSHH/fR+lAHB6p8JbK4DPZyQk9iV8tx+K4rJHgfxVpbBdO1nWIIgOlvdbwPwNd1PY+OdLIabTYdTRR8zWU6sW99snl4Ptk1WPirU4Di48Na5BgZbfZu//oG8frQByc2jePeAPE+uFQOn2ZWP51HF4Z8eXCES+I9bIPriL9RXVj4h2ocp/ZevrMONq6RdZ+n3MVJD4p1u/uhBaeFNcniP/LVoDCP/ACJtoA5OL4Z65dtv1HU7u5Pfz712H5Aiuh0T4a2GmvvuJoVY9REME/8AAjz+tb0kPjSdR9j0OK2zxi4ukX89panReC/FupxbdW1rTtNUnJFjC00mPQO+0D/vk0AU9X1vw74M0+SZFgibucjfIfr1P4A1gaZp3jH4mgGUXHhnwwzZaYgrd3aHsgP+rU/3jya9J8OfDfw5od0l79lfUNTX/l9v286UH/ZyNq/8BArsqAMfwn4a0nwpo8Wl6FZx2tpHzheWdu7MerE+prYoooAK4fw//wAlY8Vf9elp/wCz13FcPoH/ACVjxV/152n/ALPQB3FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAHoarSdas1Xl60AZGvc20Kjq0yiqxB3E1a1Uhp7RD2YufwFIkfmRNt+9jj60ANU5WlQ4aq9nMJ4VccZ4I9CKskcZFAFyJs1IxwtU4Xwand/3eaAKlxJgHmvLviNdPeXVvpYZxAym4uNp+8AflU+xPNekXTHa1eQ6/K0nirWXPSPy4V/AUAUrdMNuNLqFuLuzeHdtYkFSeQCKWFsrT3AKcgH60Ac9FavaS7rpLAIOpLHn8K6K0mm1WNbHR7IQJJ8rXJTGR32DqfrVZEjV9yxoD6hRmvR/A2nhbUXkozJJwuey0AXdE8L2tnaQxyR+YUXHzcgVry6bbCPHkpj0xWip2qMYqvcSDnmgDk9X0TzBuspDG6nPlk/I3t7Vj2c4YS288eGHySxP2/8ArV1t5KFBJri7tGu9XBjcxsv3pB6ehoAsxWNpZIZop7mONBnyxKSPoBWvaTpeiN4oycrghhzjuKoiwvbm1Js5okcHCuy8j146VV065utE1G3TUVkCE7PMbkMM+tAHWaDOtjef2cSzIVzEScn6Vb2/Y9fTAO2ZcE+pFYWsP9jv7e5jbIhlDZx1Rq1vFcxjuLCdGwBIpBHcGgDI+LcefCd/tznfGeP94V2Fqw+2Qr3Ma/yrmfibtfwVqrHr5cZH/fYrf05t+uRKMfJbjNAGjqal5oUXqWFSXCl9RtsDKxhmJ9O1BHmah7IM1K5IWR+emBQBlThrnUIkUAhn3Nn+6P8A6+Kz/GPhq317UdPm+36jYXloGEc1jN5bbW6g+o4rW02Mfari5fG1AI0IbOe5/U4/CrNlH5kjzP1Y8fSgDkpvA7wwF28W+KuP+n7/AOtVSx8HT3AJbxd4qxnA/wBN6/pXXa5K0my2h++xwT6DualskWJFCjCqMCgDkLvwbJBk/wDCX+KuB0+2/wD1qjh8GzyQlm8X+K8npi9x/SuivpDPdLGpOM81fkURW4xxgUAefWHhq8nkto5vEPi9JpnKMragVCKM5Ycc9vbmt4fD5sf8jd4s/wDBif8ACtSyULevfTE8p5agnovt9f6VpWmrWLi0iR/La4DeQhB+cL1xQBzf/CAP/wBDb4r/APBgf8KhPgdlu1hPi7xVlk3Afb/T8K72qOopiW1mH/LOTB+h4oA5f/hAn/6GzxV/4MD/AIVj+KdH0rwppov9f8deJbK0LiMSSagSCxBOOF9Aa9Orzz4yWUmo2nhy0i275dVRcOxUH91JxkdP1oA4dfF3gFsBPihr7EnHF8/X/vmpR4l8EGRU/wCFk+JN7Haq/bJMk+n3a8d8d6BrPw+8VHUNJS5NsRm5sJ/mAQH7ykfeUdiOV9q9A8LeKNE8XaclnqE81tdSqGtLrzCrhx0Kt03D0PUenSgDqv7Y8J/9D/4r/wDAiT/4ij+2PCf/AEP/AIs/8CJf/iK6Dwb46ubF00nxmSsqnZDqypi3uPQOf+Wb+xwD2r01SGAZSCDyCO9AHiX9seE/+h/8Wf8AgRL/APEUf2x4T/6H/wAV/wDgRL/8RXt1FAHiP9seE/8Aof8AxX/4ESf/ABFaXhfxP4H8P317ep4h1S/vLxUSWa+8yVtq52gfLwOTXrlFAHD/APC1PCP/AEE2/wC/En+FH/C1PCH/AEE2/wC/En+FdxRQBw//AAtTwh/0E2/78Sf4Uf8AC1PCH/QTb/vxJ/hXcUUAcP8A8LU8If8AQTb/AL8Sf4Uf8LU8If8AQTb/AL8Sf4V3B6VyOs+NII5ZrPQojqV+nysU4hiJ/vv0/AZP0oAov8W/BaSCN9YVZCMhDE4JHrjFVl+Nfw9Zwi+JbRnJwFCsST6dK8h+IHjowf2hYW+sNcaqY2S8vITgR5+8kfpj7ox05PJJrkfhj4PuIooLrSIs69qBxE7Hm3jPVvqR3+vtQB9JQ/F/wRPI0cGtxyyL95UickfXiun8M+JNJ8TWcl1ol4l1DFIYnKggqw5wQeh5qLwf4dg8OaQlrEzSzt800zklpH7nJ7Vj/D1idc8Z5Ocaqf8A0UlAHa0V5b+0Zqd/pPgC2uNKvrqyuDqdrGZbaZomKl+VypBwe4q18V/HWq+GNa8L6LoNhHcX2uTSossqK6oI1B2hWliVnYsMAyL07nAoA9IorwbWvjB4o8KWOl3njDR9LtY7m1vYZI7aTziuoQZKIXSRlVXG0bDlgc5NFz8TviBJq8mh6boGmSa3YaXb397HIqpG7SBWYAyXMZjRA20t+8+YHIAoA95orxz4YXJvPjn8R7pkWNp7PSZCiyCQKWts4DLw3XqODWZ8SNXkn+I1hoXgTV9cufF730M92sd7IbLT7VQA6yRA+UQRzgqWyevKggHu1FFFABRRRQA2RdyEAlSe47VH5jxjEqEj+8oz+lTUUAQC5hPSVM+hbBpkrL1zx2NOu4RIocKGdORnv7VnXcKtH5lofLLDlf4T7Ef1oAZdqskm7+LGM+1T28W2OsQ3MsUwSZGQnpk5/I9xWvZXIkGCeaAMmT/QtakgbiO7/exem4feH9a0EORg9ak1fT01GzaJmKODvjkXqjDoRWTYXrvK1reL5WoRD507OP76+oNAGmQQc0rMdhojYN160rpkcUAZ1w3ymvGvEdwI/G+s2p/iCSj8ua9luF615L4msxL4t1ckYlCoyn2IoApW3K1NKQARnmobI52gcgjINVPEjXSWg+yMysTyVHOKANDT7ea8vFht4mkYfM+3+Fe7H2r1m1kitIIog6gBQq5IGa8Y+GGqXWieJjdXm+aCWIpIsjds17Vp+r+EZIWkht7ePcSGVrbnPp0oAe97j5c4qvNeIq5Zh+dYF1HqDvPLZxKlmznyEkyHCe9ZnkalKTvUD6NmgDR1XVETPIJqvpkO6HdKMPOS59cdhWfstraV3vlkldBuEY6Mew/OtWzlluJvNZCI1PTHp1xQB2eh2SC1XfgEDJqrrlvbzwyRTxq8LDlTUIu7uK3SQ2r+Wy7gUYNge+K57V9d3xMCHRSDgsuM/SgDKXUS7XemzOX8hcRSHqydRn3HSukhu11bR9HJBU4CsCcnK/8A6q8qfU0PiaUofkSNULdNxPWu30S5FhFZCRsLuLqD33Zx/OgDb+J1zt8KajCCPmijJ/BxXTeHGWXWLyUD7kaJu/CuA+Idx5uga1JniOBB+O8V23hKTbo11dnrM3H5UAdBavvnmftnFP1Cb7PZPJ3A+UepPQVHpcZW0TI5b5jUV7Ksuox25UlIF81z2z2H9aAHQwmK1htVxuxukI9Tyf1q7I4t7csSBgUlrGcF3+83NU9QzdTLEP8AVDl/f2oArwKXZpm+8/T6VLdTC3tzk8mpSFRcngCslmN9clgT5SHHsxoAl0yFncyvnJ6VbvnBwmeB1p6sIYqy5JTczbE4QdTQBIB9pbbj92OMetSvMbWM/YrUTtbJtiiDBcse2T04pJpEgg2RffPAqSxjSG0aWQ9e57n1oA2IJ1kVN2FkIyVznB9Ki1VC+nzbfvKN4+o5/pWXZkzs0nzBc8fStklJonQHquCKAJIjujU+oBrjviJ/x/eEf+wwn/oqWussVKWcKt95VANcn8RP+P7wj/2GE/8ARUtAGz4q8OWPiTTmtb1SHGTFMv34m9Qf6d6+SfF3gLUfCep36ybBaCQFvK4WNzysijsG/Q5FfaFcV8TNLil03+0jbLOYl8m4jI/1sDHBH1BwR6c0AfPHhXWNWuI4oZrsSMpKurjJmUdmU8N9Ov8AOu70bX/Emh/u9NRrW3BDLBexO1swPZT96P6fNUfw50uOx8SXdm6LLbwxebZyEcqCeVz7cc119/4l0i11T+zry4MM5GeVJH4mgC7oXxVtZtqeIdNudMydv2pCLi1Y/wC+mSv/AAMLXe2Gp2OoIr2F7bXKkZBilV+PwrzeTw/oWpTC5jFt55GPPt5PLf8ANeapt4Kls9n9lX6HByEvEFwv055H1HNAHsFFeZy2eovCqSG9tXUY36fqLov/AHwxIrOuE8UKw+x6re7V423UgYn3yuKAPXaK8VvG8ZCICKSa5k7mK/eHH5k1Sk0rxRqEDWt5Y2bQSDDNqepy3hz/ALhO3HtigD2TUNf0fTo2fUNVsbZV6mW4Vcfmaxrjxray26zaNa3F/CxI+0keRbqPUySYBH+7mvObD4fC1KtHdW+nt1LafbKhP0ZslfwrYg8H6dHJ5129xeygY828mLkj6k0AUtc8Wprd39hl1N5Rn5rXTEchh6FsbiPc7R6Zrn/FzeJH037F4e06TS9J2/NcbgHT1IXqP96uym1bRdHIgSeBTjiK1j3H8hWhp19Fqdk1xEsqx7ijLKu1hQB8zan4bi0hbPSIEeW9vAs8zt/BET8oPfLHk98YzzmvqD4U+GI9I0pLyWLbcSoAu4cgev415r4T8KfbvGF3eSMJna5McQY52IOCfwAx/wACr6FhjWKJI0GFUYAoAfXE/Dz/AJDvjX/sLH/0UldtXE/Dz/kO+Nf+wsf/AEUlAHU6xpOm61Zm01nT7PULQsGMN3CsqEjodrAjNZieCvCyabJpyeGtEXT5JBK9qLCIRM4GAxTbgn3xmugooAx5PC+gSaZbabJoelPp1s4lgtWtIzFE4zhlTGFPJ5A7mna14Z0HXZopdb0TTNSlhGI3vLSOYoOuAWBx+Fa1FAFK00nTrK9uLyzsLSC7uVRJp4oVV5VQYQMwGSFHAz0HSsvUfA/hPU72W81LwvoV5eSndJPcafFJI5xjJYqSeldDRQAAYGB0ooooAKKKKACiiigArMkAE80I4x84+hrTrOvfl1KA/wB5GU/pQBl39v50RX7rjlG9DVSwnyAT8jhtroezCtm5j4JFYV/GIrpJzkJJhHwOjD7rfzFAHSQvvQGqup6XBqMSiYMsiHMcqHDxn2P9OlO01/MiU4wSK1I04oA5NpLvTCF1VDJCDgXkQ+X/AIGv8P1GR9K1Y3BQMCGVhkMDkEe1W9a1C202yMl0pcP8ixKu5pCewHeuLSe8hfz9OsobWLq1m0pO/wDopoA3rlec15l8QB/Zmu2uosgMFzEbaX1yOR+ma9Ks7iPUbRZ4MgHhlb7yMOqn3rD8aaMdV0S4t1A83AeJiPuyLytAHmiSLbST274Ix5sL+oNVby6BKSA4Drzk+lMmb7RYwlQY2TJhz1Ujh4T7jt7Vz9/Ks1lc28oyUBdT7YyD+YoA7DwiiyanO0iA/KuCecjvxXsWlRxi2VUAVQOAvAH4CvHPhYB4gtrySy+zzTJhfJmYo6j+8pFemrJdaNbQnVFEaHCmcMCm70PpQB0M0cQXBxj3rGvXiiVmAAAFBu/PC+W2/d0we3rUDRQTMwnPmgclScKKAPPbq/SbXHCh5AcZCKW7+1dlpE4eJmmjkiAOFVoz0/Kr4eCE4t4ljXttQc0x3Z3DFz8vc8UAOTUDp6EW1yqJ18uWMlfw7isOXUvI1MapctZXqhCht4sL17jOcmtxJJWzsywHUnkVHMsNwNktpbyKeD8uc0AeOeKdXXVPHFxdNbxWylEXyYzwFA4Naraj9uksIASpikVD9ASa6nWfA+j6jMbi2D2V7jaGHzIcdiK46fRr3QLpkvVBLn93InKtn0NAHR+NJgfh9rs2fmmKIue/zCvR1Q2+jafYQgh3VAcfTk15V4sIk8HXVqudtqscjn1O4V7HoMYup1u3+4iBUHvigDajxbwAueFFVLBPOkkZudzbmPqfSoNSma5mFvD681qW0S2tuFHb9aAHXD7E2r941Xij4qQIztubqf0FVNWumgRYLdVe5k+6pOMDuT7CgDP1SeS5uVsrXgHmV/7g/wATU8ax28apGAqqMAVXgWGzQxrKjSudzsWG5j61WubjcCMnb7dTQAt/d7xtDYToSO9QRy7QBGMH+VVzl5Bj5nHAA6LWjbWYC7pTtXqfU0APtkDfPISR396WR2u51jJxGv8ACvQCop7kyN5FoOB1PpTlUxoY4jnPLP60AXPPCERxEHHHFaNiwWQqcF25NY9mBvwo3Nnj61oxvFBMilgZScsaANFSBMUHXaDXIfET/j/8I/8AYYT/ANFS10/P9rZH3TCO/ua5j4i/8f8A4R/7DCf+ipaAOzqK7t47u1mt5hmKZGjYeoIwalooA+f/AAtZT6J4u+xzzvJEHeIq4xtPoD3/AIeDVH406NI8UWs2JeO8t0zvjOCQDgj34rqPFcQTxVfBcI8V7DcAjqdwwf0q542iWXSEDj5XDj6ZFAHlnhvU0v7KK5sr+IS9JIpR5ZDdxkV1NnrN1bIPPN9Ef+eiESrXj15K+jX6zWUSSxSAGeBhkOPb3rotI1vSJ4vMtpGts/eUORg+hHagD1az8VZAB1K13+lxCyH+dXl127K7lm0mU/8AXRh/jXlj6np55lvGcequG/SoG1jTk+aOfcP9uD/CgD1uXXdR5Bh07I6f6Vt/9lqnJr+rrl3/ALGRR3N0xP8AKvMpPEGnzv5jGPOMHMTc1H/btvG+21iidj/E8ewD8WoA9Cn8VTFsG+gLf3bWIsfzP+FZN34i3y7PJurmXsHb+lck+uTPlWu7aMH+FD/8TWLqfim4gK2dhOpmc42wJhj9SecUAds+o3d1qEWnRosEs33ljABVe+TXpmghbDwx5nUndIeewryr4e6LLZXiX17P513cb92TnbgdBXrMqD/hEfl6m1IH5UAZvwJjlu59Qv7ojzMnaoPA3MST9cAD8K9irzH4I7TpkkilcSRq20DkHLD+lenUAFcT8PP+Q741/wCwsf8A0UldtXE/Dz/kO+Nf+wsf/RSUAdtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWNeT79TtiAPLBaPd6nFaV7MILZ3JwcYH1PSs/yf8ATbOErhUQyfVun9aALLruBBrNniXftdQyHqDWs6YqtcRBxx1oAqaIBAxt3yTuIVuxx2reHAqhbW6MoyoDBt2fel1u8+waTdXPdEO36ngfrQByWoXbahq81x96CEmGEemPvNVFLmORpInnCyxYV5fuKc8jbzzSeVD9jgsbndvnUn5cjLdTyOlc/rEDw6eZ3it4IllVZZSxcbR02igDqtk0Mpn0+byZnHzErujk/wB4evuKSbWdWjVkuNGgul/v2txsb67WB/nWGzRnVYr2GbMTw7BI8wVE46hT3qtY68XghjgulnBm2G5ZD68rtIB/GgDmvEUq2eqy3Elhe2lvdMGlS4jGxX9QwJHNYGs6ayr9pt8zLgspAHzp3HHcda9tuIYrq3kt7lFlt5BtdG5BFeN3nhoWWpX1o13fyRwSZCefgBSPlIGPTigDG+G27R9Q1NYjJEJZBNBKrbWAxyB9DXp82t3F/aJb6lqgmt1YMVkCIWI6ZIAzXmUnhPSXZmhimV155nclD+f3TT7bTNPicRXdhEsmcDc7MH+mT+lAHp/h/wAR2MusalBcX1mgijXy906jjv3+lX28Q6Kh51O0AHBCybv5A15v4Y0myl1O6mt7S0jaJuN0KsDgdDntXd2i2cyKFsbe3m/u+Sq5+hxzQA6fxboW3YmpqxHQpDIT/wCg1BceLdOt7OWS1ttRv5gvyQwWzZc/U4rR8oxjACofYYpoZxkl269moAxPDvji61AzR3nhXWbExjh/KUoT6ctWm/iG9jB8nw9qEm/+9IkYI/WrXnMzESOzL7mm7QJDjoPfNAFJNY1qTpoMaDt5t+P6JTL2+1y4srhXsNIEaDePNmdypHcYxV/Z8pdmAUckngCue8RapHLYyWWnvueXCvKBxgnovrQBnNp2t6to8+mSXOmwNfkM7xwOzKAcjq1d/HJ4htLOK3XW7RdqgYisQCf++iazdEg+ygHaXn2hAD24rpLO0KMJJzlzz7CgCtZaZq4Bkm8SX6O3Xy7eBcfmhp/9kXNw5afX9ckQdMXIjBP/AAACtCWXzDtU4jXqfWo3uiSEQcdBigDOvNMtYotslxqt1K3Co2oT/Mf++ulUI/DOkw5lmtPMuGHzPJM8n4fMTxW6NsRaSRt0h7+nsKozb53OTtT07mgDBvdK0621bRJbOwtYZvtgG9IwGxj164rtZoAhZ5Wx71zGrMIr7Q8DJ+2rwPpXSzwiRvNujkKchc8D/GgBsDohLBQqjuacWnviVh+WIfekPQVxOs2+ra146GmW2vX2jWEeni522qIWkYtjJ3DpVhvDetYCr4918RL38qHH06UAdeCIFMNuCxJ+ZiMD6mnCQP8AIHAUfeYdT7CuIHhvXZjhPHev+Xnr5UPP04pz+FNYt0y3jzXgx6L5UP8AhQB2t5qHkL+5IDkYAA6UabDM7ebKSWPPNcdD4N1gOHn8d695x5CiKE7frx1rQ/4RjWo4yx8feIcDt5MGT+lAHoNrhrpCZAXEeCuecZ44rm/iJ/yEPCH/AGGE/wDRUtc/onw91wzTalceOdbW9ueGIjh4QfdX7uOBUHiHw5qela94SnvvFOp6pEdVVfIuEjCZ8qTn5VBzQB61RRTJpFhheWQ4RFLMfYUAeP8Ai+Vj4ov1EaGOS9t4t2cnIUk/TtTviTfxWGhRtJIBkNjP0rIsb59R1BN3lbtSvZLskDqEI4H0AGT71j/FyGbXNdsdCtyQhj3zMD91c84oA8jlTUPEd28Gg2rygfK023IX2B6Zrc0n4TOxVtTvI45m6qG3t+OK9R8P6JHbWkdpZQsYIxgR24wP+BPXT2um3aACBba1HsC7fiaAPLIPhDpLAAtdynvhT/jVyL4J2EhAiXUrdT/ESQB+terfYZTjzdUnHqsQC/41G+l2zt89xfufU3BFAHkOqfBaaD5LO+v5PVgzY/nWJP8ACfU4WxHqNwvruB/xr3b+xbTdlZbxT6/ajThooPMV5dA+plz/ADFAHz5dfDe/VMS6rJjoQZHArIh8B6zoV19vsBFexjl4wclh7H1r6WuNHnZcC7Dj0ljDfqDWRdeHZtpdbaJiP4oHKH9eKAPN/Amurd3kMLh4pY5WVo5BhlyOhr2bS9tx4egXr8jIRXl3iLQJzNFd2qut9GflMmBvHoT0P513PgG5nm0mRLmJo5IpOVPOM0AO+F08un67bWznfbzwPDvz92RHJ2kdjg5r2GvCXu5LLX9ShiOyWG5juoe244zgfUFh9RXtmmXkWoWMF1bsGjlUMD/SgC1XE/Dz/kO+Nf8AsLH/ANFJXbVxPw8/5DvjX/sLH/0UlAHbUUUUAFFFFABRRRQAUUUUAFFFFABSOyopZiAoGST2paz9SbzpobMZ/eHe+P7o/wAaAC3Vr6ZbmQEQL/qUPf8A2j/Sp/KZtQEp4RE2j3JqSdxDAW9OBT4wQg3HJxyaABxkVXcYNWqilWgBseB0rmvGN4s9xaabGdzZ8+YDso+6D9T/ACq1q+tJZu1taBZ77+5n5Y/dj/TrXLDahmEubme4Y+ZIGG5z/MAdOOlAEGoXcolURXKwtB89zGMYCf3s98Vy11PA9jaSW6zTWokbzY5yUSQ+jD6dK6kRSSGNUhto7tGCuh+Y+T3GT1rF1HTbqSO4tdEgJiM+ZWaUbcAfdwR0FAGDBFbLqgjt4gIZD5oiCkkEDPlhvf8AlWp4fWcpf3OlRCN2cBI16YH3sA+lS6ZEb1rq704Mt1E4hAkdQgYDBdRjr7VC7zTag893G6EEQ8MNxYjHSgDqtPslUI26VJFbzZOcqzMOR+FczrCSP4uvWiA2hI0Y+pwa39Cli80W9tBcGGMkec3CHn0PeotOjnuI729ihinE9wxCPwcL8oIP4GgDm30zzL6TAEbKowQPX1FS22hRSz7bhEKk8q4yh+npW1FHELiRn82B2PKScj/P41cVImYRNKhZwflPcd+KAMvTPCsVh532ORf3jFioOQM9q07yzxpghkjD4PSq8UUlpMWilVLdeSgjJ/Lmr4upJkUhW2nnkUAZdxby2kK/YriZWxny3O9f16VMk0gujay+W5WMSFlGBz2q+z5PKrz7U1ostvjVCSMcnFAGS9/J9uitUtYt8gyrFsVNIb2NioECEddqk5q29pGbmC4lQJJFnBBz1rRMsI5JXJ9qAOX1e2urywZQrOT/AA44/KrOk+HhLNDJcgLIijGegxWxLeptKwoxbHpisdrqe7neCOWMTxYZow2WUHpkDpQB1K28NrnaAW7t60h3SZydqfzrmowI7tJ9Ru55HHCQFtqn8B1rcLzSou1PLUj/ADigCRnyNicKKEYL8seCxpEh2r8zYHqalRVjDMAFHUk9T9TQBAEfA80rvPbsKjvEWwtTPt3KzgE7hznvzWZqGqLPcNaQRSzXIG5YIvvv7nsif7TY9ga1NG0a2mu1m8Ti3v7mdNsMZBa3hXuiA8E+rHk+1AGRq5Ed/ojv/wA/oIH4V0jz75Czrk5+Udq53xBp66XqWgWKKzlbtdi7i3y47sa6CdBEWJI3E9f6CgDlnm3fFKfzCedIUdf9sV0nyuAZm2xDoPWubtLRpPijL5gIzpCkZ/366i7iiX5T8zdgOaAHrfW8cZEa5YcAVWS4LTb2I3dh6UkFi7HLKysewq+tpDCuXfL+g7UAJDIsa7mOTV21bJEsnTspqGGxVjvmf3Cf41ZVMtgMDQBrafcCYMoxlewrl/iL/wAhDwh/2GE/9FS1s6O2NXvY8jCrHx3HFc98VbiS1fwrNDA1xIurptiVgpb91J3NAHeVwPxK1iaa2fQ9Km8qaQBr25B/49oeuB/tt0A96z/EPjTXTK1jY2EVpc4yw80SSKvryAqD/abIrxLxv8TLfTbZ9P0uT7ZfzsfOuISX3N3VCfvH/bPHoOKAOt0XVYYvGVgLlkjjSJrdBu+S3H8K57serH1r0K907Tp7lr24iiMhUKXLgZHoa8F8AeGtU1e6XUdUX5pQTFZhvkhj/vOx/rnNd8NG0yG4S2lX7fqJOVhjLMFOewJwB7tj6UAdrLrWnWieWkocKP8AVwLnFRJq91dxeZZ2D7AM77l9igfWp9K0C/eEfantrKLOfLhjDuPxPGfwNbkXh+xJU3Ecl2w6G5cuB+H3R+AoA8+udd1zfKBPpgA4VbaN5H/Xg0iXviB1JUarIfVLQKp/rXq0VvFbLiJY4h6IoUfpUEuoWsb7ZZlB6YZx/U0AecRR+JJcMItVRMcmRe/+FSrbasFH2ubXI5PWGFWU/nXpCPbyjdEwK+o5FO2LjiTP0oA8umvNXtdzR6ldFVH+qurVdzewIFXtL1+6nAEzWwlxko8bRn8D0NehFWxy+R+NU7jTLOYHz7S3fPfywD+fWgDnptRgRd11aTFcZYxr5gH5VBHr2hxRySJqEECAZKPlWx9K07vw9FtBsLia3K87CxdP57h+BFYmqxeWoXxDZrJDuwl2i7lH+8R8y/Xn60Aefa14ntT4ju5pw0dtcbRBI/KSKAB+BOP5HtXe/DvxgmmyxWmoHZp10+1Jc/LBKeisewbt7/WuR8feBp5tPW40yKHUtPALSxKcTID/ABKRwQPUAe4auM0bUm8PMkM0iyafOBCzzKGQg9EcHgg9skc9COlAH2CCCMg5HtXFfDz/AJDvjX/sLH/0UlefeGPEut6DFttJ0m03ODDeFnS2PZRJ99Qf9vPtxXX/AAbvp9Sl8WXV3DFDNJqp3JFIXUfu06EgE/lQB6RRRRQAUUUUAFFFFABRRRQAUUUUAFYl1c/Zr++uSu4wRKqjOMk84rbrktcZljmbJ/eXYB+ijigDTstWWeYW18iRStymGyre2fWtodK8vvZd5IflSa09I8RXdmgSRjdQj+Fz84Hse/40Ad7XJ69rc808lpppKRodstwvLZ7hB/WtK51qCbQri8sZBJtTGO6npgjtXB6vefY1gsoGCyyLukYdVTvz6k/1oAkM0Nn5kUXmO27LImGB/wB5j3NU7nUroti2NrbDHUR+YwP41RkuRsEcQCRjooqHOaALi3upbty6mu/HV7VSP51c0nUzLffZNTRLe6kX908L/urgdyPRvY1kCp/sv223MDHbID5kL90cdCKANDxDEvk20ko8kRzZWOMgbjn735VkWVx5WtzxFcWtwWXeo34PqG6VdaS1utBF7ewRmVid2/JCzj5SAPfBrL8PpGb6C3tpLiJid7lwGGe6gYyBjvQB0czpY6Td3cEkrvKgjjEnALH5RgfrVq0017DT4UinK+XGNwPrjn9agutNi8SauNOa6ltrTT8TSvbvsfzSPlUEdMDn8anvvDOoxCNLHxPOyswBW8t0kyBz1AB/WgCWK3nEAWVUmzzk9eayrrT/APicJcNEVQQlFH+1nJx+GK14tL8TRAnzdGvAOgXzISfzY1Ddf8JAoU3HhoyFGyGtb5JPrwVFAGdDAwJCzTp9Hpn+mWrzPDcSagycrA0qqVHce/tUl1qN1HJ+98O69H7rbK4/RqoXeo2O9XvdO1CMjkPNashH5ZoAvy6xaK0UV0/2aaQAqsgxz6Z6Zq5FdQM5jEyFx/CDyK5OHWdHMr5uL23C9pI5WU/T5aVb3wybwXS3MZue0otJN/57KAOule3dGV3BBBzzWcmtaalpJJHMlysJ2t9n/etnsMDnNZdm/he3uGntkbzpAQzJaSZYHr/DV5dQ0y0Cmx0zUmH92CywP5igCVrm91C2t5NPDaflsyfaIsyBfQL0GfetCGERySPBDHE0py7gcsfU1SXV7yVA1j4c1KTPTztkI/PJpwTxRdoQun6dZZ6GW4aYj8FC0AWJ4tkgkkZWb1x0rViuozZ+fIypGo5djgD6k1gJ4a1a6yNS1xowR9yygVP/AB5gW/Wt7w34O0a3lV7q2OoSjpJeu05B9cNkD8KAM6PW4byXZpMFxqs3TFmu6NfrKfkH51cTQtZ1YKurXKabbMObWxO+U/70p4X8M13ZijRQoAVFGAo4A/CmmZIxhF3N7CgDL0fw5YaZbGC3gSKA8sg5Ln1djyxpdb2fZ1SNI1VCGBxzx6Cpprp0y87DH8MaDP8A+usu+dZ45f7Qg8qBhhd8h3v/AMBHSgCj4ohfVdP0vU7V2jFpN50gEZMjgDG1R60RJiNJpEdGYbishyy59ferXhaUvDdWZeTzAS6GZstz7DoPapJbIIgM8hkl7ntn2FAHCvdSy/FOYQcf8ShRn/gYrqoMo2er92PaueOyH4qTKFGf7HXgdvnHWupW3aQZXvQAsNw2SIhlu7HtUkblX3L80ndiOn0oC+XhSePSmib/AJYwIDuPLk9KAFmuP4QNxPU1aslXcCcimJBCmS+4Y6sRxWF431RtM8O3sli2bqSMxW4Hdm4z+FAHTeHWWa/1O4jlWSKSRQpU5GAoHFcv8ZmC2/hgnd/yF4x8rFT/AKuTuOa6nwVpR0fw1YWjndKkKh29Tjmqnjzwu3iiwsoYdRl06e0uVuo5o41fkKwwQ3BBDGgDxXx5b315IunaWpkW4b5oUJEROfvSEcv9OlYum/Dm0tb4RNOJZl+a/v3wD/1yiA6dO3QCvXY/h3riXBnXxjJ5hGM/2Zbce4+Xg9qq6t8PtbMcSHxjNliI44l023C9cnIC+g5PsKAM3RNCudaHl2hfT9CXADgYluCPT2rvtH0PT9Gt/LsLaOMH7zHl2PqzdTWbH4Q8URoqp41kVVGAo0u2wP8Ax2qer+HfElrYXNxc+OpVijjLORplvnAHb5aANjUPEukaa227vIVcfw56fhWZc+O9CCFhfqQBkLGpJNcvpHwq1bVNNgvr3xXMk06+ZtXT4OAemcrnOKur8Hb4dPF1x/4L7f8A+JoA5/xR49vtRVrfRYpLaE8GVvvt9PSuGe0vJnLyNM7HnLMa9fT4S6in3fF0/wD4Lrf/AOJqdfhfqq9PF0v/AILbb/4mgDyrR7nWtHnEthPMnqjEsp+ortbb4haqkYE+lRO/95XIzXR/8Kz1f/obpf8AwW23/wATR/wrPV/+huk/8Ftt/wDE0AcXqPj7xHI/+jwwWyjsFLH9a1vDHxInM62+vQqiscCeMcD6jtW1J8LdVf73i6b/AMFtt/8AE1Xb4RX7dfF0/wD4Lrf/AOJoA7mGSO6iWSJkdCMhlPUUkifKQw3KeCCP5iuTsvhrrtiALXxxexqOgFjb4/8AQa0x4R8VDGfHE7cY50y2/wDiKAKdxoc2mXbah4eJVycy2ZbCSDvt9D7dK4/xb4SsNaiOraYnlW7sUvbRo8iNj1Yr6eo/EV3n/CIeKMY/4TWX/wAFlt/8RVceBfEa3r3S+NZxI6bHX+zbba49SNvJ96APPtF0K/8AD1zHZCRmiwBCXkBZFPRQ54ZfQNwemQeK7X4ExvFB4qjkKl11VgxWAw87E/g7VYb4f681vDC3jKVo4j8gOm2xwP7v3entXQeAfCR8J2l+kmozahPe3JuZJZI1TBIAwFUAAcUAdTRRRQAUUUUAFFFFABRRRQAUUUUAFcvrsDNb3sScyJKJ19wetdRWbfRr/aUDEf6xGjP060AcBeRnJrMZmRutdXqNltlcAcZrnr22KseKAMe7zJvKySRO3V42IJ+o6H8arsXaZ5ZpGlmkxudu+OnHar7wmomtzQBDEpY1ZWI4p0EeDVwLxQBR8sirVjkTp9aVo81NYxHzh9aAK43pb6zbxpGyRXayEv0QEKxP86r20MWlSalrT3T3koQeSmwgszDgY757AVbtroKdRmGwx3F0Vbf0WNVClvzHFbGh6elzrMEcYzp+lLuHcPMw4/IGgCn4ENumi750XUY5y07XturbmkJ+dJF6qynj6flXU6XeacZwtjGwBBJEgbOf+BVla3oN5Z6o+veFGWLUmx9rs2OIb5R6j+GT0b86v6VqGm67me1jaHUIlKzWcg2yIR1BFAG/9qIGFh/JaYbmZiNkOPqMVWtZJmjxFaY/3jV23W7z+8jQD2oAjlS9mT/XCH/dIFUJ0a2+a4vJZD6Bya22hkbsBWJr2nXEsR8qcRkc5CA4/OgDIu9ZuGkdFsNRCKPldVDBv1p9vf3csK75JoweVVxtYflVizuo4IQkhDyjgknGT9BUDTy3MbSQW68k4Zl6/SgCa1upA7LLPKQeQdxq4CjdWaT8Sax4ob2VsxqiN67ehrRXTr2ZAJZ2A7jNADy0cBOVRFPd2C/zqOW+hRf9cpPoik05vDqSwsJZeSOM+tSWlhZwxATsDIvBGaAM64ui5DW8DyEf3zx+QpC9+XjJconXYo21sNe2duMRoCRWVqWrkqVRVHccUAdLpzvcRnzQRjG0+oq0YlxgnH0rl/CmpzXDyRvgL2B610/lN160AV5hHAhMYIz/AHBljWXc2puNxdvsyt1K/NKw+vat0xEjDEKvtUOILf7oBf1PNAGHaJa6XqlvFDF5bTg8nlmx1JP+NVJoLpfEFzK+oTSwhcC38vCR575HU+5NXtTniSeJzjzi4+YjJ2+ntWfr2LPW7fU5ZgtpLF5bK821Q+eG29zzigDmgVX4rTcf8whf/QxXWrd7VIhAL46noK5K5hx8UpdzhidIU4Xp98d63YZN7bACFBx0xQBoopkjw0hY/wATkfyp0UKom6JsgdTRFuRd2fl9+lQy3MYfauD7Hp+VAFg3rupiQ4HTd/hWBLDFr/iKBFdZbGxIMpU8bxzj65xxV28e5Cobcpy3zFxwi+v/ANapdH09LGIRWSgRsxd37ux6saAOzt3V4lKfdxTnrN02XbP5AViNu9m7A5xj9K0m60AKOBzVdY4riSG6wSUB2c8YPf8ASk1Of7Lp8839xCQKxfFGv/8ACN6PYyR2E9/cXUyWsNvAyqzOyk9TwBhTQBuzzrGOvNcj4mlbU7rT9GTn7XLvmGf+WScn8zxVGfxD4llPPgbU/wDwPgrP0TUfEtnql7qN34Hv3uZz5ce29hIjiHRevXufegD1JFCIFUYUDApa4d/F/iFEZn8DaiFUZJN3DwPzqrZePdcvbWO5tvAurtDJypM8QJ/DNAHoVFcKPGPiIj/kRNV/8CYf8aX/AIS/xF/0Imp/+BUP+NAHc0Vw58X+IgCf+EE1Pj/p6h/xqnb+P9auLs20XgbVvOC7yGuIhx9c0AeiUV57e+PdbsoDNc+BtWSNTgn7REf61NL401+KLzH8C6psxnIuoTgfnQB3lFeX/wDC0r/58eCtXOw4bE0Rx+tTWfxI1S8i8y28E6s6evnxf40AelUV5g3xQ1FXKN4J1gMDggyxcfrVmP4h6u91BbjwTqglmUtGGuYQGx2znr7UAejUVxH/AAlniP8A6EXUv/AuH/Gl/wCEt8R/9CLqX/gXD/jQB21FcO3i7xEqlj4G1LAGT/pcP+NdH4W1qLxF4fstVghlgjuYw4ilxuT2OKANWiiigAooooAKKqabqdhqaztpt7a3iwTNbzG3lWQRyr95GwThhkZB5Gat0AFFFFABWfqp8ueylJICy7T+IxWhVXU7c3VjLEv38ZQ+jDkUAZLReckpPJWRlP51iahaZzxW9pE4uZZVIwJVEoHo3Rh9cipLyz9qAOCltyrHIqFoq6m6sQc8Vlz2ZGeKAMdUx2qYAYqSWAr2pqRmgBUjzS3b/YNNubrGWRMIPVjwBVuCPOMiqOtSwvqdnazMRbWxFxOFGdz/AMCn+dAERRdJ0xUnjWaKOFSQwGDOW4HuSxrtvD1i2naPbwSYM5HmSsB1c8mvP9VRtQfTII43giiu0vZlIIJG8qgOfXJP4V6k33jQAleS/GzULrw1qui65YgorsYp3jGGJGMHPcgZ4PUcV62Mn3rmfiT4fXxD4QvbNgPPRfOgLf315x+IyPxoAqeCfHFt4rtikEqQ6rGu4xg/LOn99f6jqK1H8VxQXDQzTHzFOCohfIP5V8qwG60mb7Xp7yJHvEqmNsPE3cqexzwR3r374YfE608RmGw1VbX+18YSQEAXGPbs3qKAOzHiBJCNssuD0Ahf/wCJqtf+bfbRA919pQ71JDBG/wBlunBrblv5VcqbTbj3I/pUsckkkYOFHtk0AYkVgYishVIGblhjkfjU1tFZ2pZ4RliclFJCk/TPH4VoXUE86IoEe3PzjnJHsawr6zuoJQINgHuKAGX9/dpOpihjhiJ52Ekn8ai/tS9EwRnXDdMVX1XS76aEu+qJFDjmNF7/AFqtpkUkMLKxWVl+6wBH6mgDWMt5IOXaq8trO0gk34I6+4qSGSaVQQtWCShXzAvPHTNAAmnxkB2l+tEsVjHHliGI9aq3l2lm+25kWKFhkMxwBWFN4n0C1Zll1SzYjssoc/kKAOm02/soJS6Kq7eSScV1y3KSQLJEchhkV4rN4htbiU/YrXUbpT0MVnJg/iRiuw0HxDqj6YkcHh66kkQYDXFxFFge43Z/SgDsnlY/ebk9h1qqbe4nJA/cp3buawjqXiR42CwaLZMehMskzD8AoH61nXR8RXQ23PiIWydxaWiqT9CWyKAOongtoYntbaNppiCXYfMV9yaoarPHZaLb3t28SJbtucyMBhDwev4VycukQCNhc6pq9wD97fdbVP1AH9aNF0HR/InE2nRSmPJBlLOcde5oAwU8XaNffFGWa3v4lsxpax/aGBIJ39FCgkn8q7jT9T0rUpbhNMnN1LbbfMBjdAuRkfeAzxWVqAstC06e6it48ZyiLGuWc8Kq8Z5NXfDttNpdiv2gLJcTEzXTE8tIeePYdAPQUAaAuHkO1jkjoOwpZYhhSPnfrkDgfSp1jW4jDqCqnkKBg0ROIjgj86AK8DFG/fD5a0WvAtuwtNof0YZFVplFxwnWqkVvIspYqwCH5c8Z96AOu0mLbbLK6YmkALc8+1W+9UdHlc2+HUjHNWEmDXRiA5C7j7Z6UAZ/it2Gl+WnWWRI/wAzXO/EVsT+FIz21iL/ANFyV0Hihjs09BnLXSdPauI+Id/JN4s8LWMChlj1SOW4c/wApIFH1ODQB6lQaKhlnRJBGCGlIyEHX8fSgDJ8QXLTQJp1uClxd5VgeqR/xMfw4H1qeGOKBYIANoA2ooHYVYtLFIZ5riT57mb7znsOyj2FWUznldtAFG4aOJwGbaOmSKnKLIYgpBQHccc5qbYDkv8AMPcVHEqjcyqBn0oAbcyrFbTysQAqk5PSuN8DTNea9e3cikO8Q4J6c11WpFXsJUDcFTkjmuL+H10JPEmrwjGYo1wR+PWgDX8Uxedo90uM45rQ1i1bV/BssEDmOWa3/dsDyGxxTb5Q9pOp5BU1Z8MN5vh61BOSI8UAeJP5z2qRW8zx38ACOAPvEcFSO/8Ajj1roPDwe1i86Mbo3HzqBxnuR6fTtVzx7pSWeox39ttRi26QDj/gR9j0P59q3vDQs7+1DxqElHEkfoaAKrQQ3gB48w9Cf4vY+9VW0y4KCKNmV0YPDKBkow6V0/8AZEayZQYU9RWhFAqKARnHegBuga19s22l+ot9TRAXiPRx/eT1H8q26xLqzhudhdcSRnMci8Mh9j/SgaheWWPtUJu7cdZoF+cfVO/4ZoA17n/j2l/3D/KuV+Ev/JPdG/64/wBTXQxX1tf2EktnMkqbSMqehx0I7Gue+Ev/ACT3Rv8Arj/U0AcL8c760034kfCm81G6gtLSHULlpJ55BGiDYnJY8AfWsz4kfEXW5PF8Fj4X8R6LpOgz6a1xZ6zPdxC1ubgOVZfNMMyttwcxjYxwfmHAr3uigD508RePfHem61p+hxalDPeeKrPT5NJu4LVTFayFlW5Kh0BZSMuBICQCKk1Lx34zXx/rFg+vaRosemajFDBY6nIqNf22cb0jW3aSVpOuY5FC9NvevoeigDyX9nT/AJBnjn/sbNQ/9p1yBTw83xm8FXXgmXSruEz3QuYNKiaK9hBQBnvZCzM6hg2FdUIzjmvomigAooooAKKKKAOd1NTpOoLdLhbSdxuP/PKQ8ZP+y3Q+9b4AkQFhyRVfVRC2m3IuUEkPltuU9xiue0DVpbB00vUzl1TzIZf+ekR6HPqvQ/nQB0M1mrjjrWXc2OM8VvgggEUyRA4waAOSmsAe1VWswp6V01zGFzxWTevHDG0krBUHU/0+tAGFqlyNMsnnC75WIjhi/wCekh4A/wAfasdLZ7SRbOW/jN5dtvuZWwZGkP3QB2A7Vavy8l3FcTb47mUNFZDZuW3JH32/2jUGkiMX0Up8uZUQobiZNsskiDqM9R9KANzRtFk1hNXLXDwP50UcUwUNxGAc4PB+YtW5/wAI9fyA/aPEWoNntFFFF+oXP61L4GiMfh2B2+9OzzH/AIExNb9AHNjwfZPzdX2r3J/6aahLj8gwFTJ4O8PK4dtItJXHR5k8w/m2a3qKAPAPi34Pi8M6kNbsbWJfD1y+28iiTAtmbguAP4SeT6GvLfFPha6sC+p6XGheEhimTtkHVWBH5gjpX2ZdW8N3by29zEksEqlHjcZVgeoIrxPxt4VufB1u82n28194bCldq5eWxB7Y/ijHY9V+nNAEXww+LKahpVvBr0m2SNQrO/34yDjDnv8AXvXsMWoxsiMVVkcZSROVYeor5CuI3t4zrlhHHcW7hluYcfLIOjA+xBrvPDvjRfD2lRaYJpr3RdWjDaLJM3KM3BiLD7rIc8H0HNAHuV/4y0KxYpc6raxupwVBLEH0wAa5q88W6dNcST6cmp3kTjJSK3OA3qNxHWqGg6HpVhapDDAJZIgPNkDHczHksec8nNbMa2CqVFvx3DAt/PNAHMXPiDUbmZGs9DuAo6+fcLHn6jBP606TVvELbf3OlWbnuySS/wDswH6VtFpUjI2qpU4DKuM+nFUriJLgp9tkBUHO0cZP1zQBTD63JIRJrbRK3O22tY1/VgTUTaJJdMTe6nq9z7PeOi/98qQK19qIgI7dDTxIByuTQBir4Q0jJd7C3eT+/Ku9vzNXLeCzsVAiijjK9Qihf5Vbd5pMhVOKhFvIZMMBgjrQA6e5BUPEmSPaptM1JorjMzBFYYwarravtK5YqPyrJvL3TrMlbi+tkcHGzzAz/wDfIyf0oA7e48xwPLbr3pILEAZkYk+pNZek6rcXtsg0zR9RumxjzHjEEf5yEH8ga0ho+u3YLahqNnpdvn7lqplkx7yPgA/8BNABe3GnaTCZ7po0I5BkOMfQdT+ArGtpNY1a/wAaRZJaWs6H/S9RQgPxxtjBBI9yfwrpdO0HRtNZZ7aBr297XN0xlfPqM8D8AK03V4XiuLgncXAyaAOB0KCTXNXb7QVaDRXMT7R8klz3wPRR+tb10mx/n5zXmnjzX9S8B/GDz9MtzLpV9Cst3aKMBwOC4HZh6969SkuLXUNNg1OwuUexmUOr4+77H0oAitBIZ98JwMc7jgfWrriOZA0TBieCcd/asKS9eZmYqducDjAI9celW7CCRF84yBEzwCeW9gKALPzQ5wOnU1atJ0kYBiM1DcBrqFhCwjf3GcVVtFYMu6N42LbQG6t7j2oA7SMKlsMHCgZJqtpEi3EUl0oGJWO0+oHAqHUjL/ZywR7g0vyM4/gXuf6VoWiLHbRIi7UVQFHtQBn6+mVs5MZEdwpJ9M8V5/4jeOBLG+lDmR/EiBto3MQqSKoA/AV6ddxrNE0b/dNeX/ECaXTbe0EWwyx6/DMgfgYaNzn8yRQB31xd3MsO+Y/2fAe7ENKw9h2P51BZzWca+XbZVW5Yk5dz6sepri77W23eZdXGWGeT2J9K5y48bW0N39ns5TPcZA2RAuefZQaAPZhdIGGWHsKf9vgU7WcbvrXjcep67dPI39l6okCcmdoCF+oHX9KtaVqsrK8t157FW2iNULOx9l60Aes+eZT8pwtVtbvGs7BzCA82MImcZPTP0Ga5E+J72O2H9n6Bfykj/XXLJDGv1y2T+Aqt4eXVdbkurrUJ4BJC2C8RJjQY+6MjnHU++KAL2s+JIbXQrsoGLQDy845dvb8a5r4X6nFYJqN5fOTPdXG3bjoO1YnifUWutSl03R5zcHeEjbGUt/8Aab1fv6Cun0nwleWlhGi6gwA+ZmdVPPckkUAbmt+J7K1ikhjWWaVwVAReAaTwP4hh+wy294RbTwOwCScbl6jH4VnxeHVuZCP7aMrjqsUiZH5c1W1bwjZJbgFpjPICI5t53rIOV5/OgC74mC+IZv3cq2zRAPBcAh1cfxqR6Y5/Os/wuptriYQODJCdskQOSn+K+hrm/CXiKzsNYfTteTypLhvlmX5UYr/EB2b17EV0XilbLRtStbyOXbbXGEhu7eQAj/YY8gj0zQB28OqQgqkx2O3TPerD6hCq7hvZe5UZxWDp+n3eqWvn6brSSJj/AFFzbhgT7kEH8cUabJq1zqZ0u4s4dPkRdzzOfMEg/wCmYGM/jjHpQBtrqtoV3F2VR1LLjHv9KsrGjOssTnkZ+VvlYfSqE/hi6lbcut3MZ64WJNufpj/9dUZNE16yz5M1nfxYyAgNtIp/2eWU/Q4oAn1+O2iWSe7gliQqQby2Yq6cfxFecUz4P4Pw30Mhi48gYYnOfeqUPidbULZ6zFPZXDqyBbpQu7g/db7rfgc1d+EOD8OdExgDyO31oA7GiiigAooooAKKKKACiiigAooooAxvE03+iR2UfM944jQegHLH6AfzrL8S2EtzZR/YyqXtoQ9s7dMgYKn/AGWHB+tWos33i+4nHzQ2UItwf9s/M36ECti5tvMjPrQBgeGNeS7gjK5EO7ypI3+/bSjqje3oa3r3UrWzIWaUeYRkIvLH8K4jVtPvbPVG1LR3ijviuyWGcfublR0346EdmFUoL65TCatBJb3tySDcLh4mcg4APXHpkdqAOn1LXHkQ+RAsXbfO2APwFYM7BbmFr2WWa4kyqNs+SM46gdBVWyDXQjRjHqFlEu5bt2Hzyg9MDgYrnNcttU84RztJdNqJAFv52I4trZ2ggjJx3/nQBXnuri+tYbkNcX62M7M7sSGJzx8q9j0FaNjFaXMl5cie6mltlaYCZiPIZhgrjv8AWs+8d7a/mg1sva22FfFoAcY4BHrxnJPNb1jEH8P6nOkPkNcbnCsuH29s5oA9M8PJ5ehWCHqsKj9K0aqaRj+y7THTyl/lVugAooooAKRgGUhgCDwQe9LXmXxb8azaVs0PSGK6hcJulmU8wofT/aP6CgDidW8O2MWu+JtO0xGjtXnB2Y+VHZcsF9q810PSom1/UvCGrXBawjk+02KH7qXRALDPbjt612fw+upbPwve315PLd3Mc0kkhmcuzSscImTyTWd4i0N7Lw/LfoS2oGUS+Z3Muck0AUvEWqa34VezmgndLlWEdtcSk+W6nrHKO44/A17F4S/tTxBocOo2erWPmsP3sEtoAYn7r8vP41yelwwfFHS49PltoYEtCn26WXlhJ1CRj3Izn8KzRoV94I8T3JZbyWzuYxF59tMySqoOe3Uds9cUAemzWfidQVR9Bm46ssyf0rPuLHxO+N1nobsPSZx/OuMuvHOnXImh2+IBG2SqreOik9gTkkfnXCal40vdBuImjtVM04O2NrmWbI9yzdaAPZJrHxNawvKukadIc5ZYZ5HZvoBVPTT4yubvyjo+n2UZ5ElyJsAV5PH8RvG05ZLdbW2TAwEh7H3JrSt/EPjqW3U3E8DgttIe1Vgc9OooA9buNL8SmMhNc0SOUdUih3EfTdUa6JdvDnUvFc6sOSLZEjx+XNeYw+LPFmkXa7YLIFsbj9nUZHfHFeweEIZ9S0u31dDBN9qjDMI7dFAPpkAHP1oAz28LaLK8clwt1qP+1dXDOD74rZtNOtLBf+JdYWlvkYykYzWrFaSGQ+YW56LgDFWjFHAmZWSMf7TUARaVcNArm4Yle+egrWCR3ipIGDR9vSuZvdahjLx2SvJNjAfoo/xq1bDULmFGkCwoQMhe/wCdAG8Zba3O2MB5PQc1Q1NmmjDSnlDuVR2qK3iMT4t03OerGrNxamC0klmcl8dKAPF/2i7Z/wC1vDOrQXJtireU0uMhVP8Ae9RUngvWL3w5cJFexwTaHfMPMaJtyRuejAdga3vivp82qeAGZVVjboXJbqpU5FcH4Wtor7QGZoXjt5Y8kwvuX8F9aAPaXVQ8jBY5B1jPoKzpfNmxsmwD3A/r2qLwBfw3+jtZuTJLZgAPj769j9fWrd1uaUm3X90DtZn+VR9PU0ASwCVTu35K9z3rb0pBNciWZR5gGAP7orCsX8yQxxiRtv8AEVwD9K2reWQy+RZjdOeGbGViHqff2oA0bljd3Qtoj+7jwZmH6LWgOB7VDaW6WsIjjyccknkse5NSOcCgCKVua8m+PlrINN0HULJJpLtNThh8mEZaYFXwPqDn8zXqrnJrkPiD/rPC/wD2GYv/AEXJQBh+H/hvNqhW88YuSn3o9OichU/32H3j7dK9G0rRdN0mIR6ZYW1qg7RRha0KbLIsUTySMFRAWYnsBQBU1jU7fSrJri6cAZCoueXY9FHqTWHEINKin1LUVjF/c/M+B9wdlFZsULatqsfiXVWK2duGGm2jDgZ485vVj29BXE+N9dl1OWW3gkxn5Pp6mgDJ8a+M7rWLh7fSXKxbtm4dEHdvrWBrPxEaOK18M+GJ5/sKYinvFH+tkP3seoHOfesPxJcm2tE07Sf+Py8PlRkdcd3rS07QU0gW8HlKJIYggYjkknLE/lQB1WgXNi/iL7DYAJBaAPJI55kkbua9B1fw7Jrqx+frcy26/wDLCPaErzf4K2YmbVr6SEXAnuWxvIAIHA616PdRN5wjWzsoZDyI7aJZZNvqSeFH4GgA0TwnY6DI81tfuJW+8XcYP4Vb124ifSLgidWmiAlVl9Qf/wBdZd3HLpTea1mYrckbrh5shSf7wUAAe+DW2RcyWM8Uscb742AKyhuo+lAHz945tpItZtdTVi0UVwspPojcH+dXfEl9d+GoBDdbLzwxqZBUsObOU9x/sn9K2tU09dS8OmB/4kaAn3Bx/UVa+HEEfi74cTaPq8yP5G+2kDJk5HA57UAJ4S1+60CWJ4pGmszgEnnb7H2969htby08SacHt5PKuU+aNx96NvX6V8z6LNdaBq0+g3x3yW/EZbpNF2/H/wDV6V3vhzWH0q6jaKQrC+CpzkY9KAPYvD+tteXE2nalGttqtvy8WciRe0iHup/TpW7XJX9ouv2NnqmmuseqWvz28p7/AN6Nv9k1uaDqkerWCzqvlyqTHNETzG46qaAJtVs7e9sJ4byCOeJkIKyKCOlcz8IUWP4c6IiDCLBgD0Ga625/49pf9w/yrlfhL/yT3Rv+uP8AU0AddRRRQAUUUUAFFFFABRRRQAVX1G4+yWFxcdfKjZ/yFWKzPEys/h7UVQZYwPj8qAM/wnA0eiwF3Pn3H7+R+5Zjk/4V0SkEcHIrC8OSLLpNk6EEeSmCPpWjchvOhlichgdpXsQev8qAGajaLOp45rg9WWM67a2RlQJC5kYFsb5McKB3wCSfwrpPFuuLZWmy3kbzHUu0kY3FE6ZA9T0FcD4ij0u2gs72d7m0vyv7mSMbpVBPzEg8d+T70ARajJp1omrW2nzmCXaE8o58pSTztA5z71SuYoVu7VW1DJhs8opU8HHTPYnOetWryYJcavDqAWWPyxOjKmxuOhJHXPesizisL8y3Opr5j7NyWkQw0uMcr/doAltIWv8ATU8qOSae2wyRKcGdM5GT14PbvXUaXaJb2N5hLxrmOIoTdHO7jOB6gVzXlW8s8N1YS/YbaI75o5ychsfIqnuOua6bQnucpb3EimNl3LKH3edkcjPfFAHoPhK4a78M6ZO67WkgRiPQ4rWrnPh8xbwvbqTwjui/QMQK6OgAooooAK+cPGElzr3xC1dokUSWsqxxhTnci/KT9c19GTsqQyPIwVFUlmPYetfL2hXK6drV/qsDia0t3ll5PMq7jj8yR+dAG3aWEem6pHpCqrBJPtk4X+KZhhQfoMn8q29YVHRYmAMcK+Y+ehPYVi28s1u/2xWEl/KTdSq/Vg/8I+gwBW9bXFpfWTOGXB+bdIwUEj60AcBZazL4E8Q216hcwXWftqAcKhPD49V/lmvfofsetaRFNceXJhdysehz647V4l4qGlzadPHNf25kc/vXX5j9BgUz4I+P4VvZ/Dt08zraDfatMuDLAOoGe69fpQBoeMvCk8F7Je2zvJC7YHy7Vz7L/WvKfFPh26tb621K+SWGCeTZHLIMnIH3R2Gfc9q+tdSf7dERp8UcxK5Esv8AqlPqfUV4l8RdDaKzk1PXdTklSM5V5EClzkfLCh4Ue5zQBR0m3UJCdoLNH1x6V3Vmq3dnIjKMvF5i49RXBaDewu1kbd2MZfADtubB9TXoWkQiL7KxbhZWjIPoaAJdV0uDUNEgnRBvK+nIIrirzwpezeM9Mj07XtR0q1uiGkW0c7W9fl6ZPrXp+nRg6fdW+OYpDge1c54s0mK90pUk3B4SQGUkMPQgigDsp1lihjsobmUJEAu53zI3uT60W2hyXDFpGdh1yxNeefDDw/bWGnprEF9q8t1IzKyy3zvGuD3jzjt3FeiJc31z8olkwfw/lQBeFhY2GDM6huuO9WLa4ku4iFJZUOASu3IrL/s8uN079K0Ib2G1giigTzWJxweF+tAGrZSYjOFwfWpnQOpaY/L71BHcts+RAT64qJ/NnfaxP4dKAMHXVju9IvbVQQshZDjuCMV87+ALmSwupbdkO6NyhCybTnPXaeDX0zfwLEsqRsFJwTnnrXlnh/4dxXHie71a5nI08uZDEDgNIfvAH+5nNAGt4OvX066kvLqecxMNv2eODe7e+Eya6qO7l1MNdaZZRmKY5825k2/+OjJH0IFWYh9jsRNazo8Cf8s40ATGcYGKLEJFrWoKhIR1SUr2DEcn8aAMyS2v4pS2uXR/s8sFxYHYEBPG/PJHuK7uzggtbdY7ZFSIDjFcx4jnSHRLotgtIvlRr/eZuB/j+FWYNUS2s4oGk3SRoqv9cUAdDJKEwOpJxiqr3aMTgjHOPp61ymoeJbeIbp51jyMAbufyHNVba71XU0zpOmzMhxia5/cxke3cigDp5L8b2Kcog5929K4Pxf4gtb7WfC9lazi4kXV4zIYlLLH+7k4ZhwD7Hmups/B32nbL4iunvHHP2aEmO3X/AICOW/4Fmq/jq0t7GDwvDZwRQQrrMOEjQKB+7k7CgDt65rxm/wBpWz0hWZRevmYqeViXlvpngV0jMFUsxAUDJJ6CvK5/Ea341PW0OIJGNpYn+9GpwXHsWyfpQAvjHXgyrZ22Ag+VQp6AcCvOdSnS2sXeXOXG4nPO31+p6D2rR8zeZbq4LfMNoHfb0492PH0zXF65PNr+rRaTbMf9IfDsvQKPvN9McCgDY+FWg3PiDXrrXZbcy28YIgJIChR1PPr/ACxWlr0ki2t/qDHG0O36HH8q9E0+1Hh7wdLb2c8MWYxGFC5PpXnPjh4rTwfqDyNgxwlRjv8A5zQB0Pwc00/8IxAZHuQjLvZY0zyeea6e636TqlxIRcSafdxBJJcEyRMAcHGM45/Oub8HW2n6T8P7PWNVu5beF4VkmmeYqBkdh2pkfjrwYB+48TXqdx5kz4/DNAFjTzY2WlXWlaNcajqct6TukugxWMN1JJHb0rvNIhtrSxggjcnagXLKctXBL448JkAHxTdNuHSOR2z+IqXR/EHhnX79bO1vrqaU/dWeR1L/AEyeaAKNxbtbrfpyUW4cqD68n+grC+GF1Lp/xA8Q6bDEjJc7blAzADnrWppKsg1K0bJWC9K/OSSAcY/nXPaHIbT4p6ZLnDXFu0ROP7tAHU/F3whe6hZR6xZW0A1CzywMcgyy91x3/wAa4rw9fx6nYorEKx5IPGG6Z9gTwfQ17vcTSKSkiKykd1rwnx7or+Gde/tGzwNOvJMlcYWKQ9j/ALLfoaAPXPhVqfE+nzSHevzJnrWzqEzeH/GVrfZ26Zq2La4GOEuB9x/+BDIP0FeP+H9YfzLe9tZSlzCc89eOCG9fQ17av2Lxf4aaKQkRXCjJU/NFIDkEe4IBoA6S5/49pf8AcP8AKuW+Ev8AyT3Rv+uP9TTfCGvzXttfaTq6iLWLDdHIO0qgcSL6ginfCX/knujf9cf6mgDrqKKKACiiigAooooAKKKKACmyIJI2RuQwINOooA43waWtdOe0dstaTyQH2AY4/TFdC9wF+bPA5Nc/dKdO8V3Uci7YdTUSwv28xVAZT74ANSPKW3RynCkEHtxQBzemTS3V7qEsLKrooijPUKcf41yl2gV7PT7hv7QmSVpZZ0kyRJ18sZ7ZAyD6jFbWkXGnQ/bWDOw8xriFATuKdAR6k44FZE8EFkI7a0tpY57pTPBcXLYkifqQR2wB1PrQBPpUF7e2lpJcTboo5XEglJDkg/dAI+YY7c1nPaJbxS6g0s8G1yUEjbQM9dgAzn1qvczQR2KC81Bp7kM7qsLrIqLnlWY8bvpUogknjtoUNvNFF+9jVXWR2QnJXAOST6UAaWnzXbzi0+2afdpsWWNJDnCdWbd2Iz3robaKBUN29qkUVsHMEiPldpHJ696506UmqSkT24t7mSNpWto02F04AUntXUrZS3Xk6VBuMlwVaYZysMQ6gfyFAHZ+D4Ps/hyxXnLJ5hyOctyf51s02NBHGqLwFAAp1ABRRRQBX1Db9gufMQyJ5bbkH8Qx0r5Y06yudXshHYNb23k3PmtHOpbKDO0cY/H6Cvq8jIIPQ182eMNKvvCPjG8kSHFhLIZoSnTYxyR+BzQAzUNJv5YlefWZVwD5RghWJVJ6qxO44P14rNsrPTLfUEnNtLczIf8ASLW6lZy5HdBkKT+HNW5dW84PLbnzLaX/AFsB+9GfUe1ZOpCOaIF2YMnMU6/eT2PqKAO3g1KC/wBLFxZQQW9vISkUEEKxMxHHzYGRXh/i7z9N8ZpqOk3B+1WDC4luFHyIw/5Z++ehFdrDqk7xPBNJiedQhkU7fMHsex965rxevnxi1e2ax0y358lVJaU+rN3oA+ifhj4ltvFXhy0uIZfItJkLLBjmNh96Mn0B6eoIrK8a+FodStLrUri1i1S4gUtEt3I0dsgHPQdh1J74ryH4N65Po/iy2tLkNbaXqbiNUPBWQD5JMdh29+K+hvE0dhqdilnqUc1xK2U+xxHaJWBxj+X86APDtKkilt/OiaGSQSKzvbw+XED6Lnkj3xXqcSj7DMcfdZJRXk+iLJbtqtmbZoUtH2YLbgpDfd3Dg8V63A4fS92cFrYGgDa09le7uVHAkTP14qnqUYaymHfaD+VO05yt3at2dADVXWZHiLqp4wwoA4H4b2JsfiTqfljNvPEXdN7AZ9cdCenpXrb6nChMcJUMOw5P6V4VfXsmm+JLfUoXkRlHlyhf44iRuH1xXuV1dPfeHYYvDGpW9g8qgxyuoIA7j1BoAYrm8kCtOis3RXbaT+BrUtNJMBBlYgA5x0qjNeW1toS22ualY38wiKzBAC8hx0AHPWsT4fXccvh/ZbzXMcybtkHn+aBycfKeV+lAHoUSDoDgVKWSIYjUM3YCqMFynlbpriFAB8xZCmPzrI1HUjdo0dkZI7Nvla5Aw8x/uxj/ANmoAZqkv9oXT28EhaMnZPIpxuP/ADzX+pq95UVtb5ZVWGFchF6cdKq6bEtqViVFEmMIi9Ix6f4mi6mW6YnBazgbJx/y2k7KPYUANO2HT0SfbEpzPMQMBFzmsiyvpHa5vpiIlmPmfMeEjHC5/CotXuGvLs2EZBywkvXB4/2Yx/Wse1aXxXrLaZpU0UdpbMPOkc/fPqq/xAdu1AFu71d9Rv7dxFJLjiztkXc7k/8ALRh29icAD61vaf4R1G+Il1q7NrEeTbWxBc/7z/0A/Guq0PRLPRoClqhMjcvK/LufUmtOgDI0rw5pOlsXs7KJZScmV/ncn/eOTWvRRQAVx/xH/wCZZ/7DMP8A6LkrsK4f4rTS29n4ekt4DcTjWIQkYOMkpIBk+negCt8V9VupNOfQNHcpe3gCTSgf6qNjjH+83T6ZNcR4nSGxgsdJsjtgtI1jA9h1rpb1GttVnuLmYTGzUyTyf89Llh0Hsi5AHvXmGtar/rbyQkM3IHf2oAg8Ua0Ird41cL8pLEfwjGCR/wCgj6mug+EHh+NFbU78B7q4AZY152IOiiuS8F6LL4n1bzZxutYn+YYyHf0+i/zr3vS9JktUSK3gcIowDIPl/KgDM8T6hbtaJbxxlG8zJJBHQev415D8V5S3hXyUwXuJNv1ywFeq+MtOeztFuJEjDO+Mh8nt2rx/4nZ+x6Eucb7pAf8Av4KAOi+KEMH9n+DtBkuxbQsdxDAFSVAwCDwav2+hP5ab4NLvlUY8t0MR/Ajisf4w3kFj4l8PNeWwuLT7Md655X3FY8eq6QoBtNdu7eP/AJ5tzj25oA725VUKA+GQrKuFMDqq/mCP1rGgt7o+J9OdtOsbKBZ1YM07SzM3oueBXM6l4ns0CZ1i4ZAMYi7+/NO8E67Y3/jXTre1huZZPMyZ52yBj0oA9D1Rja+JNeRfuu8Up/I/4VxWoOYvHmlnA2xXDAH/AHq6/wAROR4p1fccqYYyPbrXE6hdb/H1lEhyzSq59uKAPoeza4MaMIYipHd8/wBKp+KNJ/t3SLjT7mC3aGVSCGOKlgt55reJklRflGRmmzafcMxxdRAejGgD50vrG98I6ybK9OcDKSDkSIOh/wB4dD616V8OfEos9QSBnH2S5wOvCt2P9PyrZ8eeDX1zRJV8+3F3H88UgHzKR6V4jpVxd6bcTWdzGUmgfDoeCD7ex6igD3f4nQ3FheWmu2LeUxUxNKBnbJj5cjup6Gtz4Nu8vwz0CSUASNbgsB0zWX4S1W18V+E7zStQZZZBAUfJwXUjhvY1q/BuPyfhpoMWSdluFyTnOKAOzooooAKKKKACiiigAooooAKKKKAMvxJpS6zpUltv8qcESQSjrHIPut/nsTXF3F49/wCHNTMyeVqVpE8V3CTyrY+8P9k9Qa9IrnfFPheDXEeWGd7K/MbRfaIxnchGCrr/ABD+VAHBXcVjd2FlA/mWzrOkaOsW7eyjp9Pest3Jl1vZYPGtxIsfl3spWORiccYGc8A9a6ufS9Y03T0s7+OW4jVQovbBCzYHqnUH6ZHvVTUru3uHtQ97NbLDIHZJLdgz+g+YcfhQBzN9aGGCOeySO+tI5BFd2YjLjf3ZS3OR69qs2+lwpaP/AGPpcV0sEoSJ1uSGOfvFyO65rWea2vL9JolvTPAHWBba2lZPm/iYBeT9a1NH0K+ZIRaacLR1TY1xOPLX3IjBJJ+uPrQBnf2YkNlDo1pCJp5JBJDCrsNoBzukbOdoP59K9B8PaNHpFu+5zNdzHdPO3Vz7egHYU/RdHttLjYx5kuJOZZ35Zz/Qe1adABRRRQAUUVjXvijRLKQxTalbtOOsMTebJ/3wuW/SgDZrL8QaJaa5ZGC7T5hnZIB8yH2/wrOPia4uR/xK9E1GcHpJOq2yfXDkNj6LVe7ufEckHmSXGnaag+8IY3unx+O0fzoA8T8W+APFWmaiRp2lTXkO/wDdzWjA498HkD1ByKwbzSvE2mpJJqWh+TIpxIhmjYv7hQxYfqK9/TRv7Q2i9u9a1FT82Hk8iL8lx+Wa0bXSLLTxuhs9Ptdo/wBYw8x/zOT+tAHzBa+G/FWp3LxaV4ZvpEfDFpcJFz6lufyFdRp3w8+IaS26CfR9Mi/iMtwbrYPTZgfzr3tJxcgqpubwg9lMcf69atCymkjxM8dtF/diHP8A30aAPJbzwzq9i0QWx0nUJmaMNepbiGRfmGSFO7OPUYrrYDcahAk+qWsUJSRobpEB3rKv+rkQjpx1rq4zaWjhLOPfKeN33mP40xLVYHuJJSsP2g73UHJLetAHzPr1jeaZqWqXuj6Jfvb3O4TKV2lJAc5CDrnrkcfSvTdGlNxocTgMu61UEEYIOORXpMEEzyboYxbw95JPmdv8K5TxJ4fkTUbjUtFlmuJHj2z2mRtAHeMAcH1HegCunyGw9doqn4kl23ajPXNL/aEXm2yPmKaNQWhl+RwD32nmud8Y6ohneSFw6x8uV5CD1PpQBweuTh5cFdx3n5fXnpXtVh4akgs7aS3jkk0+ZVbyNwMtqcdVbkOn1rynTvCms6tAt0kSwW7hpEmm4LDrkL1Ne6eDL8N4dt1aHe0KAlIW3A/7Seo9u1AHJ3FqtvNNCGWRlc7pFQLnPsKu/DjUgmgjT44nu7yKR+JEHlRAnoW7fTrWdJcyazrt5BD+4aeXk4/1car8x+tdVptlBbxQWUCGCGRC21Thiv8AUnuaAGzj7U4+zpHf3W7AUErbQe5H8RH5+9X4h5TbmkF3eBcNKThE/oo/WrF01rZWgFw8VtbKP4m2CofMtRbIxXZbMfkTGPMP06mgCip86Oe4nnaKzX/XXBG0ygfwqOy/qayNd1kqIoLJQk5X90hH+oT++w/vHsKn8Raw5k+yQRo10oyEPKW/oz9i3otc9pFjcapdPbaexd9265vH5CnuSe7eg7UAWdGs21KdtLtd4hHzXk+eQD1Gf7zfoK7ifQNKmsILNrONYbcYgKZR4vdHHzKfoan0jTbbSbFLW0XCDlmP3nbuxPrVwUAZEb67pBHkSDWbIf8ALKYhLlB/ssOH+hAPvWto3iHT9WYxQyNFdr9+2nXZKv1U9fqMilqlqml2WqoBfQB3X7kqkrIn+645FAHR0VyUT65o/wDqXOtWY/5ZyER3KD2b7r/jtP1rY0TX9P1hpo7SYi6gx59rKpSaEnpuQ8j69D2oA1a4v4nEiLw3g4P9sw4Pp8kldpXnXxu1EaToGi3pRpDDq0JVF5LMUkAH5kUAcx8RNQttMEek2zs0khaRwTlmHVmP1rx/VHm1O/Wzs8SXczZwDgRr0LH+Qre8Yak2kpdX+sEy6tdnDKvO3P3Yl+nf8q2vhP4WWFTqWrlEnmId93BA7IPYUAeg+CNGn0TRLeKC1hjOwdZOf5V0scty/wDx8GNB6rJn+lM+12DgLHFLIOg8sE/yqeC3R+Y7Vh7y5AoA5Tx3kWNswkjc+bjaHye1eM/FNQ9hpdwePs9wG/JhXtXxBt2gsbYstuoeTH7sc9u9eJ+PS11pF5Bn/VuSPx/+vigCb9oiC5ubbwxeWW4u0ZTCjnpmvKLfSNeuGCRKJZT/AAKu419CWtufHnws0q805Ulv7I8ROcfMvDIT2zWLpsVrETHdDULWQcNbW0JVgfQnBz9aAPKB4C8XSDLWuxeuQRXY/Bnwrq1l4/hk1eO5CxxMVLHK5r0XUbNESKQ6LdSKV4P2nnHuAetb3gWyCLJeC2mtkbgLK+7A7n2oAxvEBMniXWyD91I1/Q1wEZSTx3p8kowDJgE9ztrr9TvVm1a/uYjmG4kbafUKMVy+kMD4rs1kAP71toYe1AHvUF9AIo1aAbgB0YVYbUIFb5o9p/2jUEd7aLFGoa33bRwRzmmvqAVsGK2J/wB0k/yoAtx39u4JRM49Oa8x+Lfhpb2I6zpKlNQhXBXBxKvdSP5e9el2t/OY2kjhiCA4J2YH8qtG7u54WjeBWRhjAQ/4UAfPPhDVLp4YtQ0ibZqFuW/dMcCQY5jYete//BqRpfhloEjrsZ7YMV9Ce1eJfEPwjP4e11vEOnRT/ZJcm9t0jOGH98e4r2r4KOsnwt8OOmdrWqkZ64oA7eiiigAooooAKKKKACiiigAoooJAGTwKAIbu4jtLd55m2ogyff2HvWBb32p3XiG3jQhLcIZJ4io/dqfugnruPWuF1PUvtfid/EM+szW/hLTGeBC7bxcT4yWjUDBC4KjO7nOKlsPHt9ZXuoKmjRmwWz+2runCSQ55BuZGOFLDnABIoA9apkjxpzIyL/vECuM0Xx7BqN/awyW6Q289oLhJTMGMjE4wi9WX0Pf0rI+JE9lqzJbzySWsdqBJeTIFdwCRshUH/loxx9BnPWgDrf7bnfV7KO3hiOn3LNGHJIdiBncB029q6CvG/C/jGOPUNe+3JHLqmlwqVeafEcMBGQCwUID2O0HJ710E/wAQJJb3S5LKK1TSbiUxSXE7kGTapLmIcfKpGMnqeg70Adrfapb2d5aWkm57i6YrHGgycAZLH0A9fer9eKS+N2j1O81iwSxudQlZI0FxMFW3ty+FQd2kbknoAOvTFdXD8RlTW7+wvtMmiZPL+wqrKz3hYfwrnI9ckAAdaAO/ZlXG4gZOBk9TS145beMtS8SeKJrSXSIpZNHuGENpa3e4TzBRku5UBQgYjODlm46Zr1TRLuW+0+OeeMRyN1VTkCgCfULK31Gyms76FJ7aZSkkbjIYHsa5aHwze+H41XwzLE9knSwuhkAeiSfeH0ORXY0UAclBr9uLlbTVIpdMvT0jufuOf9iQcNWx6H8j61evLS3vbd4LyCKeB+GjkUMp/A1z0nhq409d3h2/a3Uf8ul3maA+wJO5PwJA9KALclsrSeZHJLDJ3aNsZ+o6GmmKVJfM2Q3GOgcbW/PpWeNd+xy+Tr1pJpkvQSsfMt3+kgHH/AgtbCMroroVaNhlWU5BHsR1oAjXVGRNr2U0Mh6bhlPzFIY0u1L3lyZFHWOM4X6VPn0NNIBPIBP0oAkTPl7bdFhjH8VR7oImyoM0p71GbeMuWwwJ64Y0wxToG+zXIR+2+MMB+ooAsiC4ucNcN5UX9xepp7z29igSNQCeirySaqRyaht/0iS3dugMalc/mTiq7teIx2WSOD/EJuT+a0AR6jp1jqkqzapZQSOBhdyAtj0zUCaRp1rbGKCytre33biuwEk+vvU32m8BUtp8yKTgncrEe/Wr8H2fBZw5Yf30NAGO1vJMC9qBbQj71xP3HoorCtZn8J38rQQzNoN2cpKqljbSnqdvXYfbpXYXrBmVihkYcLuUkL9B0qjd2V3LIzAJKccNI36AYwKAPPbawv8ASvFF3qN5dwHTZ5JAViUlo1fo5Pp0r0BX82yh8+za6CgbZLdgwPH3h6UW2hKV/wCJhIJx/wA80G1foT1appNA0x0CrbGFB/DDK8a/kpAoAz55rKwTz5IoLY/89Lt97/gOtZVzPrOrSY0bT7lEYYbULkiMkekYP3R7109joemWU3nQWiednIkkJkYfQsTj8K0ySTknNAHH6b4NAQLqdyDD1NvbZUOe5dzy1dVaW0FnbpBaQxwwoMKiDAFS/SqmoalY6bj7fdw27HkIzfO30UfMfwFAFulHJ4BJrBl1fVLyGQ+HtDmuWA+SW/k+yRN9OGf/AMdFc8tp8Rbst/a+m6YYieILDV2t1x7sYGc/gRQB2Opavp+mjN9eQxMeiZ3OfYKOc1Uj1LU78D+yNHlEbdJ78+So99n3jWXpVv4j0olrDwPoUUh+9KdaZpG+rm3LH8TWl/avjb/oVNI/8Hbf/I9AFiPw5f3gzresTup629l/o8f0yPmYfU1taVpGn6TGyabZwWwfljGgBY+pPUn61z39reNv+hU0j/wdt/8AI9H9reNv+hU0j/wdt/8AI9AHX15/8ZJkt9J0GWXPlrrEBYgdBtk5rR/tbxt/0Kmkf+Dtv/keuL+J7+JtXstDstX0ix0u1l1WEfabfUDdMp2vgeWYlyDznmgDgZLePx54zlvWtidLtZDHZRgcNjq5P8q9g0lI9NtkitdM+4MAnFcNp0jaVqtw9kbG2iB2GJQyISOpAOdufauos9fhcAzW02e7wuJl/Qg/pQBunUNSY4S2jjX3cClNzcE/vriFPYZNQQaxpEijNzbKx/hlBU/rWlBcxMB9n+ykHoVwR+lAHB+PZ5ZJ9PthP5odt2AuMc//AFq8xvoPtkkrKTh3kDDrlVNe0eKNNa7Z9RGALeFxGo+9JIeBjPGKwbTSrDSbCNZ5ILidFiIijPmMWJO8YXPrQB47oF/rfgjXZ18Pt9psZsSvascrKD3A7Ee1ei2XxK0vVZcX+ltBMOvmH8+cVsyeEjFdyXVkkaQsd9ukmPMjf2Aydp98Gut0zQ18qO8jghBdcywyxqxDd8MBkjNAHM2WtaHcTwraae88svC7WyKqeM9XvLqwm07T91pkAS3BACQoeoH+0RxivRrGyliB3GOBG/hgRVBHpkc/rWJ4n0/TMxb4vtdy0g8mIt+7Rv7xH8RHvmgDy68tVtLSFPs+wGMeWzckJggD6nqaxriEaRrdlfSf6uG5DSegjcYJ/A16pe6Rv1byFQuyRbpWYcs7DgD6Bf1rBv7Sxt2VNatw0vRwrdEbvj+lAHo9vqVuIotiwOCo2kLnNSXGp7ARlYuP7tch4e8R2unxtbPLLdxocQeVb8hfQkmreoeJnc7Yra2QH/nvJlv++U/xoA2rbUHZSVuZJTnqFpbnV1t0L3U4iUd5WxXJSaleTLh5boR5z+5At1/76bJrHu/Iy8jvalz/AHi9w/580AdVP4ns9TimtoNrxbGL3Ey/IBjsO5roPg3j/hWegbfu/Zxj6V5TNcKYX3xythT8zYjUce+TXqfwW5+F/h4/9Oy0AdtRRRQAUUUUAFFFFABRRRQAVHcwJc28sEwJjkUowBxkHrUlUtauHtdIvJ4o3kkjiZlROSTjjFAFR/DejSWNjZvp1u1rZHNvEV+WM4I4H0JrPuvh/wCFLv7P9p0Kzk+zkmMMp4z688/jmuGtr3xLolif7UE8uqx+VEs6l/IjgZc7lBDAvuG0lgefQYrVOueKxayW11b7pzbpMZY4Mrhsrs/3slSfQZoA63QvB3h7Qbl7jR9ItbSd+C6Lzj0Geg9hVrXrC2udLu0k02G+LfvPIZQPMcfdyfy5rnPDF9r0mpRG+MrWUlq0/kGAL5fzEIobqWwOcmuPR76S7v7qwuL9riUEG+WOWOa23SqvlyxsSjEAnBUcY96AO303wJpMqwXmvWFre6qCHaVkGEPZVA42r2BrootG06J3dLG3DM28nYOvr7V5cfF3iSExm6nFtbyyLbsWh8x4W3ckDaCTtBJzuFWtP8Va7cal5DXjb7WRA8LWgHmxEFmkc4+X5SvAxz2oA9Jm0rT5v9dZWz9OsS9jn09abf6Pp1+GF3ZwykgDcVw3HTkc1ynxIur240bTZNGN2VEy3kj224M0UY3leOTu4GO9Y1te6vFZ+LdTvjfxXdxGptocMwiUKBhFHGQc5I60Ad3P4a0iVYlNjEgiztMY2HnGQSOucDrVPxTfzaSmlQ2rJa2k9wIZrgrkQptJHsMkAZPrWJ4IWG21UtYSX50yS3jh3XBkYTTjJZgGyRxgE8ZNdX4gvprG1Robfzg7hWypYKPcCgDBl1aZdagsX1VI7FrdpUvNqjzX3kbAeh2gDp1zSaNqGo33inUrYXbyW1rJGAVVAoUpkgjOeTVnVtdura4ht4LBJP3ayOrIx8rPQ8cH0wPWotO8R6hNeW0cuhzRieUJLKqcRDB4b1PA56c0AdfRRRQA2WNJYykqK6HqrDINc1N4VFo7zeHbt9MkY7jCBvgc+6Hp9RXT0UAcdJrF1pjBPEVg9sn/AD+22ZLc+57p/wACAFbFvNFcwrNbyxzQsMq8bBlI+orZrnr7wtatLJc6RLJpV6/LSWuAjn/bjPyt9SM+9AFvpRWLLfappI/4ndh9otx/y+WClgB6vEeR9QT9K0rC9tdQg8+wuI7iLuYznb9R1H40AWKKKKAClpKKADJo7UVBfXltYReZfXMNsnbzWAJ+g6n8KAJ6KxY9ckviV0TS7u9HaaQeRCf+BNkn8qnTRdavjnU9VWzhP/LDTk2n8ZGy3/fOKALWoahZ6bEJNQuoLZD0Mrhc+w9az49Yur5tui6RdXC8YuLkfZ4seo3fMw+gNbOmeHdK02YzW1mhuT1uJSZZT/wNst+ta1AHLJoWr3w/4m2rm3jPWDTl8sY95D8x/IVp6V4e0rSmZrOyiWVjlpWG52PqWPNa1FABRRRQAUUUUAFFFFABXmH7Qc5tvCGmTKSCmqwHIbafuv3r0+vPPjXpEWvaHommXEssMVzq0KNJFjcvySHjII7UAeVWmqxHLbrlCfpItaNrqFru/wBdbBz3dGiP51vT/ALT87rTX9Rhb1McR/koqEfBHUYiRbeMbsDsJIA39aAKy30UnDSb/pIko/I81FJ5Ocr5XPbYyfy4q23wc8RKf3fifT5R/wBNtNH9GqpdfCrxbBzDNoV77ASQH+ZoAgmRZVIcvj/ZmPH0o0pVtr9Ws9xkPGC+CaguPCPjHTgPN8PyzoO9hqAc/wDfLAVh32qXejS7r/TtbsJB3urMMP8AvoA0AfQOjJcy6ZEyxRRsy/MVUMw+tXLJDCpjbzPMzy+zA3epHvXivhXxbYPOJU1C1ctjK+Uc/Q7WBFd/YeLEjuPNheOa1OAyRyFmU/Ruf8KAN2eJpt0ct1BDAvLRxZBYe57ViiKOK9lubm4SNv8AlhG2CEX+9Vca9Fd6r9ngkiYofOuHzlSf4UrctLq6lXc0tmHcbieWJHsOmKAPP77VNQs7u5Npqf2pnfeWSELuP168Csdr0xN5t95ULtyZJmyx/Op/iPIbq5On+GJ7rUNbdxvtrFchPd2HCj6mqOgfBjxZqTJNr+q2ekxk5aO2j+0Tkf77cA/gaAI7nxFpsWcztL7IpI/wrOl8eWkHy28W0+m5VJ/LJr1vSfg34Us9rX0N3qso/ivrhnB/4AML+ldrpug6RpYA03S7G1xxmGBUP5gUAfNZ8ReIL759O8N31wD0dLOSX9SMVC3/AAn1yxC+HNeUnsLQxj9RX1ZRQB8snwZ4/uY2kbw3KwKkn7Rexr29M17h8FUeL4XeHY5VCyLaqrKDnB7iuyuf+PaX/cP8q5X4S/8AJPdG/wCuP9TQB11FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEckEUrxvJGrPGcoSMlT04psVtDEZTHEimVt0hA+8fU+tTUUAAGBgcCiiigAooooAKKKKACiiigAooooAKKKKACsPUvDGn3lwbqASWN91+02jbGJ/2h0b8Qa3KKAORkbXdIUm+t11e0X/lvZrtnUf7UROG/wCAkn2q5pup2WpoxsbhJWT78fKyR/7yH5l/EV0VZWr+H9O1WRJbmDbdJ9y5iJSVPow5oAhvLq3sofOvZ4beL+/K4QH8TWUmum8bZomnXmonHEoTyYP+/j4z/wABBrUsPC2lWdyLkwG6vByLi6czSD/gTdK2wAAABgUAcwmk67fNm/1KLT4TwYbBdz/9/XH/ALLV3TvC+k2MomW1E9yOfPuWMr59QW6fhituigAooooAKKKKACiiigAooooAKKKKACiiigArj/iP/wAyz/2GYf8A0XJXYVx/xH/5ln/sMw/+i5KAOwooooAKKKKACkdFdSrqGU8EEZBpaz9f1WHRdIub+4yUhXIUdWboB+JxQB5P8adB8LzrFY22kxL4guv9XPaDyniH95tvX6GuJ0+zm0O2axF4bkwj97fTYxAT/AD/ABGt2GW9v7m41O4O3UL4k7yP9RF6j37Cnaf4NvvFs8cVkFtdLt2w1zOpYE9wq9Gb1J4oA5mzmn064km0bUFubZwWmt5I2DOO+Din6rr2oXWhvbaLeG2NwSizudpiPdPYnpXrUfwj0WO1Ki5vDcEf61mBGfXb0rzjV/Cuo6FqMtpqkQltJztaWPow/hce4PUUAdT+zXqFnHoF7oRjjj1KylLysR88ysfvsepOcj8q9mr5X0a6uvDHjCz1cgiW2k+zXgA4kiJA3flg/hX1NE6yxJIhyrAMD7GgB1FFFABRRRQBHc/8e0v+4f5Vyvwl/wCSe6N/1x/qa6q5/wCPaX/cP8q5X4S/8k90b/rl/U0AddRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWN4p8O2fiXT4rS/kuolimWeOS2mMUiOoIBDD2JrZooA4f/AIVzaf8AQweKf/BrJR/wrm0/6GDxT/4NZK7iigDh/wDhXNp/0MHin/wayUf8K4tP+hg8U/8Ag1kruKKAOH/4Vzaf9DB4p/8ABrJVXUPhTpGpQiG/1jxLcRA7gj6pJjNehUUAeaD4M+HQCBqHiEAgKf8AiaSdB2q9a/DDTbS3SC11vxNFCgwqJqkgArvaKAOH/wCFc2n/AEMHin/wayVWvvhVpN+qreax4lmVc7Q+qSHGeteg0UAeW3HwP8LXBcz3WvSFxht2pSHI9614fhpYQxJFFr3ihI0G1VGqyYA9K7uigDh/+Fc2n/QweKf/AAayUf8ACubT/oYPFP8A4NZK7iigDh/+Fc2n/QweKf8AwayUf8K5tP8AoYPFP/g1kruKKAOHb4b2bKQfEHikgjB/4msldR4f0e10HRrTS9PEgtbZBHH5jl2x7k9TWhRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Level I consists of the cardinal and uterosacral ligaments, and suspends the vaginal apex. Level II consists of the endopelvic fascia connections to the arcus tendineus fascia pelvis, which attaches the vagina to the aponeurosis of the levator ani. Level III consists of the perineal body and includes interlacing muscle fibers of the bulbospongiosus, transverse perinei, and external anal sphincter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy; 2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26693=[""].join("\n");
var outline_f26_4_26693=null;
var title_f26_4_26694="Approach to the patient with muscle weakness";
var content_f26_4_26694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with muscle weakness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26694/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/4/26694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient presenting with a complaint of &ldquo;weakness&rdquo; involves three steps:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distinguishing true muscle weakness from asthenia or motor impairment not due to loss of muscle power",
"     </li>",
"     <li>",
"      Localizing, within the neuromuscular system, the site of the lesion that is producing weakness",
"     </li>",
"     <li>",
"      Determining the cause of the lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the approach to the patient with muscle weakness by addressing these three issues. The specific tests used to assess muscle weakness are discussed separately, as are the clinical manifestations and evaluation of respiratory muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=see_link\">",
"     \"Muscle examination in the evaluation of weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISTINGUISHING TRUE MUSCLE WEAKNESS FROM ASTHENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients who complain of weakness are not objectively weak when muscle strength is formally tested. A careful history and physical examination will permit the distinction between asthenia, motor impairment due to pain or joint dysfunction, and true weakness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a variety of systemic disorders may interpret difficulties performing certain tasks as weakness. Included in this group are cardiopulmonary disease, joint disease, anemia, cachexia from malignancy or chronic infectious or inflammatory disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression. Patients with any of these conditions may be functionally limited but not truly weak. Furthermore, careful questioning will reveal that the patient is limited by shortness of breath, chest pain, joint pain, fatigue, poor exercise tolerance, paresthesias, or spasticity rather than a true decrease in muscle power.",
"   </p>",
"   <p>",
"    Patients with asthenia often complain that they are weak. In comparison, those with true muscle weakness typically complain that they are unable to perform specific tasks, such as climbing stairs or combing hair, or that they have a feeling of &ldquo;heaviness&rdquo; or &ldquo;stiffness&rdquo; in their limbs. Muscle pain is relatively uncommon in patients with many types of myopathy and true weakness but is often a problem for patients with overexertion, cramps, or fibromyalgia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the history, the physical examination should include a careful search for one of the disorders that can cause the perception of weakness, as well as testing of muscle strength. In addition, two general observations may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite advanced generalized muscle atrophy, muscle strength is relatively preserved in patients with cachexia.",
"     </li>",
"     <li>",
"      Muscle tenderness is usually not associated with one of the causes of true muscle weakness. There are, however, exceptions to this general rule including infectious myopathies such as trichinellosis and viral myositis, certain drug-induced myopathies, thyroid myopathy, and the inherited metabolic myopathies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True muscle weakness is documented by formal muscle testing. The strength of each muscle can be assessed by determining how much force is required by the examiner to overcome maximal contraction by the patient. A widely used system to measure muscle strength is the grading system from the Medical Research Council which is based upon a scale of zero to five [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26694/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Zero &mdash; No muscle contraction",
"     </li>",
"     <li>",
"      One &mdash; Flicker or trace of muscle contraction",
"     </li>",
"     <li>",
"      Two &mdash; Limb or joint movement possible only with gravity eliminated",
"     </li>",
"     <li>",
"      Three &mdash; Limb or joint movement against gravity only",
"     </li>",
"     <li>",
"      Four &mdash; Power decreased but limb or joint movement possible against resistance",
"     </li>",
"     <li>",
"      Five &mdash; Normal power against resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LOCALIZING THE SITE OF THE LESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One useful systematic approach to the myriad lesions of the neuromuscular system that can cause true muscle weakness is to place the various lesions into categories determined by the organization of the neuromuscular system. This begins with the motor cortex and proceeds through the corticospinal tracts, anterior horn cells, spinal nerve roots, peripheral nerves, neuromuscular junction, and finally muscle (",
"    <a class=\"graphic graphic_table graphicRef61167 \" href=\"UTD.htm?14/13/14556\">",
"     table 1",
"    </a>",
"    ). Lesions of the central and peripheral nervous systems should be identifiable from a detailed neurologic examination. The distribution of weakness, the presence or absence of deep tendon reflexes, the Babinski sign, and related sensory defects are all important in localizing the lesion in the nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .) Confirmation of findings derived from the physical examination can usually be obtained from electromyographic (EMG) testing in a cooperative patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26694/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Distribution of weakness as a guide to localizing the lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the pattern of muscle weakness is also diagnostically important. Generalized weakness occurs in some cases of myasthenia gravis, long-standing periodic paralysis, advanced disuse atrophy from prolonged bed rest, muscle wasting from malignancy, or longstanding motor neuron disease (",
"    <a class=\"graphic graphic_algorithm graphicRef67588 \" href=\"UTD.htm?10/47/11007\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the weakness is not generalized, it can be characterized as symmetric or asymmetric. Asymmetric weakness most likely reflects disease of the central or peripheral nervous system; furthermore, lesions of the motor cortex, spinal cord, spinal nerve root, and peripheral nerve each have distinct distribution patterns. Symmetric patterns of weakness can be divided into distal, proximal, or specific distributions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Distal weakness is characterized by decreased grip strength, weakness of wrist flexion or extension, decreased plantar flexion strength, and foot drop. These patients have difficulty walking on their heels or toes. Foot drop can be detected by opposing the patient's attempt to dorsiflex the ankle. Distal symmetric weakness is characteristic of early motor neuron disease or peripheral neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"       \"Overview of polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proximal weakness involves the axial muscle groups, deltoids, and hip flexors. Affected patients may have difficulty flexing or extending the neck against resistance. One way to detect the presence of neck flexor weakness is to observe the patient sitting up from the supine position. In this setting, the head will lag behind as the patient sits up. Sitting up may be difficult or even impossible in patients with more severe proximal muscle weakness or, at times, may be the only objective evidence of weakness. Deltoid muscle strength can be assessed by pressing down on the patient's fully abducted arms with the elbows flexed. The examiner should not be able to overcome the patient's resistance if strength is normal.",
"      <br/>",
"      <br/>",
"      The patient with quadriceps weakness may be unable to rise from a seated position without the use of the upper extremities and is usually unable to perform a deep knee bend. These individuals may suddenly drop into the chair when trying to sit down slowly. Patients with proximal leg weakness may rise from sitting on the floor by &ldquo;climbing up their legs with their hands.&rdquo; This is termed Gower's sign and is characteristic of, but is not specific for, Duchenne muscular dystrophy. Proximal muscle weakness is typically seen in the various myopathies (",
"      <a class=\"graphic graphic_table graphicRef70008 \" href=\"UTD.htm?0/23/381\">",
"       table 2",
"      </a>",
"      ), certain muscular dystrophies, and myasthenia gravis.",
"     </li>",
"     <li>",
"      Specific distributions of weakness are characteristic of certain neuropathies or muscular dystrophies. Examples of localized disorders include facioscapulohumeral dystrophy, scapuloperoneal dystrophy, and scapulohumeral dystrophy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DETERMINING THE CAUSE OF THE LESION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the neuromuscular site of the lesion causing weakness has been identified, the disorders at each site can be categorized as genetic,",
"    <span class=\"nowrap\">",
"     inflammatory/immunologic,",
"    </span>",
"    infectious, neoplastic, toxic, or metabolic in origin (",
"    <a class=\"graphic graphic_table graphicRef61167 \" href=\"UTD.htm?14/13/14556\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sites of lesions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lesions of upper motor neurons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper motor neuron impairment can occur with the common acute stroke syndromes, space occupying lesions of the central nervous system, and lesions of the spinal cord. Spinal cord lesions can be related to trauma, infection, tumor, vascular anomalies, hypertrophic degenerative skeletal changes, demyelinating diseases, and congenital leukodystrophies. Appropriate imaging studies of the central nervous system and spine and cerebrospinal fluid examination may be necessary to identify the primary disease. Depending upon the suspected site of the lesion, magnetic resonance imaging of the brain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spinal cord, plain radiographs of the spine, radionuclide bone scanning, or CT scanning may be appropriate imaging modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anterior horn cell lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness due to involvement of the anterior horns cells is seen in motor neuron disease, familial spinal atrophy, lead poisoning, and poliomyelitis, which is still a threat to unimmunized individuals. West Nile and other virus infections represent additional causes of lower motor neuron disease. The time course of the illness, the age and family history of the affected individual, the exposure history, and the cerebrospinal fluid examination help to differentiate between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lesions of the peripheral nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of peripheral nerves typically presents in one of two patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A symmetric polyneuropathy with weakness and sensory symptoms is a frequent sequela of diabetes mellitus. Other etiologies include a variety of toxic or metabolic insults, as well as heritable disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=see_link\">",
"       \"Overview of polyneuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mononeuropathy may be the result of nerve compression (eg, carpal or tarsal tunnel syndrome, ulnar neuropathy, radial neuropathy). Mononeuropathy multiplex (ie, asymmetric polyneuropathy) occurs in diabetes mellitus or one of the vasculitic syndromes such as polyarteritis nodosa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"       \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, weakness may result from involvement of the neuromuscular junction. This can be induced by anti-acetylcholine receptor antibodies in myasthenia gravis or drug-induced myasthenia, inhibition of acetylcholinesterase by organophosphate poisoning, or interference with presynaptic calcium channel function in Lambert-Eaton syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"     \"Organophosphate and carbamate poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=see_link&amp;anchor=H14#H14\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\", section on 'Lambert-Eaton myasthenic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major categories of muscle disease include inflammatory disorders, endocrinopathies, metabolic myopathies, drugs and toxins, infections, and the various causes of rhabdomyolysis (",
"    <a class=\"graphic graphic_table graphicRef70008 \" href=\"UTD.htm?0/23/381\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26694/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The specific diagnosis may be suspected from the age and sex of the patient in the muscular dystrophies.",
"     </li>",
"     <li>",
"      A history of recurrent episodes of exertion-related pigmenturia and weakness suggests a metabolic myopathy. However many metabolic myopathies have a slowly progressive rather than episodic course. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"       \"Approach to the metabolic myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication, alcohol, or substance-abuse may be a clue to drug-induced myopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of features of a systemic rheumatic disease, such as scleroderma, systemic lupus erythematosus, or an overlap syndrome, may be indicative of myositis.",
"     </li>",
"     <li>",
"      Endocrinopathy, such as thyroid dysfunction (hypo or hyperthyroidism) or Cushing's syndrome, also may be present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"       \"Hypothyroid myopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical investigations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some laboratory studies may be useful in the general evaluation of patients with true weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemistry and urinalysis &mdash; Elevations of plasma muscle enzymes (creatine kinase, aldolase, lactate dehydrogenase, and the aminotransferases) are highly suggestive of muscle diseases. They can, however, also be elevated in motor neuron disease or can be induced by strenuous exercise, intramuscular injections, or muscle trauma in the absence of generalized muscle disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26694/abstract/5\">",
"       5",
"      </a>",
"      ]. A positive test for urine blood, in the absence of red blood cells in the sediment, is suggestive of myoglobinuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"       \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serologic tests &mdash; Serologic tests including antinuclear antibodies, antibodies against extractable nuclear antigens",
"      <span class=\"nowrap\">",
"       (anti-Ro/SSA,",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-La/SSB,",
"      </span>",
"      anti-Sm, and anti-RNP), and &ldquo;myositis specific&rdquo; antigens (eg, anti-histidyl-t-RNA synthase [anti-Jo-1]) should be obtained if an inflammatory myopathy or associated connective tissue disease is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anti-neutrophil cytoplasmic antibody (ANCA) titers, hepatitis B and C serologies, and cryoglobulins should be obtained in patients with suspected vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Electrophysiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve conduction and electromyographic (EMG) studies are used when the site of the lesion causing weakness is suspected to be in the peripheral nervous system, the neuromuscular junction, or the muscle itself. The EMG is also of value in directing the site of muscle biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) may be useful in selecting a muscle for biopsy and has an advantage over EMG in cases of suspected inflammatory myopathy in that the actual muscle to be biopsied can be identified, rather than the muscle contralateral to one with EMG abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle biopsy may be necessary to determine the precise form of myopathy. Characteristic changes of dermatomyositis, polymyositis, inclusion body myositis, certain drug-induced myopathies, the muscular dystrophies, or vasculitis may be seen on routine light microscopy. Electron microscopic examination may be useful in some cases (eg, to confirm inclusion body myositis). Some pertinent issues in performing muscle biopsy and specimen handling are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .) Special stains can demonstrate enzyme deficiencies and abnormal accumulations of glycogen or lipid in the metabolic myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26694/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing is becoming increasingly useful in confirmation and categorization of patient with muscular dystrophies and heritable myopathies. (See appropriate topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RESPIRATORY MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle weakness may occur in patients with skeletal muscle weakness from a variety of causes and can rarely lead to respiratory failure. Patients who present with muscle weakness should also be assessed for respiratory muscle weakness, particularly in the presence of signs or symptoms of ventilatory compromise (eg, tachypnea, shortness of breath, or somnolence) or oropharyngeal muscle weakness (eg, a history of impaired swallowing, dysphonia, or nasal regurgitation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the patient presenting with a complaint of &ldquo;weakness&rdquo; involves distinguishing true muscle weakness from asthenia or motor impairment not due to loss of muscle power; localizing, within the neuromuscular system, the site of the lesion that is producing weakness; and determining the cause of the lesion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients whose weakness is the result of a non-neuromuscular disorder (eg, those who are easily fatigued due to cardiac or pulmonary disease, limited by joint pain or stiffness, etc.) can usually be distinguished from those with weakness that is due to reduced muscle strength based upon the history and physical examination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Distinguishing true muscle weakness from asthenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom formal muscle testing confirms the presence of muscle weakness, a neurologic examination is performed to localize the site of the lesion (ie, to the central nervous system, peripheral nervous system, neuromuscular junction, or muscle). The distribution of muscle weakness (ie, generalized, distal, proximal, or localized) may help to narrow the number of possible causes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Distribution of weakness as a guide to localizing the lesion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory tests that may be useful in the evaluation of weakness include serum electrolytes, calcium, magnesium, phosphate, creatine kinase, aldolase, lactate dehydrogenase, serum aminotransferases, and thyroid stimulating hormone. In patients with clinical features that suggest a systemic rheumatic disease, serologic studies are warranted, including antinuclear antibodies (ANA), antibodies against extractable nuclear antigens (ENA), and myositis specific antibodies. A positive urine test for blood in the absence of red cells in the sediment suggests myoglobinuria. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrophysiologic nerve and muscle testing (ie, measurement of nerve conduction velocity, sensory action potentials, and electromyography) may be of value in localizing the site of peripheral neuromuscular disorders. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Electrophysiologic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the evaluation suggests that myopathy is responsible for weakness and if no drug, toxin, metabolic, or endocrine disorder can be identified as the cause, then we recommend a muscle biopsy as the next step in attempting to arrive at a specific diagnosis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient who presents with a complaint of muscle weakness should also be assessed for respiratory muscle weakness, particularly if signs of ventilatory compromise or oropharyngeal muscle weakness are present. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Respiratory muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Medical Research Council. Aids to the Examination of the Peripheral Nervous System. Memorandum no. 45. London, Her Majesty's Stationery Office, 1981.",
"    </li>",
"    <li>",
"     Aminoff M. Clinical electromyography. In: Electrodiagnosis in Clinical Neurology, Elsevier, Philadelphia 2005. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26694/abstract/3\">",
"      Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     Miller FW. Inflammatory myopathies: Polymyositis, dermatomyositis and related conditions. In: Clinical Primer in Rheumatology, Lipincott Williams &amp; Wilkins, Philadelphia 2003. p.182.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26694/abstract/5\">",
"      Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28:859.",
"     </a>",
"    </li>",
"    <li>",
"     Bossen EH. Muscle biopsy. In: Diseases of Skeletal Muscle, Lipincott Williams &amp; Wilkins, Philadelphia 2000. p.333.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5155 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26694=[""].join("\n");
var outline_f26_4_26694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISTINGUISHING TRUE MUSCLE WEAKNESS FROM ASTHENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LOCALIZING THE SITE OF THE LESION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Distribution of weakness as a guide to localizing the lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DETERMINING THE CAUSE OF THE LESION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sites of lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lesions of upper motor neurons",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anterior horn cell lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lesions of the peripheral nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical investigations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Electrophysiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RESPIRATORY MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5155|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/47/11007\" title=\"algorithm 1\">",
"      Diagnostic approach to weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/13/14556\" title=\"table 1\">",
"      Anatomic diagnosis of weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/23/381\" title=\"table 2\">",
"      Major causes of myopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29060?source=related_link\">",
"      Muscle examination in the evaluation of weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7369?source=related_link\">",
"      Overview of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_4_26695="Enhanced elimination of poisons";
var content_f26_4_26695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Enhanced elimination of poisons",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Michael J Burns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Larissa I Velez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26695/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/4/26695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unintended and intentional poisonings and drug overdoses constitute a significant source of morbidity, mortality, and health care expenditures. An estimated two to five million such events occur annually in the United States, although the true incidence is unknown due to under diagnosis and underreporting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management of the poisoned patient begins with a thorough evaluation, recognition that poisoning has occurred, identification of the agent(s) involved, assessment of severity, and prediction of toxicity. Therapy involves the provision of supportive care, prevention of poison absorption, and, when appropriate, the administration of antidotes and enhancement of elimination of the poison.",
"   </p>",
"   <p>",
"    Methods to enhance the rate of elimination of poisons following a toxic ingestion are reviewed here. General issues regarding the management of toxic ingestions, and specific issues related to decontamination and gastric emptying are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=see_link\">",
"     \"Approach to the child with occult toxic exposure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enhanced elimination techniques can accelerate removal of a toxin, but few studies have investigated whether they actually shorten the duration of clinical toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improve clinical outcomes. The main methods of enhancing the elimination of toxins are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef57040 \" href=\"UTD.htm?23/49/24347\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    General indications for enhanced elimination techniques include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ingestion of a poison whose elimination can be enhanced",
"     </li>",
"     <li>",
"      Failure of a patient to respond to maximal supportive care",
"     </li>",
"     <li>",
"      The clinical course is predicted to be complicated based on the nature",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concentration of the toxin, impaired clearance of the toxin, comorbid illness, or some combination of these three elements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, the expected benefits of the use of an enhanced elimination technique must be carefully weighed against the risk of potential complications associated with the technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MULTIPLE-DOSE ACTIVATED CHARCOAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (MDAC) is a commonly used method for enhancing the elimination of toxins and may play an important role in specific poisonings. MDAC is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993821#H18993821\">",
"     \"Gastrointestinal decontamination of poisoned adults\", section on 'Multidose activated charcoal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     URINARY ALKALINIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinary excretion of some drugs can be enhanced by altering the urine pH [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Altering the pH converts a lipid-soluble intact acid (HA) or base (BOH) in the tubular lumen into the charged salt (A- or B+):",
"   </p>",
"   <p>",
"    &nbsp;HA &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H+ &nbsp; + &nbsp; A-",
"   </p>",
"   <p>",
"    &nbsp;BOH &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;B+ &nbsp; + &nbsp; OH-",
"   </p>",
"   <p>",
"    The charged particle is lipid-insoluble and cannot easily move back across the renal epithelium. This leads to a marked increase in drug excretion.",
"   </p>",
"   <p>",
"    Raising the urine pH to 7.5 to 8.0 in patients poisoned with weak acids (such as salicylates and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) will drive the first reaction to the right, producing the desired increase in concentration of the charged salt (A-). Importantly, phenobarbital is the only barbiturate for which alkalinization is indicated, as short-acting barbiturates are metabolized in the liver, not eliminated via the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary acidification (urine pH below 5.5) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25411?source=see_link\">",
"     ammonium chloride",
"    </a>",
"    or ascorbic acid was historically used to treat intoxications with weak bases such as amphetamines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , or phencyclidine. However, this practice has been abandoned, as efficacy has not been established and iatrogenic toxicity (severe acidosis) can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that are likely to respond to urinary alkalinization usually meet four criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They are predominantly eliminated unchanged by the kidney",
"     </li>",
"     <li>",
"      They are distributed primarily in the extracellular fluid compartment",
"     </li>",
"     <li>",
"      They are minimally protein-bound",
"     </li>",
"     <li>",
"      They are weak acids with pKa ranging from 3.0 to 7.5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary alkalinization may be useful for the drugs listed in Tables 3 and 4 (",
"    <a class=\"graphic graphic_table graphicRef56838 \" href=\"UTD.htm?11/47/12027\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75710 \" href=\"UTD.htm?6/17/6427\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    -poisoned patients may be improved by the use of urinary alkalinization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. One study of 16 phenobarbital-poisoned patients found that the concomitant use of both urinary alkalinization and MDAC doubled the rate of elimination and shortened the period of unconsciousness by up to 50 percent compared with patients receiving supportive care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/5\">",
"     5",
"    </a>",
"    ]. No comparable data exist showing improved clinical outcomes with the use of urinary alkalinization in other types of poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urinary alkalinization is the most effective single method short of hemodialysis to enhance salicylate excretion, producing a mean elimination half-life of 5 hours versus half-lives of 8 and 19 hours in patients treated with forced diuresis or standard supportive care, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of urinary alkalinization is to achieve a urine pH of 7.5 or higher while maintaining a serum pH no higher than 7.55 to 7.60. This is generally done by administering an IV bolus of 1-2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    of 8.4 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , followed by continuous infusion of sodium bicarbonate. The fluid for continuous infusion is mixed by placing 150 mEq of sodium bicarbonate into one liter of 5 percent dextrose in water. Prior to the initiation of therapy, baseline measurements of electrolytes, blood urea nitrogen, serum creatinine, glucose, systemic pH, urinary pH, and serum drug concentrations should be performed. Placement of a Foley catheter is recommended to accurately measure urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial fluid resuscitation and intravenous bolus of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , the sodium bicarbonate continuous infusion should be administered at approximately 200 to 250",
"    <span class=\"nowrap\">",
"     cc/h.",
"    </span>",
"    The rate should be titrated based on the urinary and systemic pH, which should be monitored throughout treatment. Intravenous fluid should be adjusted to maintain a urine pH &ge;7.5 and serum pH &lt;7.60.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial fluid resuscitation and intravenous bolus of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , the sodium bicarbonate continuous infusion should be administered at approximately 1.5 times maintenance fluids (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    ). The rate should be titrated to maintain a urine pH &ge;7.5. Increases in serum pH up to 7.60 are well tolerated in patients with normal renal function. Subsequent fluid administration should be based on urine output and ongoing losses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used to alkalinize the urine. Acetazolamide raises urine pH by lowering systemic pH, which may cause deterioration in some cases. Close monitoring of blood and urine pH, electrolytes, respiratory status, and urine output is important when diuresis and urinary alkalinization procedures are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"     \"Salicylate (aspirin) poisoning in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urine alkalinization is contraindicated in patients with established or incipient renal failure, pulmonary edema, and cerebral edema. In addition, volume overload may complicate therapy in patients with preexisting cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of alkalinization include hypokalemia, alkalemia, and ionized hypocalcemia, which results from increased protein binding of calcium. The administration of 20 to 40",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    may be required if the plasma potassium concentration falls during urinary alkalinization. Monitoring and repletion of ionized calcium is recommended to prevent a deterioration in cardiac function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     HEMODIALYSIS AND HEMOPERFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis (HD) is rarely needed in the care of poisoned patients, although HD was used in 90 percent of patients in whom an extracorporeal method was employed to enhance poison elimination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/1\">",
"     1",
"    </a>",
"    ]. During HD, up to 400 mL of blood per minute passes through an extracorporeal circuit in which toxic compounds in blood diffuse through a semipermeable membrane down a concentration gradient into a dialysate. Electrolyte disturbances and metabolic acidosis induced by certain drugs also can be readily corrected with this intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoperfusion refers to the circulation of blood through an extracorporeal circuit containing an adsorbent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    or polystyrene resin. In contrast to HD circuits, hemoperfusion devices contain thin, highly porous membranes and adsorbents that provide a large surface area to directly bind toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/11\">",
"     11",
"    </a>",
"    ]. Clearance rates are higher with hemoperfusion than HD if the adsorbent binds the ingested toxin; the extraction ratio for hemoperfusion approximates 1.0 for some poisons, and drug clearance rates approach the rate of blood flow through the hemoperfusion circuit.",
"   </p>",
"   <p>",
"    Peritoneal dialysis is",
"    <strong>",
"     much less effective",
"    </strong>",
"    than HD or hemoperfusion, and is rarely if ever indicated in the care of poisoned patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD is most useful in removing toxins with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low molecular weight (&lt;500 daltons)",
"     </li>",
"     <li>",
"      Small volume of distribution (&lt;1",
"      <span class=\"nowrap\">",
"       L/kg)",
"      </span>",
"     </li>",
"     <li>",
"      Low degree of protein-binding",
"     </li>",
"     <li>",
"      High water solubility",
"     </li>",
"     <li>",
"      Low endogenous clearance (&lt;4",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per kg)",
"     </li>",
"     <li>",
"      High dialysis clearance relative to total body clearance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of HD and hemoperfusion is limited when the drug is not concentrated in the extracellular fluid because of high lipid solubility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tight tissue binding. These characteristics are present with tricyclic antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and calcium channel blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=see_link\">",
"     \"Digitalis (cardiac glycoside) poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=see_link\">",
"     \"Calcium channel blocker poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis removes the toxic metabolites of methanol and ethylene glycol, corrects acid-base abnormalities, and reduces end-organ sequelae and mortality associated with these poisonings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Although HD clears ethylene glycol and methanol efficiently, HD is rarely indicated when acidosis is not present, as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/3/2102?source=see_link\">",
"     fomepizole",
"    </a>",
"    effectively blocks the activation of these alcohols to the toxic acidic species [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .) HD also substantially increases the rate of elimination of isopropanol, salicylates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , although data regarding clinical end points are sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/11,17-20\">",
"     11,17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drugs adsorbed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    can be extracted by hemoperfusion, and the rate of removal may exceed that achieved with hemodialysis. The extraction ratio of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    with hemodialysis, for example, is approximately 50 percent as compared with 99 percent at the beginning of hemoperfusion (before the cartridge becomes saturated). As the extraction ratio only reflects the percent removal of drug presented to the dialysis membrane or hemoperfusion cartridge; these techniques remove only a small fraction of body load of drugs with large stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"     \"Theophylline poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High extraction ratios and clearance rates, however, do not necessarily predict improved clinical outcomes. No controlled clinical studies in poisoned patients have been performed to determine if hemoperfusion reduces morbidity or mortality as compared with supportive measures. Evidence of clinical effectiveness for hemoperfusion is based upon favorable pharmacokinetic data, animal studies, anecdotal case reports, case series, and uncontrolled retrospective studies. Three clinical studies have retrospectively compared hemoperfusion with supportive care for poisoning from a variety of drugs, but do not allow firm conclusions to be drawn regarding the relative efficacy of different management strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When intoxication has occurred with a drug whose HD clearance is significantly greater than endogenous clearance, the use of HD should be considered if the patient's condition progressively deteriorates, or when measured drug concentrations are predictive of a poor outcome without HD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/11\">",
"     11",
"    </a>",
"    ]. Practically, HD is indicated for a limited number of poisonings (",
"    <a class=\"graphic graphic_table graphicRef82353 \" href=\"UTD.htm?18/21/18779\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hemoperfusion may be considered for use in severe poisoning from the toxins listed in Table 6 (",
"    <a class=\"graphic graphic_table graphicRef71695 \" href=\"UTD.htm?14/31/14844\">",
"     table 5",
"    </a>",
"    ). It is significantly more effective than HD in enhancing the clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    but is associated with a higher complication rate and is not available at many medical centers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/24\">",
"     24",
"    </a>",
"    ]. If hemoperfusion is available, it is preferred over hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD and hemoperfusion require central venous access with a double lumen catheter. Acute vascular access for hemodialysis or hemoperfusion is best accomplished with femoral catheters, which can be rapidly and safely inserted. Subclavian catheterization can also be used; however, there is a risk of pneumothorax or hemothorax, and therapy may be delayed because of the necessity for radiographic confirmation of proper catheter placement. The duration of these procedures for poisoned patients is usually four to eight hours but should be governed by the clinical response and serum drug concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=see_link\">",
"     \"Overview of central catheters for acute and chronic hemodialysis access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;HD and hemoperfusion normally require systemic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and patients with active hemorrhage or coagulopathy may not be candidates for these procedures. HD and hemoperfusion also may not be possible in hypotensive patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=see_link\">",
"     \"Hemodialysis anticoagulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential side effects of HD include hypotension, bleeding due to anticoagulation, hypothermia, air embolus, and complications that may result from obtaining central venous access (",
"    <a class=\"graphic graphic_table graphicRef77376 \" href=\"UTD.htm?11/30/11755\">",
"     table 6",
"    </a>",
"    ). Hemoperfusion has these same complications, but also poses potential risks of charcoal embolization, hypocalcemia, hypoglycemia, leukopenia (10 percent reduction), and thrombocytopenia (30 percent reduction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEMOFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data available on drug removal by continuous arteriovenous (CAVH) or venovenous (CVVH) hemofiltration. Hemofiltration has been used to enhance elimination of aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and metal chelate complexes, but the technique does not remove highly protein-bound drugs effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26695/abstract/25\">",
"     25",
"    </a>",
"    ]. It may also be of benefit for intoxications with drugs that have a large volume of distribution, tight tissue binding, or slow intercompartmental transfer (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27909?source=see_link\">",
"     \"Drug removal during continuous renal replacement therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood may be pumped by the patient's own arterial (CAVH) or venous (CVVH) pressure, or by a hemodialysis machine entrained in the circuit (CAVHD, CVVHD). Blood that enters the hemofiltration circuit passes through filters (sheet membrane or hollow fiber) with large pores, and an ultrafiltrate forms which drags solutes with molecular weights up to 50,000 daltons (depending upon hemofilter pore size). Cells and solutes larger than the pore size remain in the blood and return to the circulation.",
"   </p>",
"   <p>",
"    In contrast to HD or hemoperfusion, CAVH is driven by the patient's own blood pressure and can be run continuously. The rate of fluid removal, which is equivalent to the plasma clearance of drug, can exceed 100",
"    <span class=\"nowrap\">",
"     mL/h;",
"    </span>",
"    thus, fluid replacement is an essential component of the hemofiltration regimen.",
"   </p>",
"   <p>",
"    Complications of hemofiltration include clotting of the filter and bleeding due to the requisite use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Fluid and electrolyte losses from the ultrafiltrate must be replaced continuously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EXCHANGE TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exchange transfusion refers to the removal of a quantity of blood from a poisoned patient and its replacement with an identical quantity of whole blood; the process is usually repeated two to three times. Exchange transfusions are rarely indicated but may be useful in the treatment of massive hemolysis (eg, due to arsine or sodium chlorate poisoning), methemoglobinemia, sulfhemoglobinemia (eg, secondary to hydrogen sulfide exposure), or in neonatal drug toxicity. Complications of the technique include transfusion reactions, ionized hypocalcemia, and hypothermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of patients who have ingested a poisonous substance or a toxic quantity of a drug can be managed with supportive measures and possibly the administration of a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      . However, the severity of the ingestion and pharmacologic properties of the toxin may prompt consideration of techniques to enhance elimination of the poison in a small percentage of cases.",
"     </li>",
"     <li>",
"      Few studies have assessed changes in clinical outcomes when enhanced elimination techniques are employed, and the efficacy of these techniques has been judged primarily on the basis of improvement in elimination kinetics. Each technique is associated with potential complications, and the decision to use a particular technique should be based upon the drug ingested, the actual and predicted severity of poisoning, the presence of contraindications to the technique, and the effectiveness of alternative methods of treatment. In general, the decision to employ enhanced elimination techniques is reserved for patients with severe poisoning who have failed to respond to aggressive supportive care.",
"     </li>",
"     <li>",
"      Despite these concerns, the following general recommendations can be offered:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      may be useful following specific ingestions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link&amp;anchor=H18993821#H18993821\">",
"       \"Gastrointestinal decontamination of poisoned adults\", section on 'Multidose activated charcoal'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Urinary alkalinization and forced diuresis may be useful after poisonings with agents that are weak acids and eliminated to a large extent in the urine (eg, salicylates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hemodialysis may be useful for patients with significant ingestion of alcohols,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , or salicylates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"       \"Theophylline poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9225?source=see_link\">",
"       \"Lithium poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=see_link\">",
"       \"Salicylate (aspirin) poisoning in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemoperfusion is an alternative to hemodialysis and may result in more rapid clearance of toxins such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , valproic acid, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=see_link\">",
"       \"Theophylline poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=see_link\">",
"       \"Carbamazepine poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=see_link\">",
"       \"Valproic acid poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritoneal dialysis, hemofiltration, and exchange transfusion are rarely indicated in the management of poisoned patients.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/1\">",
"      Litovitz TL, Smilkstein M, Felberg L, et al. 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1997; 15:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/2\">",
"      McCaig LF, Burt CW. Poisoning-related visits to emergency departments in the United States, 1993-1996. J Toxicol Clin Toxicol 1999; 37:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/3\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/4\">",
"      Morgan AG, Polak A. The excretion of salicylate in salicylate poisoning. Clin Sci 1971; 41:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/5\">",
"      Bloomer HA. A critical evaluation of diuresis in the treatment of barbiturate intoxication. J Lab Clin Med 1966; 67:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/6\">",
"      Henry JA. Specific problems of drug intoxication. Br J Anaesth 1986; 58:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/7\">",
"      Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol 2004; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/8\">",
"      Garrettson LK, Geller RJ. Acid and alkaline diuresis. When are they of value in the treatment of poisoning? Drug Saf 1990; 5:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/9\">",
"      Frenia ML, Schauben JL, Wears RL, et al. Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J Toxicol Clin Toxicol 1996; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/10\">",
"      Prescott LF, Balali-Mood M, Critchley JA, et al. Diuresis or urinary alkalinisation for salicylate poisoning? Br Med J (Clin Res Ed) 1982; 285:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/11\">",
"      Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/12\">",
"      Pappas SC, Silverman M. Treatment of methanol poisoning with ethanol and hemodialysis. Can Med Assoc J 1982; 126:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/13\">",
"      Peterson CD, Collins AJ, Himes JM, et al. Ethylene glycol poisoning: pharmacokinetics during therapy with ethanol and hemodialysis. N Engl J Med 1981; 304:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/14\">",
"      Gonda A, Gault H, Churchill D, Hollomby D. Hemodialysis for methanol intoxication. Am J Med 1978; 64:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/15\">",
"      Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001; 344:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/16\">",
"      Brent J, McMartin K, Phillips S, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999; 340:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/17\">",
"      Cutler RE, Forland SC, Hammond PG, Evans JR. Extracorporeal removal of drugs and poisons by hemodialysis and hemoperfusion. Annu Rev Pharmacol Toxicol 1987; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/18\">",
"      Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/19\">",
"      Rosansky SJ. Isopropyl alcohol poisoning treated with hemodialysis: kinetics of isopropyl alcohol and acetone removal. J Toxicol Clin Toxicol 1982; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/20\">",
"      Winchester JF, Gelfand MC, Helliwell M, et al. Extracorporeal treatment of salicylate or acetaminophen poisoning--is there a role? Arch Intern Med 1981; 141:370.",
"     </a>",
"    </li>",
"    <li>",
"     Volans GN, Vale JA, Crome P, et al. The role of charcoal hemoperfusion in the management of acute poisoning by drugs. In: Artificial Organs, Kenedi RM, Bourtney JM, Gaylor JDS, Gilchris T.  (Eds), University Park Press, Baltimore 1976. p.178.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/22\">",
"      Hampel G, Wiseman H, Widdop B. Acute poisoning due to hypnotics: the role of haemoperfusion in clinical perspective. Vet Hum Toxicol 1979; 21 Suppl:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/23\">",
"      Bismuth C, Conso F, Wattel F, et al. Coated activated charcoal hemoperfusion: experience of French anti-poison centers about 60 cases. Vet Hum Toxicol 1979; 21 Suppl:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/24\">",
"      Shannon MW. Comparative efficacy of hemodialysis and hemoperfusion in severe theophylline intoxication. Acad Emerg Med 1997; 4:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26695/abstract/25\">",
"      Golper TA, Bennett WM. Drug removal by continuous arteriovenous haemofiltration. A review of the evidence in poisoned patients. Med Toxicol Adverse Drug Exp 1988; 3:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 325 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26695=[""].join("\n");
var outline_f26_4_26695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MULTIPLE-DOSE ACTIVATED CHARCOAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      URINARY ALKALINIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HEMODIALYSIS AND HEMOPERFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEMOFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EXCHANGE TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/325\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/325|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/49/24347\" title=\"table 1\">",
"      Chemical elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/47/12027\" title=\"table 2\">",
"      Poisons amenable to forced diuresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/17/6427\" title=\"table 3\">",
"      Alkaline diuresis in poisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/21/18779\" title=\"table 4\">",
"      Poisons and drugs amenable to hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/31/14844\" title=\"table 5\">",
"      Hemoperfusion in poisons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/30/11755\" title=\"table 6\">",
"      Complications of central venous catheterization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22474?source=related_link\">",
"      Approach to the child with occult toxic exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11577?source=related_link\">",
"      Carbamazepine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27909?source=related_link\">",
"      Drug removal during continuous renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38120?source=related_link\">",
"      Hemodialysis anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9225?source=related_link\">",
"      Lithium poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16442?source=related_link\">",
"      Overview of central catheters for acute and chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/28/19913?source=related_link\">",
"      Salicylate (aspirin) poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/16/13578?source=related_link\">",
"      Theophylline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=related_link\">",
"      Valproic acid poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_4_26696="Reversible cirrhosis thalassemia major";
var content_f26_4_26696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F51765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F51765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Reversibility of cirrhosis in thalassemia following hematopoietic cell transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial liver biopsies illustrating reversibility of cirrhosis in a 25-year-old-female with thalassemia major, transfusional iron overload, and anti-hepatitis C virus antibodies. Panels A and B were obtained at the time of diagnosis of cirrhosis, four years after hematopoietic cell transplantation. Panel A (Masson trichrome stain) shows cirrhosis and active hepatitis; panel B (Perl's Prussian Blue reaction) shows severe iron overload (23 mg/g of liver dry weight). The liver biopsy shown on panels C and D was obtained 10 years after transplantation, four years following completion of phlebotomy treatment; abnormal aminotransferase levels normalized without antiviral treatment. It shows regression of cirrhosis, marked improvement of hepatitis, and absent iron overload (0.9 mg/g).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136:667. Copyright &copy; 2002 American College of Physicians-American Society of Internal Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26696=[""].join("\n");
var outline_f26_4_26696=null;
var title_f26_4_26697="Chiari malformations";
var content_f26_4_26697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chiari malformations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26697/contributors\">",
"     Chaouki Khoury, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26697/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26697/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/4/26697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10173921\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chiari malformations are a heterogeneous group of disorders that are defined by anatomic anomalies of the cerebellum, brainstem, and craniocervical junction, with downward displacement of the cerebellum, either alone or together with the lower medulla, into the spinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review anatomic and clinical aspects of the various types of Chiari malformations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1239375\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chiari malformations were first described by John Cleland in 1883 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. They were later classified by Hans Chiari in 1891, into four groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chiari I malformation (CM-I) is characterized by abnormally shaped cerebellar tonsils that are displaced below the level of the foramen magnum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68681 \" href=\"UTD.htm?4/47/4852\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chiari II malformation (CM-II), also known as Arnold-Chiari malformation, is characterized by downward displacement of the cerebellar vermis and tonsils, a brainstem malformation with beaked midbrain on neuroimaging, and a spinal myelomeningocele (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71208 \" href=\"UTD.htm?40/26/41377\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61496 \" href=\"UTD.htm?38/15/39155\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef61495 \" href=\"UTD.htm?12/35/12851\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chiari III malformation (CM-III) is rare and combines a small posterior fossa with a high cervical or occipital encephalocele, usually with displacement of cerebellar structures into the encephalocele, and often with inferior displacement of the brainstem into the spinal canal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74322 \" href=\"UTD.htm?19/18/19746\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chiari IV malformation (CM-IV) is now considered to be an obsolete term that describes cerebellar hypoplasia unrelated to the other Chiari malformations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the classic types of Chiari malformations, further subtypes (not widely used) have since been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"     4",
"    </a>",
"    ]. These include the Chiari 0 malformation, characterized by anatomic aberration of the brainstem (posterior pontine tilt, downward displacement of the medulla, low lying obex) but with normally placed cerebellar tonsils [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/5\">",
"     5",
"    </a>",
"    ], and the Chiari 1.5 malformation, which is a CM-II like malformation without spina bifida [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/6\">",
"     6",
"    </a>",
"    ]. Both of these subtypes show crowding at the foramen magnum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1308662\">",
"    <span class=\"h1\">",
"     ANATOMIC ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, Chiari malformations are congenital conditions that are defined by anatomic anomalies of the craniocervical junction with downward displacement of the cerebellar structures. Chiari malformations are often associated with spinal cord cavitations (ie, syringomyelia). In most cases of Chiari malformations, the posterior fossa is small, and neural elements are crowded and impacted at the foramen magnum.",
"   </p>",
"   <p>",
"    With any of the Chiari types, other bony abnormalities may also be seen, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atlas assimilation",
"     </li>",
"     <li>",
"      Atlantoaxial dislocation",
"     </li>",
"     <li>",
"      Klippel-Feil anomaly (congenital anomaly consisting of failure of segmentation of any two of the seven cervical vertebrae)",
"     </li>",
"     <li>",
"      Platybasia",
"     </li>",
"     <li>",
"      Basilar invagination (protrusion of the odontoid process through the foramen magnum into the intracranial cavity)",
"     </li>",
"     <li>",
"      Luckenschadel, also known as lacunar skull (an ossification disorder in which the fetal skull appears fenestrated)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15846546\">",
"    <span class=\"h2\">",
"     Chiari type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chiari type I malformation (CM-I) is characterized by cerebellar tonsils that are abnormally shaped and downwardly displaced below the level of the foramen magnum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68681 \" href=\"UTD.htm?4/47/4852\">",
"     image 1",
"    </a>",
"    ). The normal cerebellar tonsils may lie up to 3 mm below the foramen magnum in adults. In general, tonsils lying 5 mm or more below the foramen magnum on neuroimaging are considered to be consistent with a Chiari malformation, though there is no direct correlation between how low the tonsils are lying and clinical severity. With infants, however, tonsils as low as 6 mm below the foramen magnum can still be normal.",
"   </p>",
"   <p>",
"    The frequency of spinal cavitations (syringomyelia, hydromyelia or syringohydromyelia) with CM-I varies in the literature between 40 and 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Some patients even have a holocord syrinx that extends the whole length of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atlas assimilation, often associated with the Klippel-Feil anomaly, is common in CM-I [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/7\">",
"     7",
"    </a>",
"    ]. The Klippel-Feil anomaly may not be evident in infants and young children, as the fusion site might still be cartilaginous at an early age.",
"   </p>",
"   <p>",
"    The prevalence of hydrocephalus associated with CM-I is approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15846561\">",
"    <span class=\"h2\">",
"     Chiari type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chiari II malformation (CM-II) is characterized by downward displacement of inferior cerebellar vermis (involving the nodulus, pyramis and uvula), and cerebellar tonsils and medulla through the foramen magnum into the upper cervical canal, in association with a myelomeningocele at the lumbosacral or occasionally a higher level of the spinal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71208 \" href=\"UTD.htm?40/26/41377\">",
"     image 2",
"    </a>",
"    ). The malformation obstructs the outflow of cerebrospinal fluid through the posterior fossa, causing hydrocephalus. Almost all patients with a myelomeningocele have CM-II, and most have associated hydrocephalus. A reduced volume of the posterior fossa with an enlarged foramen magnum and low torcula with ventral displacement of the tentorium cerebelli are constant features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional findings that may be associated with CM-II include the following (",
"    <a class=\"graphic graphic_figure graphicRef61495 \" href=\"UTD.htm?12/35/12851\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61496 \" href=\"UTD.htm?38/15/39155\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inferior displacement of the fourth ventricle into the upper cervical canal",
"     </li>",
"     <li>",
"      Elongation and thinning of the lower pons and the medulla",
"     </li>",
"     <li>",
"      Beaking of the quadrigeminal plate",
"     </li>",
"     <li>",
"      Kinking of medullary spinal cord junction in the cervical canal",
"     </li>",
"     <li>",
"      Stenosis or atresia of the cerebral aqueduct",
"     </li>",
"     <li>",
"      Upward displacement of the upper cerebellum into the middle fossa",
"     </li>",
"     <li>",
"      Cerebellar dysplasia",
"     </li>",
"     <li>",
"      Colpocephaly (abnormal enlargement) of the posterior lateral ventricles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infrequent supratentorial anomalies found with CM-I and CM-II include dysgenesis or absence of the corpus callosum, agenesis of the septum pellucidum, polymicrogyria of the cerebral hemispheres, and heterotopia of cerebral gray matter [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,13-15\">",
"     1,13-15",
"    </a>",
"    ]. In addition, CM-II is rarely associated with rhombencephalosynapsis, consisting of agenesis of the cerebellar vermis with fusion of the cerebellar hemispheres [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24684203\">",
"    <span class=\"h2\">",
"     Chiari type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare Chiari III malformation (CM-III) combines inferior displacement of the medulla with a high cervical or occipital encephalocele that typically contains much of the cerebellum (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74322 \" href=\"UTD.htm?19/18/19746\">",
"     image 4",
"    </a>",
"    ) and may also involve supratentorial tissue, including the occipital cortex and part of the occipital horn of the lateral ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. In addition, CM-III may be associated with any of the features of CM-I and CM-II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13738661\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of congenital Chiari malformations remains the subject of debate. Multiple theories have been proposed, though none explains all the features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The molecular genetic theory postulates that Chiari malformations result from primary defects in the genetic programming of hindbrain segmentation and of growth of associated bone and cranial structures [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,18\">",
"       1,18",
"      </a>",
"      ]. Another growth abnormality theory proposes that collision between caudally-directed cranial growth and rostrally-directed cervical growth is the underlying abnormality in CM-I [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. However, most Chiari malformations are sporadic and not inherited. Thus, the cause might be either a spontaneous mutation or deletion, or a mutation induced by an exogenous teratogen.",
"     </li>",
"     <li>",
"      The crowding theory postulates that restricted growth of the posterior fossa causes compression of neural tissue, which is then squeezed through the foramen magnum like toothpaste through a tube [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/13,21\">",
"       13,21",
"      </a>",
"      ]. In support of this theory, the posterior fossa is abnormally small and the torcula is displaced downward in patients with Chiari malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,10\">",
"       1,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hydrodynamic pulsion theory suggests that early progressive fetal hydrocephalus pushes down on the brainstem and cerebellum [25-28].",
"     </li>",
"     <li>",
"      The oligo-cerebrospinal fluid theory proposes that defective closure of the neural tube in early fetal development results in leakage of cerebrospinal fluid, and thus insufficient cerebrospinal volume to fully distend the embryonic ventricular system, which leads to a small posterior fossa and cerebral disorganization [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One early theory suggested that the downward displacement of the cerebellar tissue was due to traction by a tethered cord [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/24-27\">",
"       24-27",
"      </a>",
"      ]. However, several studies have demonstrated that the caudal traction on a tethered cord is only transmitted rostrally as far as the caudal-most pair of dentate ligaments, thus disputing the notion that traction transmitted all the way to the brainstem and cerebellum [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Furthermore, not all Chiari malformations are associated with tethering [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chiari type I malformation can be due to either neuroectodermal or mesodermal anomalies. Isolated CM-I is thought to be of mesodermal origin. In contrast, CM-I that is associated with syndromic or nonsyndromic craniosynostosis, or associated with other neurological disorders such as mental retardation and epilepsy, is thought to be of neuroectodermal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"     4",
"    </a>",
"    ]. Occasionally, CM-I can be associated with occult spinal dysraphism (ie, spinal bifida occulta) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"     11",
"    </a>",
"    ]. The remaining types of Chiari malformations are due to neuroectodermal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of spinal cord cavitations (syringomyelia) associated with Chiari malformations has been the subject of debate. Initially it was thought to be due to cerebrospinal fluid being forced into the central canal because of impaired subarachnoid circulation at the level of the foramen magnum. However, cine phase contrast MRI studies have shown that the syrinx of Chiari malformations is noncommunicating. Therefore, it is more likely that the syrinx results from craniospinal pressure dissociation due to the blockage of cerebrospinal fluid flow in the subarachnoid space at the level of the foramen magnum. This leads to pressure backup into the venous system, with initial engorgement of the Virchow-Robin spaces. The excess fluid then dissipates into the substance of the spinal cord leading to spinal cord edema. As fluid accumulates beyond the resorptive power of the parenchyma, it dissipates into the central canal and dilates it, leading to syrinx formation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10173927\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true frequency of CM-I is unknown. In the MRI era (that is, since about 1985), CM-I is increasingly detected, with a prevalence in some studies of 0.1 to 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although once believed to be a disease of adolescence and adulthood, CM-I is now recognized in younger children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"     4",
"    </a>",
"    ]. Prior to the advent of neuroimaging with MRI, CM-I was only diagnosed when patients presented with symptoms that warranted investigation. Therefore, in most early series, there were no children younger than 12 years, and it was mistakenly assumed that CM-I occurred only in adolescents and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/32\">",
"     32",
"    </a>",
"    ]. However, with the widespread use of MRI, asymptomatic or minimally symptomatic patients are being diagnosed at earlier ages. Thus, CM-I is the most common type of Chiari malformation. The most frequent type of Chiari malformation presenting in childhood is CM-II [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5294754\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In retrospective studies, Chiari malformations have been associated with Robin sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], neurofibromatosis type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/35\">",
"     35",
"    </a>",
"    ], and Noonan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. As an example, in one report of 198 patients with neurofibromatosis type 1 who had neuroimaging, CM-I was found in approximately 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, among 130 patients who had surgery for CM-I, neurofibromatosis type 1 was diagnosed in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10173933\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a wide spectrum of clinical symptoms associated with Chiari malformations. The major categories of symptoms are those related to obstructive hydrocephalus, abnormal eye movements, cerebellar deficits, and spinal myelomeningocele [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with CM-I are spared the latter, as they do not have neural tube defects such as a myelomeningocele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7708132\">",
"    <span class=\"h2\">",
"     Chiari type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true natural history of CM-I has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/38\">",
"     38",
"    </a>",
"    ]. In most cases, CM-I does not become symptomatic until adolescence or adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. In addition, symptom onset is often insidious. In one study of 43 patients with CM-I, the mean age at presentation was approximately 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manifestations of CM-I derive mainly from the following categories [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,4,39,40\">",
"     1,4,39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated intracranial pressure",
"     </li>",
"     <li>",
"      Cranial neuropathies",
"     </li>",
"     <li>",
"      Brainstem compression",
"     </li>",
"     <li>",
"      Myelopathy",
"     </li>",
"     <li>",
"      Cerebellar dysfunction",
"     </li>",
"     <li>",
"      Pain (mainly neck pain and occipital headache)",
"     </li>",
"     <li>",
"      Syringomyelia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81030 \" href=\"UTD.htm?39/25/40337\">",
"       image 5",
"      </a>",
"      ), often accompanied by scoliosis, and presyrinx",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are asymptomatic cases where the radiologic diagnosis of CM-I is discovered incidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial neuropathies or brainstem compression can present with hoarseness, vocal cord paralysis, dysarthria, palatal weakness, pharyngeal achalasia, tongue atrophy, recurrent aspiration, and nystagmus (especially down-beating). Less common symptoms and signs include oscillopsia, sensorineural hearing loss, sinus bradycardia, syncope and hiccups. Other manifestations of brainstem compression include central sleep apnea and long-tract signs such as weakness, spasticity, hyperreflexia and Babinski responses. The latter can result from either brainstem or spinal cord compression. Cerebellar symptoms include nystagmus, scanning speech and ataxia, with truncal ataxia being more common than appendicular ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/32,39\">",
"     32,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scoliosis is usually due to an asymmetric spinal syringomyelia leading to differential growth of the hemicords and the vertebral column [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"     11",
"    </a>",
"    ]. Since the advent of MRI, syringomyelia is often diagnosed prior to reaching the stage of the classic cape-like suspended sensory loss. Thus, scoliosis has become the most common presenting symptom of a spinal syrinx.",
"   </p>",
"   <p>",
"    In children with CM-I, an associated syrinx occurs in 30 percent. Of patients with neurologic deficits due to a syrinx, the earliest sign is loss of the superficial abdominal reflexes. Other signs and symptoms include gait disturbance, radicular pain, dysesthesia, upper motor neuron signs in the legs, and lower motor neuron signs maximally in the arms in those with a cervical syrinx, the most common location associated with CM-I. Of note, patients may also have signs and symptoms of brainstem dysfunction if the syrinx extends into the medulla (syringobulbia).",
"   </p>",
"   <p>",
"    Presyrinx is a potentially reversible condition characterized by spinal cord edema due to obstruction of cerebrospinal fluid flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. It occurs most often in the cervical region and is detected by MRI, appearing similar to a true syrinx on T2-weighted images but lacking discrete cavitation on T1-weighted sequences (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75789 \" href=\"UTD.htm?21/0/21509\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pain or headache due to meningeal irritation is the most common presentation in patients with CM-I. The pain is usually either occipital or nuchal in location. The pain is typically paroxysmal, but it may be dull and persistent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/32\">",
"     32",
"    </a>",
"    ]. Both the pain and a feeling of dizziness are exacerbated by physical activity or by Valsalva maneuvers such as coughing, laughing, or sneezing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/4,32,44\">",
"     4,32,44",
"    </a>",
"    ]. Thus, patients with CM-I may present with cough headache, and CM-I should be considered as a potential etiology in secondary cough headache. It is postulated that Valsalva maneuvers leads to exacerbation of the pain by causing impaction of the cerebellar tonsils at the foramen magnum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although CM-I typically is not symptomatic in young children, one retrospective series identified 39 patients younger than six years who had early surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/45\">",
"     45",
"    </a>",
"    ]. Children up to age two most often presented with oropharyngeal dysfunction, while those ages three to five typically presented with syringomyelia, scoliosis, or headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7706943\">",
"    <span class=\"h2\">",
"     Chiari type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it is nearly always associated with a lumbosacral or thoracic myelomeningocele, CM-II is usually detected prenatally or at birth (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71208 \" href=\"UTD.htm?40/26/41377\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]. Manifestations in infancy may include dysphagia, arm weakness, stridor, apneic spells, and aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/46\">",
"     46",
"    </a>",
"    ]. In late infancy and childhood, progressive hydrocephalus is a common problem in CM-II [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, CM-II may be associated with one or more of the syndromes associated with CM-I, such as syringomyelia and scoliosis. (See",
"    <a class=\"local\" href=\"#H7708132\">",
"     'Chiari type I'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Despite the extensive malformations, some patients with CM-II have normal intelligence and function well independently [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20314753\">",
"    <span class=\"h2\">",
"     Chiari type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;This rare malformation is associated with a high cervical or occipital encephalocele that typically contains much of the cerebellum and may also involve supratentorial tissue, including the occipital cortex and part of the occipital horn of the lateral ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1,17\">",
"     1,17",
"    </a>",
"    ]. Data are limited regarding the natural history and clinical course of CM-III [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with CM-III have a high mortality rate, often due to respiratory failure in infancy. Those who survive beyond the neonatal period often have severe neurologic impairments, such as mental retardation, epilepsy, hypotonia or spasticity, upper and lower motor neuron signs, and lower cranial nerve palsies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10173939\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Chiari malformations is based upon neuroanatomy. There are no biomarkers in blood, cerebrospinal fluid, or cultured tissue to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, neuroimaging is of prime importance, and MRI is the best imaging modality for evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. Sagittal, coronal and axial views of the brain along with sagittal and axial images of the entire spinal cord (cervical, thoracic, and lumbar) using T1 and T2-weighted MRI sequences are useful for detecting cerebellar and brainstem displacement, associated craniocervical junction abnormalities, and hydrosyringomyelia. CT, especially thin-section multiplanar CT with reformatted images, retains importance in the evaluation of the associated bony abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1308662\">",
"     'Anatomic aspects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who cannot have MRI, high-resolution CT scan with sagittal reconstructions can be used to make the diagnosis of Chiari malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases of fetal ventriculomegaly, a Chiari malformation can be diagnosed in utero using fetal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is general agreement among experts that the radiologic diagnosis of CM-I in adolescents and adults is made by MRI when one or both cerebellar tonsils are displaced by &ge;5 mm below the foramen magnum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/8,11,42,54,55\">",
"     8,11,42,54,55",
"    </a>",
"    ]. Borderline displacement of the cerebellar tonsils (&ge;3 to &lt;5 mm below the foramen magnum) is considered pathologic if it is associated with additional features of CM-I, such as other craniocervical junction anomalies or syringomyelia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1308662\">",
"     'Anatomic aspects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a series that compared 200 normal subjects and 25 patients with CM-I, using a cutoff of 3 mm below the foramen magnum as the lowest normal position of the cerebellar tonsils predicted symptomatic CM-I with a sensitivity and specificity of 96 and 99.5 percent respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/56\">",
"     56",
"    </a>",
"    ]. In the patients with CM-I, the mean position of the cerebellar tonsils was 13 mm below the foramen magnum (range 3 to 29 mm below). In the normal subjects, the mean position of the tonsils was 1 mm above the foramen magnum (range 8 mm above to 5 mm below). In infants, however, tonsils as low as 6 mm below the foramen magnum may be normal, since the cerebellar tonsils have been shown to ascend with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted earlier, Chiari malformations are typically associated with a small posterior fossa. On neuroimaging, this may result in obliteration of the subarachnoid spaces at the level of the foramen magnum.",
"   </p>",
"   <p>",
"    The diagnosis of CM-II should be suspected in a fetus or newborn with clinical evidence of a spinal myelomeningocele. MRI can confirm the diagnosis of CM-II by demonstrating downward displacement of inferior cerebellar vermis and medulla through the foramen magnum into the upper cervical canal.",
"   </p>",
"   <p>",
"    Similarly, the diagnosis of CM-III is made in a fetus or newborn with clinical evidence of a high",
"    <span class=\"nowrap\">",
"     cervical/occipital",
"    </span>",
"    encephalocele and confirmatory MRI showing inferior displacement of the medulla and a high cervical or occipital encephalocele with descent of cerebellar structures into the malformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10173945\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of Chiari malformations depends upon the nature of the malformation and the degree of associated neurologic impairments. Particularly for CM-II and CM-III, surgical interventions may include closure of open neural tube defects shortly after birth, treatment for hydrocephalus (most often by use of a shunt), and decompression of tight posterior fossa structures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"     1",
"    </a>",
"    ]. Medical issues involve management of neurogenic bowel and bladder, neonatal feeding difficulties, respiratory failure, and apnea.",
"   </p>",
"   <p>",
"    The management of myelomeningocele is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=see_link\">",
"     \"Urinary tract complications of myelomeningocele (spina bifida)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19688?source=see_link\">",
"     \"Orthopedic issues in myelomeningocele (spina bifida)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of hydrocephalus is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=see_link\">",
"     \"Hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymptomatic patients with an incidental diagnosis of CM-I who do not have syringomyelia can be managed conservatively with clinical and MRI surveillance (eg, six months after the first encounter, and yearly thereafter) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/38,58\">",
"     38,58",
"    </a>",
"    ]. However, not all experts agree with this approach, and a minority advocates prophylactic surgery to prevent development of syringomyelia and other associated complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decompressive surgery is indicated for patients with CM-I who are clearly symptomatic with lower cranial nerve palsies, syringomyelia, myelopathy, cerebellar symptoms, severe neck pain or occipital headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24684417\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For asymptomatic or oligosymptomatic patients with CM-I who are neurologically intact but have syringomyelia on MRI, management is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/38\">",
"     38",
"    </a>",
"    ]. As discussed below, there are occasional reports of spontaneous resolution of tonsillar displacement or syringomyelia within the context of CM-I. (See",
"    <a class=\"local\" href=\"#H10173951\">",
"     'Prognosis'",
"    </a>",
"    below.) Therefore, some have argued that a period of watchful observation is warranted in asymptomatic children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cine phase contrast MRI may be valuable in certain patients with CM-I to look for impairment of cerebrospinal fluid (CSF) flow across the foramen magnum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11,62\">",
"     11,62",
"    </a>",
"    ]. This information can be used to select patients for surgical decompression of the foramen magnum in order to establish normal CSF flow. Thus, some have recommended obtaining a cine phase contrast MRI in all patients with CM-I; those patients without CSF flow obstruction would undergo a watchful observation strategy, while patients with CSF flow obstruction on cine MRI, whether symptomatic or asymptomatic, would be treated with surgery.",
"   </p>",
"   <p>",
"    We suggest obtaining a cine phase contrast MRI for asymptomatic or oligosymptomatic patients with CM-I who are neurologically intact but have syringomyelia on MRI. We refer such patients for surgery if the study shows complete CSF flow obstruction. Alternatively, we continue to follow them with clinical and neuroimaging surveillance if the study shows partial or no CSF flow obstruction, but refer patients for posterior fossa decompression at the first sign of clinical deterioration.",
"   </p>",
"   <p>",
"    In small uncontrolled studies, obstruction of CSF flow correlated with clinical symptoms, and a postsurgical increase in CSF flow was associated with clinical improvement or stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Cine phase contrast MRI may also be useful for postoperative follow-up of patients with 'failed' surgeries, such as those who experience delayed deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/62\">",
"     62",
"    </a>",
"    ]. Furthermore, a retrospective report of 130 patients who had decompressive surgery for CM-I found that normal CSF flow by cine phase contrast MRI before surgery was predictive of symptom recurrence after surgery (relative risk 4.8, 95% CI 1.9-12.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/64\">",
"     64",
"    </a>",
"    ]. This result suggests that even symptomatic patients with CM-I may not benefit from decompressive surgery if there is no evidence of CSF flow obstruction.",
"   </p>",
"   <p>",
"    Polysomnography should be considered in patients who present with sleep apnea, to demonstrate whether their sleep apnea is central or peripheral [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"     11",
"    </a>",
"    ]. Central sleep apnea is more suggestive of brainstem dysfunction and would prompt referral for surgical decompression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24684417\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of surgery for Chiari malformations are to decompress the craniocervical junction and restore the normal flow of cerebrospinal fluid (CSF) in the region of the foramen magnum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50\">",
"     50",
"    </a>",
"    ]. The most common procedure is posterior decompression via suboccipital craniectomy with or without duraplasty. Other procedures included anterior decompression of the foramen magnum by odontoidectomy, and shunting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88306577\">",
"    <span class=\"h3\">",
"     Posterior foramen magnum decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main surgical approaches to posterior fossa decompression are decompression with dural opening and decompression without dural opening.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most surgeons perform a posterior fossa decompression with opening of the dural sac for optimal decompression [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50,65\">",
"       50,65",
"      </a>",
"      ]. The procedure involves a limited suboccipital craniectomy, C1 laminectomy, duraplasty and arachnoid dissection. In an international survey conducted between October 2001 and March 2002, approximately three-quarters of the 76 neurosurgeons who responded favored opening the dural sac [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/58\">",
"       58",
"      </a>",
"      ]. Potential complications include pseudomeningocele formation, CSF leakage, acute postoperative hydrocephalus, and meningitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50,65\">",
"       50,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other surgeons favor a more conservative approach consisting of posterior fossa bony decompression without opening the dural sac [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/50,59,66,67\">",
"       50,59,66,67",
"      </a>",
"      ]. The major potential advantage of this method is avoidance of CSF-related complications such as CSF leak, pseudomeningocele, and aseptic meningitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The available data, though largely retrospective and uncontrolled, suggests that the more conservative surgery without duraplasty is associated with a reduced rate of CSF-related complications and an increased rate of the need for reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. A meta-analysis published in 2008 identified seven pediatric studies that compared posterior fossa decompression (PFD) surgery with and without duraplasty for children with CM-I [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/68\">",
"     68",
"    </a>",
"    ]. The following observations were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There was a higher rate of clinical improvement for PFD with duraplasty compared with PFD without duraplasty (79 versus 65 percent, relative risk [RR] 1.23, 95% CI 0.95-1.59) and a higher rate of postoperative reduction in syringomyelia size (87 versus 56 percent, RR 1.43, 95% CI 0.91-2.25). However, these differences were",
"      <strong>",
"       not",
"      </strong>",
"      statistically significant.",
"     </li>",
"     <li>",
"      The reoperation rate was significantly lower for PFD with duraplasty (2 versus 13 percent, RR 0.23, 95% CI 0.08-0.69)",
"     </li>",
"     <li>",
"      The rate of CSF-related complications was significantly higher for PFD with duraplasty (19 versus 2 percent, RR 7.64, 95% CI 2.53-23.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study not included in the meta-analysis reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if the findings of the meta-analysis and the subsequent report comparing decompression with and without duraplasty are generalizable, since the surgical techniques utilized among the included studies were not standardized, and outcome assessment was not blinded [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, the complication rates for individual centers and surgeons vary widely. As an example, a retrospective series of 40 patients (mean age 13.3 years, range 3 to 45 years) with CM-I who had decompression with duraplasty reported a low perioperative complication rate (3 percent), attributable to the development of a pseudomeningocele in one patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/70\">",
"     70",
"    </a>",
"    ]. There were no episodes of CSF leak, meningitis, or postoperative hydrocephalus.",
"   </p>",
"   <p>",
"    Given the absence of high-quality comparative studies, the utility of duraplasty for CM-I is uncertain, and more rigorous studies are needed to resolve this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88306584\">",
"    <span class=\"h3\">",
"     Anterior foramen magnum decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior decompression of the foramen magnum, typically via transoral odontoidectomy, is an alternative surgical approach to treating Chiari malformations. It is most often used for patients who fail posterior decompression. Some experts advocate this approach to reoperation when cine phase contrast MRI imaging shows anterior obstruction of CSF flow [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/62\">",
"     62",
"    </a>",
"    ]. Anterior decompression has also been used alone or in combination with posterior decompression for patients who have pronounced ventral brain stem compression associated with a Chiari malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88306592\">",
"    <span class=\"h3\">",
"     Shunting procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syrinx shunt placement has been used mainly for patients with CM-I who fail posterior decompression due to progressive symptoms or syrinx enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, some surgeons employ shunting rather than posterior fossa decompression as primary treatment for syringomyelia associated with CM-I [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/73\">",
"     73",
"    </a>",
"    ], while others routinely combine posterior fossa decompression with shunting for such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/74\">",
"     74",
"    </a>",
"    ]. However, syrinx shunts are controversial, particularly as primary therapy for CM-I related syringomyelia, on the basis of lesser benefit than bony decompression reported in some studies, and the potential for acute deterioration due to shunt malfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10173951\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of CM-I is unpredictable. Some patients remain asymptomatic, and occasional patients have spontaneous resolution of tonsillar displacement or spinal cord syringomyelia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/38,75-77\">",
"     38,75-77",
"    </a>",
"    ]. Others have a relentlessly worsening syrinx [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/78\">",
"     78",
"    </a>",
"    ]. Also, long-standing disease may lead to scarring with limitation of surgical benefit, especially if the syrinx has been present for more than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted earlier, there are few data regarding the natural history of CM-I. Limited evidence suggests that most patients with minimal or no symptoms remain stable. In one report, a series of 22 children with CM-I who had mild or absent clinical manifestations were followed without surgery for a mean period of 5.9 years (range 3 to 19 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/38\">",
"     38",
"    </a>",
"    ]. At last follow-up, symptoms were absent or improved for 17 patients (77 percent), while clinical deterioration was noted for five (23 percent). The deterioration was mild in two patients. The remaining three patients required surgery. Syringomyelia was present at study entry in only one child and did not change over 19 years of follow-up. However, cervical syringomyelia developed de novo in three children during follow-up.",
"   </p>",
"   <p>",
"    Surgical outcome for CM-I varies. There are no data from randomized controlled trials, but in largely retrospective series, postoperative improvement or stabilization has been reported for the majority of patients who have posterior fossa decompression with or without duraplasty.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective series reported 157 patients (mean age 38 years, range 16 to 75 years) with Chiari-related syringomyelia who had posterior fossa decompression with dural opening [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/79\">",
"       79",
"      </a>",
"      ]. At a median follow-up of 88 months, clinical improvement or stabilization was noted in 63 and 31 percent, while deterioration or death occurred in 6 and 1 percent. Factors associated with a poor outcome were older age at surgery and the presence of a long-tract deficit. The extent of the syrinx and level of tonsillar descent before surgery were not associated with outcome. However, syrinx size on postoperative MRI was a predictor of poor outcome.",
"     </li>",
"     <li>",
"      Another series retrospectively analyzed 130 children (mean age 11 years, range 2 months to 20 years) with CM-I who had posterior fossa decompression (with duraplasty in 129) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/65\">",
"       65",
"      </a>",
"      ]. At a mean follow-up of 4.2 years, improvement in preoperative pathologies was noted in 83 percent.",
"     </li>",
"     <li>",
"      A third retrospective study included 96 children (ages 0.5 to 18 years) with CM-I who had posterior fossa decompression surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/59\">",
"       59",
"      </a>",
"      ]. At a mean follow-up of 2.3 years, improvement was reported for approximately two-thirds of patients. Favorable outcome was significantly higher for children who were younger than 8 years of age at the time of surgery (odds ratio [OR] 3.0, 95% CI 1.2-7.5). Surgical technique (dural scoring versus duraplasty) had no effect on outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these series, reoperation for persistent or progressive symptoms was performed in 4 to 13 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26697/abstract/59,65,79\">",
"     59,65,79",
"    </a>",
"    ]. Reoperative procedures have included repeat posterior fossa decompression (or rarely odontoidectomy) after incomplete initial decompression, and ventriculoperitoneal shunt placement for symptom progression and persistent large syringomyelia despite complete initial decompression. (See",
"    <a class=\"local\" href=\"#H24684417\">",
"     'Surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H837826\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are three main types of Chiari malformations (see",
"      <a class=\"local\" href=\"#H1239375\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1308662\">",
"       'Anatomic aspects'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chiari I malformation (CM-I) is characterized by abnormally shaped cerebellar tonsils that are displaced below the level of the foramen magnum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68681 \" href=\"UTD.htm?4/47/4852\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chiari II malformation (CM-II), also known as Arnold-Chiari malformation, is characterized by downward displacement of the cerebellar vermis and tonsils, a brainstem malformation with beaked midbrain on neuroimaging, and a spinal myelomeningocele (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71208 \" href=\"UTD.htm?40/26/41377\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61496 \" href=\"UTD.htm?38/15/39155\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef61495 \" href=\"UTD.htm?12/35/12851\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chiari III malformation (CM-III) is rare and combines a small posterior fossa with a high cervical or occipital encephalocele, usually with displacement of cerebellar structures into the encephalocele, and often with inferior displacement of the brainstem into the spinal canal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef74322 \" href=\"UTD.htm?19/18/19746\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CM-I is the most frequent of the Chiari malformations. The true prevalence of CM-I is unknown, but available evidence suggests the prevalence is 0.1 to 0.5 percent. (See",
"      <a class=\"local\" href=\"#H10173927\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a wide spectrum of clinical symptoms associated with Chiari malformations. The major categories of symptoms are those related to obstructive hydrocephalus, abnormal eye movements, cerebellar deficits, and spinal myelomeningocele. Patients with CM-I are spared the latter, as they do not have neural tube defects such as a myelomeningocele. Pain or headache due to meningeal irritation is the most common presentation in patients with CM-I. (See",
"      <a class=\"local\" href=\"#H10173933\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Chiari malformations is based upon neuroanatomy. There are no diagnostic biomarkers. MRI is the best imaging modality for evaluation (see",
"      <a class=\"local\" href=\"#H10173939\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The radiologic diagnosis of CM-I in adolescents and adults is made by MRI when one or both cerebellar tonsils are displaced by &ge;5 mm below the foramen magnum.",
"     </li>",
"     <li>",
"      The diagnosis of CM-II is made in a fetus or newborn with clinical evidence of a spinal myelomeningocele and confirmatory MRI showing downward displacement of inferior cerebellar vermis and medulla through the foramen magnum into the upper cervical canal.",
"     </li>",
"     <li>",
"      The diagnosis of CM-III is made in a fetus or newborn with clinical evidence of a high",
"      <span class=\"nowrap\">",
"       cervical/occipital",
"      </span>",
"      encephalocele and confirmatory MRI showing a high cervical or occipital encephalocele with descent of cerebellar structures into the malformation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of Chiari malformations depends upon the nature of the malformation and the degree of associated neurologic impairments (see",
"      <a class=\"local\" href=\"#H10173945\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For CM-II and CM-III, surgical interventions may include closure of open neural tube defects shortly after birth, treatment for hydrocephalus (most often by use of a shunt), and decompression of tight posterior fossa structures. Medical issues involve management of neurogenic bowel and bladder, neonatal feeding difficulties, respiratory failure, and apnea.",
"     </li>",
"     <li>",
"      Asymptomatic patients with an incidental diagnosis of CM-I who do not have syringomyelia can be managed conservatively with clinical and MRI surveillance.",
"     </li>",
"     <li>",
"      For patients with CM-I who are clearly symptomatic with lower cranial nerve palsies, syringomyelia, myelopathy, cerebellar symptoms, severe neck pain or occipital headache related to the Chiari malformation, we recommend surgical decompression of the foramen magnum (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For asymptomatic or oligosymptomatic patients with CM-I who are neurologically intact but have syringomyelia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81030 \" href=\"UTD.htm?39/25/40337\">",
"       image 5",
"      </a>",
"      ) on MRI, management is controversial. We suggest obtaining a cine phase contrast MRI for such patients; if the study shows complete cerebrospinal fluid (CSF) flow obstruction, we refer the patient to surgery. If there is only partial or no CSF flow obstruction, we follow the patient with clinical and neuroimaging surveillance, and refer for posterior fossa decompression at the first sign of clinical deterioration.",
"     </li>",
"     <li>",
"      The goals of surgery for Chiari malformations are to decompress the craniocervical junction and restore the normal flow of CSF in the region of the foramen magnum. The most common procedure is posterior decompression via suboccipital craniectomy with or without duraplasty. Other procedures included anterior decompression of the foramen magnum by odontoidectomy, and shunting. (See",
"      <a class=\"local\" href=\"#H24684417\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of CM-I is unpredictable. Limited evidence suggests that most patients with minimal or no symptoms remain stable. In largely retrospective series, postoperative improvement or stabilization has been reported for the majority of patients who have posterior fossa decompression. (See",
"      <a class=\"local\" href=\"#H10173951\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/1\">",
"      Sarnat HB. Disorders of segmentation of the neural tube: Chiari malformations. Handb Clin Neurol 2008; 87:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/2\">",
"      Carmel PW, Markesbery WR. Early descriptions of the Arnold-Chiari malformation. The contribution of John Cleland. J Neurosurg 1972; 37:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/3\">",
"      Pearce JM. Arnold chiari, or \"Cruveilhier cleland Chiari\" malformation. J Neurol Neurosurg Psychiatry 2000; 68:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/4\">",
"      Schijman E. History, anatomic forms, and pathogenesis of Chiari I malformations. Childs Nerv Syst 2004; 20:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/5\">",
"      Tubbs RS, Elton S, Grabb P, et al. Analysis of the posterior fossa in children with the Chiari 0 malformation. Neurosurgery 2001; 48:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/6\">",
"      Tubbs RS, Iskandar BJ, Bartolucci AA, Oakes WJ. A critical analysis of the Chiari 1.5 malformation. J Neurosurg 2004; 101:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/7\">",
"      Menezes AH. Chiari I malformations and hydromyelia--complications. Pediatr Neurosurg 1991; 17:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/8\">",
"      Wu YW, Chin CT, Chan KM, et al. Pediatric Chiari I malformations: do clinical and radiologic features correlate? Neurology 1999; 53:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/9\">",
"      Fern&aacute;ndez AA, Guerrero AI, Mart&iacute;nez MI, et al. Malformations of the craniocervical junction (Chiari type I and syringomyelia: classification, diagnosis and treatment). BMC Musculoskelet Disord 2009; 10 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/10\">",
"      Milhorat TH, Chou MW, Trinidad EM, et al. Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients. Neurosurgery 1999; 44:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/11\">",
"      Caldarelli M, Di Rocco C. Diagnosis of Chiari I malformation and related syringomyelia: radiological and neurophysiological studies. Childs Nerv Syst 2004; 20:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/12\">",
"      Nohria V, Oakes WJ. Chiari I malformation: a review of 43 patients. Pediatr Neurosurg 1990; 16:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/13\">",
"      Marin-Padilla M, Marin-Padilla TM. Morphogenesis of experimentally induced Arnold--Chiari malformation. J Neurol Sci 1981; 50:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/14\">",
"      PEACH B. THE ARNOLD-CHIARI MALFORMATION; MORPHOGENESIS. Arch Neurol 1965; 12:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/15\">",
"      Gilbert JN, Jones KL, Rorke LB, et al. Central nervous system anomalies associated with meningomyelocele, hydrocephalus, and the Arnold-Chiari malformation: reappraisal of theories regarding the pathogenesis of posterior neural tube closure defects. Neurosurgery 1986; 18:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/16\">",
"      Sener RN, Dzelzite S. Rhombencephalosynapsis and a Chiari II malformation. J Comput Assist Tomogr 2003; 27:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/17\">",
"      Caldarelli M, Rea G, Cincu R, Di Rocco C. Chiari type III malformation. Childs Nerv Syst 2002; 18:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/18\">",
"      Sarnat HB. Regional ependymal upregulation of vimentin in Chiari II malformation, aqueductal stenosis, and hydromyelia. Pediatr Dev Pathol 2004; 7:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/19\">",
"      Roth M. Cranio-cervical growth collision: another explanation of the Arnold-Chiari malformation and of basilar impression. Neuroradiology 1986; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/20\">",
"      Matsuoka T, Ahlberg PE, Kessaris N, et al. Neural crest origins of the neck and shoulder. Nature 2005; 436:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/21\">",
"      Mar&iacute;n-Padilla M. Cephalic axial skeletal-neural dysraphic disorders: embryology and pathology. Can J Neurol Sci 1991; 18:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/22\">",
"      Padget DH. Development of so-called dysraphism; with embryologic evidence of clinical Arnold-Chiari and Dandy-Walker malformations. Johns Hopkins Med J 1972; 130:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/23\">",
"      McLone DG, Knepper PA. The cause of Chiari II malformation: a unified theory. Pediatr Neurosci 1989; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/24\">",
"      Lichtenstein, BW. &lsquo;Spinal dysraphism&rsquo;: spina bifida and myelodysplasia. AMA Arch Neurol Psychiatry 1940; 44:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/25\">",
"      Lichtenstein, BW. Distant neuroanatomic complications of spina bifida (spinal dysraphism): hydrocephalus, Arnold&ndash;Chiari deformity, stenosis of aqueduct of Sylvius, etc.: pathogenesis and pathology. Arch Neurol Psychiat 1942; 47:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/26\">",
"      Penfield, W, Coburn, DF. Arnold&ndash;Chiari malformation and its operative treatment. Arch Neurol Psychiat 1938; 40:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/27\">",
"      Royo-Salvador MB, Sol&eacute;-Llenas J, Dom&eacute;nech JM, Gonz&aacute;lez-Adrio R. Results of the section of the filum terminale in 20 patients with syringomyelia, scoliosis and Chiari malformation. Acta Neurochir (Wien) 2005; 147:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/28\">",
"      Yamada S. Tethered cord syndrome in adults and children. Neurol Res 2004; 26:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/29\">",
"      Yamada S, Knerium DS, Mandybur GM, et al. Pathophysiology of tethered cord syndrome and other complex factors. Neurol Res 2004; 26:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/30\">",
"      Goldstein F, Kepes JJ. The role of traction in the development of the Arnold-Chiari malformation. An experimental study. J Neuropathol Exp Neurol 1966; 25:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/31\">",
"      Speer MC, Enterline DS, Mehltretter L. Chiari type I malformation with or without syringomyelia: prevalence and genetics. J Genet Couns 2003; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/32\">",
"      Steinbok P. Clinical features of Chiari I malformations. Childs Nerv Syst 2004; 20:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/33\">",
"      Holder-Espinasse M, Abadie V, Cormier-Daire V, et al. Pierre Robin sequence: a series of 117 consecutive cases. J Pediatr 2001; 139:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/34\">",
"      Lee J, Hida K, Seki T, et al. Pierre-Robin syndrome associated with Chiari type I malformation. Childs Nerv Syst 2003; 19:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/35\">",
"      Tubbs RS, Rutledge SL, Kosentka A, et al. Chiari I malformation and neurofibromatosis type 1. Pediatr Neurol 2004; 30:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/36\">",
"      Holder-Espinasse M, Winter RM. Type 1 Arnold-Chiari malformation and Noonan syndrome. A new diagnostic feature? Clin Dysmorphol 2003; 12:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/37\">",
"      Peiris A, Ball MJ. Chiari (type 1) malformation and syringomyelia in a patient with Noonan's syndrome. J Neurol Neurosurg Psychiatry 1982; 45:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/38\">",
"      Novegno F, Caldarelli M, Massa A, et al. The natural history of the Chiari Type I anomaly. J Neurosurg Pediatr 2008; 2:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/39\">",
"      Adams, RD, Schatzki, R, Scoville, WB. The Arnold-Chiari malformation. Diagnosis, demonstration by intraspinal lipiodol and successful surgical treatment. N Eng J Med 1941; 225:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/40\">",
"      Goh S, Bottrell CL, Aiken AH, et al. Presyrinx in children with Chiari malformations. Neurology 2008; 71:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/41\">",
"      Bloch S, Van Rensburg MJ, Danziger J. The Arnold-Chiari malformation. Clin Radiol 1974; 25:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/42\">",
"      Elster AD, Chen MY. Chiari I malformations: clinical and radiologic reappraisal. Radiology 1992; 183:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/43\">",
"      Fischbein NJ, Dillon WP, Cobbs C, Weinstein PR. The \"presyrinx\" state: a reversible myelopathic condition that may precede syringomyelia. AJNR Am J Neuroradiol 1999; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/44\">",
"      Pascual J, Oterino A, Berciano J. Headache in type I Chiari malformation. Neurology 1992; 42:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/45\">",
"      Albert GW, Menezes AH, Hansen DR, et al. Chiari malformation Type I in children younger than age 6 years: presentation and surgical outcome. J Neurosurg Pediatr 2010; 5:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/46\">",
"      Vandertop WP, Asai A, Hoffman HJ, et al. Surgical decompression for symptomatic Chiari II malformation in neonates with myelomeningocele. J Neurosurg 1992; 77:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/47\">",
"      Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr 2000; 30:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/48\">",
"      Muen WJ, Bannister CM. Hand function in subjects with spina bifida. Eur J Pediatr Surg 1997; 7 Suppl 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/49\">",
"      Guillen A, Costa JM. Spontaneous resolution of a Chiari I malformation associated syringomyelia in one child. Acta Neurochir (Wien) 2004; 146:187.",
"     </a>",
"    </li>",
"    <li>",
"     Pakzaban, P. Chiari malformation. file://emedicine.medscape.com/article/1483583-overview (Accessed on July 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/51\">",
"      Gundry CR, Heithoff KB. Imaging evaluation of patients with spinal deformity. Orthop Clin North Am 1994; 25:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/52\">",
"      D'Addario V, Pinto V, Del Bianco A, et al. The clivus-supraocciput angle: a useful measurement to evaluate the shape and size of the fetal posterior fossa and to diagnose Chiari II malformation. Ultrasound Obstet Gynecol 2001; 18:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/53\">",
"      Fujisawa H, Kitawaki J, Iwasa K, Honjo H. New ultrasonographic criteria for the prenatal diagnosis of Chiari type 2 malformation. Acta Obstet Gynecol Scand 2006; 85:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/54\">",
"      Amer TA, el-Shmam OM. Chiari malformation type I: a new MRI classification. Magn Reson Imaging 1997; 15:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/55\">",
"      Pillay PK, Awad IA, Little JR, Hahn JF. Symptomatic Chiari malformation in adults: a new classification based on magnetic resonance imaging with clinical and prognostic significance. Neurosurgery 1991; 28:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/56\">",
"      Barkovich AJ, Wippold FJ, Sherman JL, Citrin CM. Significance of cerebellar tonsillar position on MR. AJNR Am J Neuroradiol 1986; 7:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/57\">",
"      Mikulis DJ, Diaz O, Egglin TK, Sanchez R. Variance of the position of the cerebellar tonsils with age: preliminary report. Radiology 1992; 183:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/58\">",
"      Schijman E, Steinbok P. International survey on the management of Chiari I malformation and syringomyelia. Childs Nerv Syst 2004; 20:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/59\">",
"      Navarro R, Olavarria G, Seshadri R, et al. Surgical results of posterior fossa decompression for patients with Chiari I malformation. Childs Nerv Syst 2004; 20:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/60\">",
"      Tubbs RS, Lyerly MJ, Loukas M, et al. The pediatric Chiari I malformation: a review. Childs Nerv Syst 2007; 23:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/61\">",
"      Nishikawa M, Sakamoto H, Hakuba A, et al. Pathogenesis of Chiari malformation: a morphometric study of the posterior cranial fossa. J Neurosurg 1997; 86:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/62\">",
"      Panigrahi M, Reddy BP, Reddy AK, Reddy JJ. CSF flow study in Chiari I malformation. Childs Nerv Syst 2004; 20:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/63\">",
"      Ventureyra EC, Aziz HA, Vassilyadi M. The role of cine flow MRI in children with Chiari I malformation. Childs Nerv Syst 2003; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/64\">",
"      McGirt MJ, Nimjee SM, Fuchs HE, George TM. Relationship of cine phase-contrast magnetic resonance imaging with outcome after decompression for Chiari I malformations. Neurosurgery 2006; 59:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/65\">",
"      Tubbs RS, McGirt MJ, Oakes WJ. Surgical experience in 130 pediatric patients with Chiari I malformations. J Neurosurg 2003; 99:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/66\">",
"      James HE. Chiari malformation type I. J Neurosurg 2007; 107:184; author reply 184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/67\">",
"      James HE, Brant A. Treatment of the Chiari malformation with bone decompression without durotomy in children and young adults. Childs Nerv Syst 2002; 18:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/68\">",
"      Durham SR, Fjeld-Olenec K. Comparison of posterior fossa decompression with and without duraplasty for the surgical treatment of Chiari malformation Type I in pediatric patients: a meta-analysis. J Neurosurg Pediatr 2008; 2:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/69\">",
"      Mutchnick IS, Janjua RM, Moeller K, Moriarty TM. Decompression of Chiari malformation with and without duraplasty: morbidity versus recurrence. J Neurosurg Pediatr 2010; 5:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/70\">",
"      Hoffman CE, Souweidane MM. Cerebrospinal fluid-related complications with autologous duraplasty and arachnoid sparing in type I Chiari malformation. Neurosurgery 2008; 62:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/71\">",
"      Hwang SW, Heilman CB, Riesenburger RI, Kryzanski J. C1-C2 arthrodesis after transoral odontoidectomy and suboccipital craniectomy for ventral brain stem compression in Chiari I patients. Eur Spine J 2008; 17:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/72\">",
"      Hankinson TC, Grunstein E, Gardner P, et al. Transnasal odontoid resection followed by posterior decompression and occipitocervical fusion in children with Chiari malformation Type I and ventral brainstem compression. J Neurosurg Pediatr 2010; 5:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/73\">",
"      Hida K, Iwasaki Y, Koyanagi I, et al. Surgical indication and results of foramen magnum decompression versus syringosubarachnoid shunting for syringomyelia associated with Chiari I malformation. Neurosurgery 1995; 37:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/74\">",
"      Alzate JC, Kothbauer KF, Jallo GI, Epstein FJ. Treatment of Chiari I malformation in patients with and without syringomyelia: a consecutive series of 66 cases. Neurosurg Focus 2001; 11:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/75\">",
"      Sudo K, Doi S, Maruo Y, et al. Syringomyelia with spontaneous resolution. J Neurol Neurosurg Psychiatry 1990; 53:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/76\">",
"      Sun PP, Harrop J, Sutton LN, Younkin D. Complete spontaneous resolution of childhood Chiari I malformation and associated syringomyelia. Pediatrics 2001; 107:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/77\">",
"      Tokunaga M, Minami S, Isobe K, et al. Natural history of scoliosis in children with syringomyelia. J Bone Joint Surg Br 2001; 83:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/78\">",
"      Tubbs RS, Wellons JC 3rd, Oakes WJ. Occipital encephalocele, lipomeningomyelocele, and Chiari I malformation: case report and review of the literature. Childs Nerv Syst 2003; 19:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26697/abstract/79\">",
"      Aghakhani N, Parker F, David P, et al. Long-term follow-up of Chiari-related syringomyelia in adults: analysis of 157 surgically treated cases. Neurosurgery 2009; 64:308.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13507 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5DB5CB92DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26697=[""].join("\n");
var outline_f26_4_26697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H837826\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173921\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1239375\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1308662\">",
"      ANATOMIC ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15846546\">",
"      Chiari type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15846561\">",
"      Chiari type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24684203\">",
"      Chiari type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13738661\">",
"      ETIOLOGY AND PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173927\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5294754\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173933\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7708132\">",
"      Chiari type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7706943\">",
"      Chiari type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20314753\">",
"      Chiari type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173939\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173945\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24684417\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88306577\">",
"      - Posterior foramen magnum decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88306584\">",
"      - Anterior foramen magnum decompression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88306592\">",
"      - Shunting procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10173951\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H837826\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/13507\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/13507|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/47/4852\" title=\"diagnostic image 1\">",
"      MRI of Chiari I malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/26/41377\" title=\"diagnostic image 2\">",
"      MRI of fetal Chiari II malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/15/39155\" title=\"diagnostic image 3\">",
"      MRI brain Chiari II malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/18/19746\" title=\"diagnostic image 4\">",
"      MRI Chiari III malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/25/40337\" title=\"diagnostic image 5\">",
"      Syringomyelia with Chiari I malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/0/21509\" title=\"diagnostic image 6\">",
"      Presyrinx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/13507|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/35/12851\" title=\"figure 1\">",
"      Chiari type II malformation and associated lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/54/5994?source=related_link\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19688?source=related_link\">",
"      Orthopedic issues in myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15288?source=related_link\">",
"      Urinary tract complications of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_4_26698="Pathophysiology, clinical manifestations, and diagnosis of migraine in adults";
var content_f26_4_26698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26698/contributors\">",
"     F Michael Cutrer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Zahid H Bajwa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Ashraf Sabahat, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/4/26698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/4/26698/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/4/26698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21673885\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is an episodic disorder, the centerpiece of which is a severe headache generally associated with nausea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    light and sound sensitivity. It is one of the most common complaints encountered by neurologists in day to day practice.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, diagnosis, and complications of migraine will be reviewed here. Other aspects of migraine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link\">",
"     \"Chronic migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link\">",
"     \"Migrainous vertigo\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"     \"Headache, migraine, and stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649620\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current state of knowledge suggests that a primary neuronal dysfunction leads to a sequence of changes intracranially and extracranially that account for migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/1\">",
"     1",
"    </a>",
"    ], including the four phases of premonitory symptoms, aura, headache, and postdrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649627\">",
"    <span class=\"h2\">",
"     Traditional theories of migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The once popular vascular theory of migraine, which suggested that migraine headache was caused by the dilatation of blood vessels, while the aura of migraine resulted from vasoconstriction, is no longer considered viable in its original form [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/2\">",
"     2",
"    </a>",
"    ]. Vasodilatation itself is probably an epiphenomenon, resulting from instability in the central neurovascular control mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649634\">",
"    <span class=\"h2\">",
"     Cortical spreading depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A causal association between migraine aura and headache is supported by evidence that both are linked to the phenomenon known as cortical spreading depression of Le&atilde;o [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. Cortical spreading depression is a self propagating wave of neuronal and glial depolarization that spreads across the cerebral cortex. Cortical spreading depression is hypothesized to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cause the aura of migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activate trigeminal nerve afferents [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Alter blood-brain barrier permeability by matrix metalloproteinase activation and upregulation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The activation of trigeminal afferents by cortical spreading depression in turn causes inflammatory changes in the pain-sensitive meninges that generate the headache of migraine through central and peripheral reflex mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/10\">",
"     10",
"    </a>",
"    ]. It has been suggested that migraine without aura may be caused by the occurrence of cortical spreading depression in areas of the brain (eg, cerebellum) where depolarization is not consciously perceived [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649641\">",
"    <span class=\"h2\">",
"     Trigeminovascular system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of migraine involves activation of the trigeminovascular system, which consists of small caliber pseudounipolar sensory neurons that originate from the trigeminal ganglion and upper cervical dorsal roots [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/12\">",
"     12",
"    </a>",
"    ]. These sensory neurons project to innervate large cerebral vessels, pial vessels, dura mater, and large venous sinuses. Most of the innervation of the anterior structures is via the ophthalmic division of the trigeminal nerve with a greater contribution of upper cervical roots to posterior structures.",
"   </p>",
"   <p>",
"    There is convergence of the projections from the upper cervical nerve roots and the trigeminal nerve at the trigeminal nucleus caudalis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This convergence can explain the distribution of migraine pain, which often includes anterior and posterior regions of the head and the upper neck. Once transmitted to the trigeminal nucleus caudalis by trigeminal axons, central signals can be modulated by projections from the rostral trigeminal nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/15\">",
"     15",
"    </a>",
"    ], the periaqueductal gray, and the nucleus raphe magnus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/16\">",
"     16",
"    </a>",
"    ] as well as by descending cortical inhibitory systems [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From the trigeminal nucleus caudalis, fibers that are involved in the localization of pain ascend to the thalamus (mostly to the ventroposterior medial nucleus of the thalamus) and to the sensory cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/18\">",
"     18",
"    </a>",
"    ]. Other second-order neurons from the trigeminal nucleus caudalis project to numerous subcortical sites including the more rostral segments of the trigeminal complex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/19\">",
"     19",
"    </a>",
"    ], the reticular formation of the brain stem [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/20\">",
"     20",
"    </a>",
"    ], the cerebellum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], the midbrain and pontine parabrachial nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], the ventrobasal thalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/19,22,25,26\">",
"     19,22,25,26",
"    </a>",
"    ], the posterior thalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/27,28\">",
"     27,28",
"    </a>",
"    ], and the medial thalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/29\">",
"     29",
"    </a>",
"    ]. From more rostral brain stem nuclei, nociceptive information is transmitted to other brain areas (eg, limbic regions) involved in the emotional and vegetative responses to pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulation of the trigeminal ganglion results in release of vasoactive neuropeptides, including substance P, calcitonin gene-related peptide, and neurokinin A [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/30\">",
"     30",
"    </a>",
"    ]. Release of these neuropeptides is associated with the process of neurogenic inflammation. The two main components of this sterile inflammatory response are vasodilation (calcitonin gene-related peptide is a potent vasodilator) and plasma protein extravasation.",
"   </p>",
"   <p>",
"    Neurogenic inflammation is thought to be important in the prolongation and intensification of the pain of migraine. Elevated levels of vasoactive neuropeptides have been found in the cerebrospinal fluid of patients with chronic migraine, suggesting chronic activation of the trigeminovascular system in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/31\">",
"     31",
"    </a>",
"    ]. Neurogenic inflammation may lead to the process of sensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203274958\">",
"    <span class=\"h2\">",
"     Sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitization refers to the process in which neurons become increasingly responsive to nociceptive and non-nociceptive stimulation: response thresholds decrease, response magnitude increases, receptive fields expand, and spontaneous neuronal activity develops [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Peripheral sensitization in the primary afferent neurons and central sensitization within second order neurons in the trigeminal nucleus caudalis and higher order neurons in the central nervous system are thought to play a role within individual migraine attacks and, perhaps, even in the transformation of episodic migraine to chronic migraine.",
"   </p>",
"   <p>",
"    Sensitization is likely responsible for many of the clinical symptoms of migraine, including the throbbing quality of the pain, the worsening of pain with coughing, bending, or sudden head movements (as is often observed during the postdrome), hyperalgesia (increased sensitivity to painful stimuli), and allodynia (pain produced by normally non-noxious stimulation).",
"   </p>",
"   <p>",
"    Functional brain imaging has identified abnormalities in the ascending and descending pain pathways of patients with migraine during and in between attacks. Alterations in blood flow to the dorsal pons, anterior cingulate cortex, visual cortex, and auditory association cortex have been seen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Patients with chronic migraine are found to have altered blood flow to the dorsal pons, anterior cingulate cortex, and cuneus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural changes in the brain have also been found. Studies suggest that patients with migraine have increased cortical thickness in motion-processing visual areas, increased density of the periaqueductal gray and dorsolateral pons, and decreased gray matter in the anterior cingulate cortex and insula [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Increased iron levels have been identified in the periaqueductal gray of episodic and chronic migraineurs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649648\">",
"    <span class=\"h2\">",
"     Role of serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although activation at serotonin receptors is of known importance in the acute treatment of migraine, its role in the generation of migraine is unclear. Some authors have suggested that serotonin (released from brainstem serotonergic nuclei) plays a role in the pathogenesis of migraine, perhaps mediated by its direct action upon the cranial vasculature, by its role in central pain control pathways, or by cerebral cortical projections of brainstem serotonergic nuclei [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Such a role for serotonin is supported by the fact that tricyclic antidepressants, which block serotonin reuptake, are effective antimigraine prophylactic agents. In contrast, however, more selective serotonin reuptake inhibitors are not very effective in migraine prevention. There is other evidence that a low serotonin state may result in a deficit in the serotonin descending pain inhibitory system, facilitating activation of the trigeminovascular nociceptive pathways in conjunction with cortical spreading depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649655\">",
"    <span class=\"h2\">",
"     Role of calcitonin gene-related peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcitonin gene-related peptide (CGRP) may also play a role in migraine pathophysiology. CGRP is a 37 amino acid neuropeptide that is expressed in trigeminal ganglia nerves and is a potent vasodilator of cerebral and dural vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CGRP may mediate trigeminovascular pain transmission from intracranial vessels to the central nervous system, as well as the vasodilatory component of neurogenic inflammation. However, the evidence is conflicting. Stimulation of the trigeminal ganglion induces the release of CGRP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/30\">",
"     30",
"    </a>",
"    ], and CGRP infusion can trigger a migraine attack in migraineurs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/44\">",
"     44",
"    </a>",
"    ]. In healthy subjects without migraine, a placebo-controlled crossover trial found that exogenous CGRP infusion causes vasodilation of the middle meningeal artery (extracranial) but not the middle cerebral artery (intracranial), whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    infusion causes vasoconstriction of the middle meningeal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/45\">",
"     45",
"    </a>",
"    ]. The lack of vasodilatory response of the intracranial artery to CGRP infusion in this trial may be explained by the inability of exogenous CGRP to cross the blood-brain-barrier. Although one study found elevation of CGRP levels in external jugular venous blood during migraine attack [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/46\">",
"     46",
"    </a>",
"    ], this result was not reproduced in a subsequent study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/47\">",
"     47",
"    </a>",
"    ]. Furthermore, CGRP did not activate or sensitize meningeal nociceptors in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated CGRP levels are normalized in patients with migraine following administration of the serotonin",
"    <span class=\"nowrap\">",
"     1b/1d",
"    </span>",
"    receptor agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/49\">",
"     49",
"    </a>",
"    ], suggesting that triptans may act to control migraine at least in part by blocking the release of CGRP.",
"   </p>",
"   <p>",
"    Pharmacologic modulation of CGRP activity offers the promise of future treatment options for acute migraine attacks. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute treatment of migraine in adults\", section on 'CGRP receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130649662\">",
"    <span class=\"h2\">",
"     Right-to-left cardiac shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine with aura has been linked to right-to-left cardiac shunts, usually in the setting of a patent foramen ovale (PFO) or, much less often, an atrial septal defect (ASD) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/50-52\">",
"     50-52",
"    </a>",
"    ] or pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=see_link\">",
"     \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence regarding the association of migraine with PFO is conflicting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 1101 stroke-free subjects (mean age 69) from the NOMAS cohort who were evaluated for PFO using transthoracic echocardiography with saline contrast and provocative maneuvers, there was no significant difference in the prevalence of PFO among subjects who had migraine compared with those who did not have migraine (14.6 versus 15.0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/54\">",
"       54",
"      </a>",
"      ]. The presence of PFO was not associated with an increased prevalence of migraine (odds ratio [OR] 1.01, 95% CI 0.63 to 1.61) or an increased prevalence of migraine with aura (OR 1.01, 95% CI 0.71 to 1.69) compared with no migraine.",
"     </li>",
"     <li>",
"      A systematic review of case-control studies published in 2008 concluded that migraine with aura (but not without aura) is more common in patients with PFO than in the general population, and that PFO is more prevalent in patients who have migraine with aura than in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While definitive conclusions are not yet possible, the population-based NOMAS study provides high-quality observational evidence that PFO is not associated with migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/56\">",
"     56",
"    </a>",
"    ]. In contrast, the association of PFO with migraine in the systematic review is supported by low or low to moderate quality evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of any possible association between right-to-left cardiac shunt and migraine is not known. One theory is that a genetic influence might predispose some patients to a higher risk of developing both atrial septal abnormalities and migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/57\">",
"     57",
"    </a>",
"    ]. Other theories focus on the shunt pathway. As examples, one hypothesis is that the venous circulation contains vasoactive substances capable of triggering migraine; these are normally inactivated in the lungs but gain access to the cranial circulation in the presence of a right-to-left shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/58\">",
"     58",
"    </a>",
"    ]. Another hypothesis is that the existence of the shunt provides a pathway for paradoxical embolism and subsequent cerebral ischemia, which in turn triggers migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Closure of the defect has been reported to prevent or reduce the frequency of subsequent migraines. However, the data are conflicting, and it is premature to recommend closure of a PFO or ASD solely as a treatment for migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link&amp;anchor=H27#H27\">",
"     \"Preventive treatment of migraine in adults\", section on 'Closure of right-to-left cardiac shunt'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130650647\">",
"    <span class=\"h1\">",
"     GENETIC BASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a syndromic disorder of the brain that is in most instances inherited. As with most common diseases, the genetic basis of migraine is likely to be complex and in some individuals may be based on the additive effect of more than one genetic source. Individuals prone to migraine have a genetic threshold that renders them susceptible to an acute migraine attack depending upon the balance between excitation and inhibition at various levels of the nervous system. Subtle abnormalities, involving membrane channels, receptor families, and enzyme systems have been linked to migraine in certain groups and individuals.",
"   </p>",
"   <p>",
"    The importance of inheritance in migraine has long been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/59\">",
"     59",
"    </a>",
"    ]. One early general population based study found that the risk of migraine in relatives of migraineurs was three times greater than that of relatives of non-migraine control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/60\">",
"     60",
"    </a>",
"    ]. However segregation analysis does not identify any single Mendelian pattern of inheritance in the common forms of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/61\">",
"     61",
"    </a>",
"    ]. Large national registry-based twin studies have confirmed a consistently higher concordance of migraine in monozygotic twins versus dizygotic twins. In one such study, using a polygenic multifactorial model, researchers estimated that inheritance accounts for 40 to 50 percent of an individual's susceptibility to migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130650973\">",
"    <span class=\"h2\">",
"     Genetics of the common forms of migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic basis of the common forms of migraine (migraine with aura and migraine without aura) has not been clarified. However, the KCNK18 gene that encodes for TRESK, a two-pore domain potassium channel (K2P), has been implicated as a probable cause of migraine with aura in a candidate gene study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/63\">",
"     63",
"    </a>",
"    ]. The report identified KCNK18 variants by sequencing the gene in cohorts of unrelated subjects with and without migraine. One particular frameshift mutation (F139WfsX24) in the KCNK18 gene, first identified in migraineurs, was then found to segregate only with individuals affected by migraine with aura in a large multigenerational kindred; it was not found in unaffected individuals. Functional analysis revealed that the mutant TRESK channels are nonfunctional and cause a dominant-negative downregulation of wild-type TRESK activity. In addition, the investigators demonstrated that TRESK is expressed in trigeminal ganglia. The results suggest that the KCNK18 mutation causes suppression of TRESK channel activity and thereby alters neuronal excitability, consistent with a possible pathogenic role in migraine.",
"   </p>",
"   <p>",
"    The minor allele of rs1835740 on chromosome 8q22.1 is a potential genetic susceptibility marker for migraine, as suggested by the results of a genome-wide association study (GWAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/64\">",
"     64",
"    </a>",
"    ]. A later population-based GWAS identified three additional susceptibility loci for common migraine, which were rs2651899 at 1p36.32 (PRDM16 gene), rs10166942 at 2q37.1 (TRPM8 gene) and rs11172113 at 12q13.3 (LRP1 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/65\">",
"     65",
"    </a>",
"    ]. However, unlike the earlier GWAS, it did not find any association of rs1835740 with migraine. Case control studies have shown modest associations with migraine for several other candidate genes, but the findings of these studies have often not been replicated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The common forms of migraine are likely to be complex genetic disorders, meaning that multiple genes at different genomic sites act in tandem with environmental factors to confer both the susceptibility to and the characteristics of the disease in affected individuals. One possible explanation for the lack of replication in genetic studies of migraine is that a few gene polymorphisms are frequently tested for association in relatively small populations in which only a portion of the subjects have migraine that arises from the studied variant, while the migraine in other case subjects has as different basis. This would tend to lower the power of many of these studies to detect a significant difference in the case subjects compared to the non-migraine control subjects. The eventual identification of the genes that underlie migraine in an individual patient is extremely important, as it may be predictive of the type of prophylactic treatment to which the patient will respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H130650654\">",
"    <span class=\"h2\">",
"     Familial hemiplegic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary feature that separates hemiplegic migraine from other types of migraine with aura is the presence of motor weakness as a manifestation of aura in at least some attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link\">",
"     \"Hemiplegic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemiplegic migraine may occur either in families or only in one individual (sporadic). The first three types of familial hemiplegic migraine are channelopathies numbered according to the gene involved. FHM1 is caused by mutations in the CACNA1A gene, FHM2 by mutations in the ATP1A2 gene, and FHM3 by mutations in the SCN1A gene. Mutations in the PRRT2 gene also cause some cases of familial hemiplegic migraine. The known types of familial hemiplegic migraine account for only a small proportion of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link&amp;anchor=H81876416#H81876416\">",
"     \"Hemiplegic migraine\", section on 'Familial hemiplegic migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674074\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a common disorder that affects up to 12 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/68\">",
"     68",
"    </a>",
"    ]. It is more frequent in women than in men, with attacks occurring in up to 17 percent of women and 6 percent of men each year [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Migraine is most common in those aged 30 to 39, an age span in which prevalence in men and women reaches 7 and 24 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef57550 \" href=\"UTD.htm?31/33/32286\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/70\">",
"     70",
"    </a>",
"    ]. Migraine also tends to run in families.",
"   </p>",
"   <p>",
"    Migraine without aura is the most common type, accounting for approximately 75 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674085\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is a disorder of recurrent attacks. The attacks unfold through a cascade of events that occur over the course of several hours to days. A typical migraine attack progresses through four phases: the prodrome, the aura, the headache, and the postdrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203275048\">",
"    <span class=\"h2\">",
"     Migraine prodrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prodrome occurs in up to 60 percent of people and consists of affective or vegetative symptoms that appear 24 to 48 hours prior to the onset of headache. Frequently reported prodromal symptoms include euphoria, depression, irritability, food cravings, constipation, neck stiffness, and increased yawning [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203275055\">",
"    <span class=\"h2\">",
"     Migraine aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 25 percent of people with migraines experience one or more focal neurologic symptoms in the second phase, called the migraine aura. Auras are most often visual, but can also be sensory, verbal, or motor disturbances. A visual aura classically begins as a small area of visual loss often just lateral to the point of visual fixation. It may either appear as a bright spot or as an area of visual loss. Over the following five minutes to one hour, the visual disturbance expands to involve a quadrant or hemifield of vision. Along the expanding margin geometric shapes or zigzagging lines often appear. The shapes account for one of the common names for aura, the &ldquo;fortification spectrum&rdquo;, because of the resemblance of the aura to the walls of a medieval fortress. The positive visual phenomena may assume a sickle or C-shape, expanding over time toward the peripheral visual field, leaving a scotoma or area of complete visual loss in their wake. As the aura moves off into the peripheral visual field, it often assumes a shimmering or scintillating quality. As the aura resolves, vision usually returns first to the areas of central vision initially affected by the aura [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensory aura is also common and typically follows the visual aura within minutes, although it may also occur without the visual aura. A sensory aura usually begins as a tingling in one limb or on one side of the face. As the tingling sensation migrates across one side of the face or down the limb, numbness is left in its wake that may last up to an hour. The sensory aura may also move inside the mouth, affecting the buccal mucosa and half the tongue. The slow spread of positive symptoms (scintillations or tingling) followed by negative symptoms (scotoma or numbness) is quite characteristic of migraine aura and is not typical for an ischemic event [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common than the visual and sensory auras, is the language or dysphasic aura that causes transient language problems that may run the gamut from mild wording difficulties to frank dysphasia with paraphasic errors. In the rarest of auras, motor aura, the limbs and possibly the face on one side of the body become weak. Because of information related to the genetic basis of the motor aura, it has been separated out from the other forms of aura and classified as hemiplegic migraine (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link\">",
"     \"Hemiplegic migraine\"",
"    </a>",
"    ) in the International Society Headache Classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]. The aura symptoms may occur either singly or in sequence but they do not generally occur simultaneously.",
"   </p>",
"   <p>",
"    Traditional teaching is that migraine aura usually precedes the headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]. However, prospective data suggest that most patients with migraine experience headache during the aura phase [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/75\">",
"     75",
"    </a>",
"    ]. It may also occur without an associated headache. (See",
"    <a class=\"local\" href=\"#H222097321\">",
"     'Migraine aura without headache'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203275062\">",
"    <span class=\"h2\">",
"     Migraine headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;The headache of migraine is often but not always unilateral and tends to have a throbbing or pulsatile quality, especially as the intensity increases. As the attack severity increases over the course of one to several hours, patients frequently experience nausea and sometimes vomiting. Many individuals report photophobia or phonophobia during attacks, leading such migraine sufferers to seek relief by lying down in a darkened, quiet room. Additional migrainous features such as osmophobia and cutaneous allodynia (see",
"    <a class=\"local\" href=\"#H21674099\">",
"     'Cutaneous allodynia'",
"    </a>",
"    below) may occur during attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/71,76-78\">",
"     71,76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, an untreated headache can last as little as four hours and as long as several days. Many attacks resolve in sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203275069\">",
"    <span class=\"h2\">",
"     Migraine postdrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the spontaneous throbbing of the headache resolves, the patient may experience a postdromal phase, during which sudden head movement transiently causes pain in the location of the antecedent headache. During the postdrome, patients often feel drained or exhausted, although some report a feeling of mild elation or euphoria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674092\">",
"    <span class=\"h2\">",
"     Precipitating and exacerbating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evidence-based review concluded that stress, menstruation, visual stimuli, weather changes, nitrates, fasting, and wine were probable migraine trigger factors, while sleep disturbances and aspartame were possible migraine triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/79\">",
"     79",
"    </a>",
"    ]. All of the probable and possible migraine triggers except aspartame were also general headache triggers. There was evidence that monosodium glutamate was a general headache trigger but unproven as a migraine trigger. Smoking, odors, chocolate, and tyramine were unproven as triggers of migraine or general headache.",
"   </p>",
"   <p>",
"    In a retrospective study of 1750 patients with migraine, approximately 75 percent reported at least one trigger of acute migraine attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/80\">",
"     80",
"    </a>",
"    ]. In order of descending frequency these included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Emotional stress (80 percent)",
"     </li>",
"     <li>",
"      Hormones in women (65 percent)",
"     </li>",
"     <li>",
"      Not eating (57 percent)",
"     </li>",
"     <li>",
"      Weather (53 percent)",
"     </li>",
"     <li>",
"      Sleep disturbances (50 percent)",
"     </li>",
"     <li>",
"      Odors (44 percent)",
"     </li>",
"     <li>",
"      Neck pain (38 percent)",
"     </li>",
"     <li>",
"      Lights (38 percent)",
"     </li>",
"     <li>",
"      Alcohol (38 percent)",
"     </li>",
"     <li>",
"      Smoke (36 percent)",
"     </li>",
"     <li>",
"      Sleeping late (32 percent)",
"     </li>",
"     <li>",
"      Heat (30 percent)",
"     </li>",
"     <li>",
"      Food (27 percent)",
"     </li>",
"     <li>",
"      Exercise (22 percent)",
"     </li>",
"     <li>",
"      Sexual activity (5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obesity has been associated with an increased frequency and severity of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Migraine headaches are often worsened by rapid head motion, sneezing, straining, constant movement, or physical exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674099\">",
"    <span class=\"h2\">",
"     Cutaneous allodynia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous allodynia is the perception of pain produced by innocuous stimulation of normal skin and may result from sensitization of central pain pathways in migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H203274958\">",
"     'Sensitization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As examples, brushing hair, touching the scalp, shaving, or wearing contact lenses may trigger allodynic symptoms of pain during migraine. Additional symptoms include soreness, tenderness, or difficulty resting on the allodynic side.",
"   </p>",
"   <p>",
"    Cutaneous allodynia occurs frequently with migraine, and it may occur even in the absence of headache. In one study, allodynia was reported by 62 percent of 11,094 patients with migraine who completed a questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/85\">",
"     85",
"    </a>",
"    ]. In an earlier survey of 157 patients with migraine and allodynia, the most common locations of allodynia were pure cephalic and cephalic plus extracephalic, occurring in 85 and 34 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/86\">",
"     86",
"    </a>",
"    ]. Pure extracephalic allodynia occurred in 15 percent. Scalp allodynia was ipsilateral to the predominant headache side in the majority of cases and occurred at the height of headache. Trunk allodynia occurred in a few patients.",
"   </p>",
"   <p>",
"    The true frequency of allodynia appears to be even higher when assessed by measurement of mechanical and thermal pain thresholds of skin. In a case series of 42 subjects with migraine, 79 percent reported cutaneous allodynia on the head ipsilateral to the migraine pain by quantitative sensitivity testing, and 67 percent experienced cutaneous allodynia in additional regions such as the contralateral head or extracephalic sites [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/84\">",
"     84",
"    </a>",
"    ]. The actual percentage of people with migraine spontaneously reporting cutaneous allodynia is lower.",
"   </p>",
"   <p>",
"    Severe or persistent cutaneous allodynia may respond to abortive and prophylactic therapy. However, existing data suggest that abortive therapy with triptans is less effective once cutaneous allodynia develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link&amp;anchor=H6#H6\">",
"     \"Acute treatment of migraine in adults\", section on 'Triptans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674106\">",
"    <span class=\"h2\">",
"     Menstrual migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A particularly prominent migraine subtype is menstrual migraine. Menstrual migraine (also called menstrually associated migraine or catamenial migraine) is defined as migraine headache that occurs in close temporal relationship to the onset of menstruation; this time period usually encompasses two days before through three days after the onset of menstrual bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/87\">",
"     87",
"    </a>",
"    ]. Women with menstrual migraine may also have migraine at other times during the month. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H4#H4\">",
"     \"Estrogen-associated migraine\", section on 'Menstrual migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of menstrual migraine is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H4#H4\">",
"     \"Estrogen-associated migraine\", section on 'Menstrual migraine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link&amp;anchor=H9#H9\">",
"     \"Estrogen-associated migraine\", section on 'Preventive therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097293\">",
"    <span class=\"h1\">",
"     MIGRAINE VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are numerous references in the medical literature to unexplained neurologic symptoms that are called migraine variant or migraine equivalent, most of these are probably not related to migraine. Nevertheless, there are several well-characterized variant forms of migraine, including basilar-type migraine, retinal migraine, migraine aura without headache, migraine with acute onset aura, and migrainous vertigo.",
"   </p>",
"   <p>",
"    Ophthalmoplegic &ldquo;migraine&rdquo; is now considered a cranial neuralgia as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097300\">",
"    <span class=\"h2\">",
"     Basilar-type migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basilar-type migraine (formerly called basilar artery migraine) is reviewed briefly here and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Basilar-type migraine predominantly affects young women and children. Symptoms may include any combination of dysarthria, vertigo, diplopia, tinnitus, decreased hearing, ataxia, simultaneous bilateral paresthesias, and altered consciousness (",
"    <a class=\"graphic graphic_table graphicRef73674 \" href=\"UTD.htm?36/28/37323\">",
"     table 1",
"    </a>",
"    ). Visual symptoms may be difficult to distinguish from a classic migraine aura, although basilar-type migraine is more likely to cause simultaneous visual symptoms in both temporal and nasal fields.",
"   </p>",
"   <p>",
"    Basilar type migraine is described by the International Headache Society (IHS) as migraine with aura symptoms clearly originating from the brainstem",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from both hemispheres simultaneously, but without motor weakness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]. The IHS diagnostic criteria require the aura to have at least two of the following fully reversible symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysarthria",
"     </li>",
"     <li>",
"      Vertigo",
"     </li>",
"     <li>",
"      Tinnitus",
"     </li>",
"     <li>",
"      Hypacusia",
"     </li>",
"     <li>",
"      Diplopia",
"     </li>",
"     <li>",
"      Visual symptoms simultaneously in both temporal and nasal fields of both eyes",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"     <li>",
"      Decreased level of consciousness",
"     </li>",
"     <li>",
"      Simultaneous bilateral paresthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neurologic symptoms are then followed by a typical migraine headache.",
"   </p>",
"   <p>",
"    The occurrence of decreased level of consciousness followed by headache sometimes results in diagnostic difficulty. It is important to remember that basilar-type migraine is rare and that there must be another brainstem symptom in addition to decreased consciousness to make the diagnosis. In the absence of a second brainstem localizing symptom, other causes of unexplained loss of consciousness such as seizure and cardiogenic syncope must be considered and appropriately investigated. Basilar-type migraine should be diagnosed only when weakness is absent, since about 60 percent of patients with familial hemiplegic migraine have basilar-type symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link\">",
"     \"Hemiplegic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097314\">",
"    <span class=\"h2\">",
"     Retinal (ocular) migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinal migraine is thought to be a rare condition that is characterized by repeated attacks of monocular scotomata or blindness lasting less than one hour, associated with or followed by headache. The International Headache Society prefers the term retinal migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ], but ocular migraine has been suggested as a more precise term, since both retinal and ciliary circulations may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/89\">",
"     89",
"    </a>",
"    ]. Occasionally the onset may be abrupt and difficult to distinguish from amaurosis fugax [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=see_link\">",
"     \"Amaurosis fugax (transient monocular or binocular visual loss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Irreversible visual loss appears to be a frequent complication of retinal migraine. In one of the largest studies to date that reported six new cases and reviewed 40 from the literature, permanent visual loss was eventually present in 20 patients (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/91\">",
"     91",
"    </a>",
"    ]. No predictors of irreversible visual loss could be identified, and no consistent pattern of visual loss was observed among these patients.",
"   </p>",
"   <p>",
"    The authors speculated that permanent visual loss resulting from retinal migraine may be a type of migrainous infarction, leading them to suggest the use of prophylactic migraine therapy with antiepileptic or tricyclic medications for patients with this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link&amp;anchor=H13#H13\">",
"     \"Headache, migraine, and stroke\", section on 'Migrainous infarction definition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097321\">",
"    <span class=\"h2\">",
"     Migraine aura without headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine aura without headache (also known as migraine equivalent and acephalgic migraine) manifests as isolated aura unaccompanied by headache. Auras without headache may be confused with transient ischemic attacks, especially in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/90\">",
"     90",
"    </a>",
"    ]. In a Danish case study, 38 percent of patients reported having both attacks of migraine aura without headache as well as migraine aura with headache, and 4 percent had exclusively migraine aura without headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097328\">",
"    <span class=\"h2\">",
"     Migraine with acute onset aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine with acute onset aura is defined as aura developing fully in less than five minutes. The acute onset of aura makes confusion with a TIA or stroke more likely. In one case series, four patients (2 percent) had exclusively acute onset visual aura [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222097335\">",
"    <span class=\"h2\">",
"     Migrainous vertigo",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migrainous vertigo is reviewed briefly here and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=see_link\">",
"     \"Migrainous vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Migrainous vertigo is a term used to describe episodic vertigo in patients with a history of migraines or with other clinical features of migraine (photophobia, phonophobia, visual aura, etc). The association of headache with vertigo is variable, even in individual patients.",
"   </p>",
"   <p>",
"    Vestibular involvement may be an integral feature of migraine. However, the varied clinical and epidemiologic findings and proposed pathophysiologic mechanisms suggest that migrainous vertigo is a heterogeneous condition.",
"   </p>",
"   <p>",
"    Proposed criteria for a diagnosis of migrainous vertigo are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef75023 \" href=\"UTD.htm?38/60/39883\">",
"     table 2",
"    </a>",
"    ). There are no confirmatory tests for migrainous vertigo, which is a diagnosis of exclusion. Other disorders, specifically Meniere disease and structural and vascular brainstem disease, must be excluded in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13436656\">",
"    <span class=\"h2\">",
"     Ophthalmoplegic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmoplegic migraine is thought to be rare and is most often seen in children and young adults. It may affect cranial nerves III (most common), IV, or VI. Permanent damage to the third nerve has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/93\">",
"     93",
"    </a>",
"    ]. In unusual cases, OM may present with isolated pupillary paralysis (internal ophthalmoplegia) due to oculomotor parasympathetic paresis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/94\">",
"     94",
"    </a>",
"    ]. The clinical pattern of ophthalmoplegic migraine is atypical for migraine, given the long duration of headache, which can last for a week or more, and a latent period of up to four days before the onset of ophthalmoplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ophthalmoplegic migraine was reclassified as a cranial neuralgia in the 2004 revisions to the International Headache Society classification system [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]. The reclassification was prompted by evidence that ophthalmoplegic migraine is associated with MRI gadolinium enhancement of the cisternal segment of the affected cranial nerve in patients with a typical clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/95\">",
"     95",
"    </a>",
"    ], suggesting that the condition may be a recurrent demyelinating neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/96\">",
"     96",
"    </a>",
"    ]. However, the cause and classification of ophthalmoplegic migraine remain controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/97-100\">",
"     97-100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H203275744\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of migraine is a clinical task and is based upon a compatible history, physical examination, and fulfillment of the diagnostic criteria listed below. There are no diagnostic tests specific for migraine.",
"   </p>",
"   <p>",
"    While the features of migraine and tension headache overlap, the clinical features that appear to be most predictive of migraine include nausea, photophobia, phonophobia, and exacerbation by physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/101\">",
"     101",
"    </a>",
"    ]. Food triggers are also more common with migraine than tension-type headache. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674113\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Headache Society (IHS) diagnostic criteria for migraine are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674120\">",
"    <span class=\"h3\">",
"     Migraine without aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine without aura is a recurrent headache disorder that fulfills the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Headache attacks last 4 to 72 hours",
"     </li>",
"     <li>",
"      Headache has at least two of the following characteristics: unilateral location; pulsating quality; moderate or severe intensity; aggravation by routine physical activity",
"     </li>",
"     <li>",
"      During headache at least one of the following occurs: nausea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vomiting; photophobia and phonophobia",
"     </li>",
"     <li>",
"      At least five attacks occur fulfilling the above criteria",
"     </li>",
"     <li>",
"      History, physical examination, and neurologic examination do not suggest any underlying organic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674127\">",
"    <span class=\"h3\">",
"     Migraine with aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;In migraine with aura, attacks include the transient appearance of focal neurologic symptoms that usually develop gradually over 5 to 20 minutes and last for less than 60 minutes. A headache that has the features of migraine without aura begins during the aura or follows the aura within 60 minutes. (See",
"    <a class=\"local\" href=\"#H21674120\">",
"     'Migraine without aura'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Previously used terms for migraine with aura include classic or classical migraine, ophthalmic, hemiplegic, or aphasic migraine, migraine accompagn&eacute;e, and complicated migraine.",
"   </p>",
"   <p>",
"    IHS diagnostic criteria for migraine with aura are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At least two attacks of aura with migraine headache",
"     </li>",
"     <li>",
"      The migraine aura fulfills criteria for one of the subforms of aura with migraine headache (See",
"      <a class=\"local\" href=\"#H21674134\">",
"       'Subforms of aura'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The symptoms are not attributed to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674134\">",
"    <span class=\"h3\">",
"     Subforms of aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IHS criteria recognize six subforms of aura with migraine headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Typical aura with migraine headache",
"     </li>",
"     <li>",
"      Typical aura with non-migraine headache",
"     </li>",
"     <li>",
"      Typical aura without headache",
"     </li>",
"     <li>",
"      Familial hemiplegic migraine",
"     </li>",
"     <li>",
"      Sporadic hemiplegic migraine",
"     </li>",
"     <li>",
"      Basilar-type migraine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674141\">",
"    <span class=\"h3\">",
"     Typical aura",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"typical\" aura fulfills the following IHS criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    First, the aura has at least one of the following characteristics without motor weakness:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fully reversible visual symptoms including positive features (eg, flickering lights, spots, or lines)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      negative features (eg, loss of vision)",
"     </li>",
"     <li>",
"      Fully reversible sensory symptoms including positive features (eg, pins and needles)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      negative features (eg, numbness)",
"     </li>",
"     <li>",
"      Fully reversible dysphasic speech disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Second, the aura has at least two of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Homonymous visual symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unilateral sensory symptoms",
"     </li>",
"     <li>",
"      At least one aura symptom develops gradually over &ge;5 minutes",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      different aura symptoms occur in succession over &ge;5 minutes",
"     </li>",
"     <li>",
"      Each symptom lasts &ge;5 and &le;60 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, a typical migraine aura that fulfills IHS criteria consists of visual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    speech symptoms. The aura is characterized by gradual development, duration no longer than one hour, a mix of positive and negative features, and complete reversibility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674148\">",
"    <span class=\"h3\">",
"     Hemiplegic migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IHS criteria recognize familial hemiplegic migraine (FHM) if the aura consists of fully reversible motor weakness and if at least one first or second-degree relative has had attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]. Sporadic hemiplegic migraine is diagnosed when no first or second degree relative has had attacks of hemiplegic migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link&amp;anchor=H1732726#H1732726\">",
"     \"Hemiplegic migraine\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21674155\">",
"    <span class=\"h3\">",
"     Complications of migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of migraine are characterized by attacks associated with prolonged neurologic symptoms or, rarely, with infarction or seizures. Prolonged symptoms may last for the entire headache, for several days or weeks, or in some cases leave a permanent neurologic deficit.",
"   </p>",
"   <p>",
"    Under the IHS classification, the following complications of migraine are recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic migraine: Migraine headache occurring on 15 or more days per month for more than three months in the absence of medication overuse (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link\">",
"       \"Chronic migraine\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Status migrainosus: A debilitating migraine attack lasting for more than 72 hours",
"     </li>",
"     <li>",
"      Persistent aura without infarction: The aura lasts more than one week with no evidence of infarction",
"     </li>",
"     <li>",
"      Migrainous infarction: The deficit lasts more than one hour and the neuroimaging shows an infarction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link&amp;anchor=H12#H12\">",
"       \"Headache, migraine, and stroke\", section on 'Migrainous stroke'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Migraine-triggered seizure: A seizure triggered by a migraine aura",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged migraine auras may take on any of the forms associated with typical aura. However, complicated migraine has been more often associated with several migraine variants. These include hemiplegic migraine, basilar-type migraine, and ophthalmoplegic migraine. (See",
"    <a class=\"local\" href=\"#H222097293\">",
"     'Migraine variants'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222096759\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging is not necessary in most patients with migraine. Evidence-based guidelines issued by the American Academy of Neurology suggest considering neuroimaging in the following patients with non-acute headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an unexplained abnormal finding on neurologic examination",
"     </li>",
"     <li>",
"      Patients with atypical headache features or headaches that do not fulfill the strict definition of migraine or other primary headache disorder (or have some additional risk factor, such as immune deficiency)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with sudden severe headache also need neuroimaging because of the suspicion of subarachnoid hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of headache in adults\", section on 'Indications for imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following symptoms significantly increase the odds of finding an abnormality on neuroimaging in patients with a non-acute headache [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/92,103\">",
"     92,103",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapidly increasing headache frequency",
"     </li>",
"     <li>",
"      History of lack of coordination",
"     </li>",
"     <li>",
"      History of localized neurologic signs or a history such as subjective numbness or tingling",
"     </li>",
"     <li>",
"      History of headache causing awakening from sleep (although this can occur with migraine and cluster headache)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A head CT scan (without and with contrast) is sufficient in many patients when neuroimaging is deemed necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?26/4/26698/abstract/104\">",
"     104",
"    </a>",
"    ]. An MRI is indicated when posterior fossa lesions or cerebrospinal fluid (CSF) leak are suspected. Magnetic resonance angiography (MRA) and magnetic resonance venography (MRV) are indicated when arterial or venous lesions, respectively, are considered in the differential diagnosis.",
"   </p>",
"   <p>",
"    No other diagnostic tests are typically necessary in patients with suspected migraine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13436872\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cortical spreading depression is hypothesized to cause the aura of migraine, activate trigeminal nerve afferents, and alter blood-brain barrier permeability. The activation of trigeminal afferents by cortical spreading depression in turn causes inflammatory changes in the pain-sensitive meninges that generate the headache of migraine through central and peripheral reflex mechanisms. (See",
"      <a class=\"local\" href=\"#H130649620\">",
"       'Pathophysiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H130649634\">",
"       'Cortical spreading depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Activation of the trigeminovascular system plays a central role in the pathophysiology of migraine, including the onset of neurogenic inflammation which is linked to the pain of migraine. (See",
"      <a class=\"local\" href=\"#H130649641\">",
"       'Trigeminovascular system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensitization refers to the process in which neurons become increasingly responsive to nociceptive and non-nociceptive stimulation and is likely responsible for many of the clinical symptoms of migraine. (See",
"      <a class=\"local\" href=\"#H203274958\">",
"       'Sensitization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic basis of migraine is likely to be complex and in some individuals may be based on the additive effect of more than one genetic source. The KCNK18 gene has been implicated as a probable cause of migraine with aura. Familial hemiplegic migraine is associated with mutations in three genes that encode for transmembrane ion channels (CACNA1A, ATP1A2, and SCN1A). Mutations in the PRRT2 gene also cause some cases of familial hemiplegic migraine. (See",
"      <a class=\"local\" href=\"#H130650647\">",
"       'Genetic basis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migraine is a common disorder that affects up to 12 percent of the general population. (See",
"      <a class=\"local\" href=\"#H21674074\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migraine is a disorder of recurrent attacks. The attacks unfold through a cascade of events that occur over the course of several hours to days. A typical migraine attack progresses through four phases: the prodrome, the aura, the headache and the postdrome. (See",
"      <a class=\"local\" href=\"#H21674085\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The prodrome consists of affective or vegetative symptoms that appear 24 to 48 hours prior to the onset of headache. (See",
"      <a class=\"local\" href=\"#H203275048\">",
"       'Migraine prodrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 25 percent of people with migraines experience one or more focal neurologic symptoms in the second phase, called the migraine aura. Auras are most often visual, but can also be sensory, verbal, or motor disturbances. (See",
"      <a class=\"local\" href=\"#H203275055\">",
"       'Migraine aura'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The headache of migraine is often but not always unilateral and tends to have a throbbing or pulsatile quality. Accompanying features may include nausea, vomiting, photophobia or phonophobia during attacks. (See",
"      <a class=\"local\" href=\"#H203275062\">",
"       'Migraine headache'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migraine trigger factors may include stress, menstruation, visual stimuli, weather changes, nitrates, fasting, wine, sleep disturbances and aspartame, among others. (See",
"      <a class=\"local\" href=\"#H21674092\">",
"       'Precipitating and exacerbating factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Variant forms of migraine include basilar-type migraine, retinal migraine, migraine aura without headache, migraine with acute onset aura, and migrainous vertigo. Ophthalmoplegic &ldquo;migraine&rdquo; is now considered a cranial neuralgia. (See",
"      <a class=\"local\" href=\"#H222097293\">",
"       'Migraine variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of migraine is a clinical task and is based upon a compatible history, physical examination, and fulfillment of the diagnostic criteria listed above. There are no diagnostic tests specific for migraine, and neuroimaging is not necessary in most patients with migraine. However, in agreement with national guidelines, we recommend neuroimaging for patients with suspected migraine or nonacute headache who have either an unexplained abnormal finding on neurologic examination, atypical headache features, headaches that do not fulfill the strict definition of migraine or other primary headache disorder, or some additional risk factor for secondary headache, such as immune deficiency. (See",
"      <a class=\"local\" href=\"#H203275744\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/1\">",
"      Cutrer FM. Pathophysiology of migraine. Semin Neurol 2006; 26:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/2\">",
"      Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009; 65:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/3\">",
"      Welch KM. Drug therapy of migraine. N Engl J Med 1993; 329:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/4\">",
"      Le&atilde;o AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/5\">",
"      Le&atilde;o AAP. Pial circulation and spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/6\">",
"      Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A 2001; 98:4687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/7\">",
"      Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/8\">",
"      Karatas H, Erdener SE, Gursoy-Ozdemir Y, et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 2013; 339:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/9\">",
"      Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004; 113:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/10\">",
"      Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/11\">",
"      Takano T, Nedergaard M. Deciphering migraine. J Clin Invest 2009; 119:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/12\">",
"      Arbab MA, Wiklund L, Svendgaard NA. Origin and distribution of cerebral vascular innervation from superior cervical, trigeminal and spinal ganglia investigated with retrograde and anterograde WGA-HRP tracing in the rat. Neuroscience 1986; 19:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/13\">",
"      Bartsch T, Goadsby PJ. Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 2002; 125:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/14\">",
"      Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 2003; 126:1801.",
"     </a>",
"    </li>",
"    <li>",
"     Kruge, L, Young, RF. Specialized features of the trigeminal nerve and its central connections. In: The Cranial Nerves, Samii, M, Janetta, PJ, (Eds), Springer-Verlag, Berlin 1981. p.273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/16\">",
"      Sessle BJ, Hu JW, Dubner R, Lucier GE. Functional properties of neurons in cat trigeminal subnucleus caudalis (medullary dorsal horn). II. Modulation of responses to noxious and nonnoxious stimuli by periaqueductal gray, nucleus raphe magnus, cerebral cortex, and afferent influences, and effect of naloxone. J Neurophysiol 1981; 45:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/17\">",
"      Wise SP, Jones EG. Cells of origin and terminal distribution of descending projections of the rat somatic sensory cortex. J Comp Neurol 1977; 175:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/18\">",
"      Zagami AS, Lambert GA. Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat. Neurosci Lett 1991; 121:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/19\">",
"      Jacquin MF, Chiaia NL, Haring JH, Rhoades RW. Intersubnuclear connections within the rat trigeminal brainstem complex. Somatosens Mot Res 1990; 7:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/20\">",
"      Renehan WE, Jacquin MF, Mooney RD, Rhoades RW. Structure-function relationships in rat medullary and cervical dorsal horns. II. Medullary dorsal horn cells. J Neurophysiol 1986; 55:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/21\">",
"      Huerta MF, Frankfurter A, Harting JK. Studies of the principal sensory and spinal trigeminal nuclei of the rat: projections to the superior colliculus, inferior olive, and cerebellum. J Comp Neurol 1983; 220:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/22\">",
"      Mantle-St John LA, Tracey DJ. Somatosensory nuclei in the brainstem of the rat: independent projections to the thalamus and cerebellum. J Comp Neurol 1987; 255:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/23\">",
"      Bernard JF, Peschanski M, Besson JM. A possible spino (trigemino)-ponto-amygdaloid pathway for pain. Neurosci Lett 1989; 100:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/24\">",
"      Hayashi H, Tabata T. Pulpal and cutaneous inputs to somatosensory neurons in the parabrachial area of the cat. Brain Res 1990; 511:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/25\">",
"      Huang LY. Origin of thalamically projecting somatosensory relay neurons in the immature rat. Brain Res 1989; 495:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/26\">",
"      Kemplay S, Webster KE. A quantitative study of the projections of the gracile, cuneate and trigeminal nuclei and of the medullary reticular formation to the thalamus in the rat. Neuroscience 1989; 32:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/27\">",
"      Peschanski M, Roudier F, Ralston HJ 3rd, Besson JM. Ultrastructural analysis of the terminals of various somatosensory pathways in the ventrobasal complex of the rat thalamus: an electron-microscopic study using wheatgerm agglutinin conjugated to horseradish peroxidase as an axonal tracer. Somatosens Res 1985; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/28\">",
"      Shigenaga Y, Nakatani Z, Nishimori T, et al. The cells of origin of cat trigeminothalamic projections: especially in the caudal medulla. Brain Res 1983; 277:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/29\">",
"      Craig AD Jr, Burton H. Spinal and medullary lamina I projection to nucleus submedius in medial thalamus: a possible pain center. J Neurophysiol 1981; 45:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/30\">",
"      Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/31\">",
"      Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001; 57:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/32\">",
"      Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001; 89:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/33\">",
"      Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996; 384:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/34\">",
"      Kaube H, Katsarava Z, Przywara S, et al. Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology 2002; 58:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/35\">",
"      Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/36\">",
"      Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001; 357:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/37\">",
"      Matharu MS, Cohen AS, McGonigle DJ, et al. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 2004; 44:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/38\">",
"      Granziera C, DaSilva AF, Snyder J, et al. Anatomical alterations of the visual motion processing network in migraine with and without aura. PLoS Med 2006; 3:e402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/39\">",
"      Rocca MA, Ceccarelli A, Falini A, et al. Brain gray matter changes in migraine patients with T2-visible lesions: a 3-T MRI study. Stroke 2006; 37:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/40\">",
"      Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001; 41:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/41\">",
"      Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007; 27:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/42\">",
"      Panconesi A. Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 2008; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/43\">",
"      Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 2011; 77:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/44\">",
"      Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/45\">",
"      Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 2010; 75:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/46\">",
"      Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/47\">",
"      Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 2005; 58:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/48\">",
"      Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005; 58:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/49\">",
"      Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/50\">",
"      Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm. Stroke 2002; 33:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/51\">",
"      Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999; 52:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/52\">",
"      Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998; 8:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/53\">",
"      Post MC, Letteboer TG, Mager JJ, et al. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic telangiectasia is associated with an increased prevalence of migraine. Chest 2005; 128:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/54\">",
"      Rundek T, Elkind MS, Di Tullio MR, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation 2008; 118:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/55\">",
"      Schwedt TJ, Demaerschalk BM, Dodick DW. Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 2008; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/56\">",
"      Kurth T, Tzourio C, Bousser MG. Migraine: a matter of the heart? Circulation 2008; 118:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/57\">",
"      Pierangeli G, Cevoli S, Zanigni S, et al. The role of cardiac diseases in the comorbidity between migraine and stroke. Neurol Sci 2004; 25 Suppl 3:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/58\">",
"      Meier B, Lock JE. Contemporary management of patent foramen ovale. Circulation 2003; 107:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/59\">",
"      Lance JW, Anthony M. Some clinical aspects of migraine. A prospective survey of 500 patients. Arch Neurol 1966; 15:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/60\">",
"      Merikangas KR, Risch NJ, Merikangas JR, et al. Migraine and depression: association and familial transmission. J Psychiatr Res 1988; 22:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/61\">",
"      Devoto M, Lozito A, Staffa G, et al. Segregation analysis of migraine in 128 families. Cephalalgia 1986; 6:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/62\">",
"      Honkasalo ML, Kaprio J, Winter T, et al. Migraine and concomitant symptoms among 8167 adult twin pairs. Headache 1995; 35:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/63\">",
"      Lafreni&egrave;re RG, Cader MZ, Poulin JF, et al. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med 2010; 16:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/64\">",
"      Anttila V, Stefansson H, Kallela M, et al. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. Nat Genet 2010; 42:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/65\">",
"      Chasman DI, Sch&uuml;rks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 2011; 43:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/66\">",
"      Kors E, Haan J, Ferrari M. Migraine genetics. Curr Pain Headache Rep 2003; 7:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/67\">",
"      Cutrer FM. Pathophysiology of migraine. Semin Neurol 2010; 30:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/68\">",
"      Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/69\">",
"      Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/70\">",
"      Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/71\">",
"      Charles A. The evolution of a migraine attack - a review of recent evidence. Headache 2013; 53:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/72\">",
"      Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache 2004; 44:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/73\">",
"      Cutrer FM, Huerter K. Migraine aura. Neurologist 2007; 13:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/74\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/75\">",
"      Hansen JM, Lipton RB, Dodick DW, et al. Migraine headache is present in the aura phase: a prospective study. Neurology 2012; 79:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/76\">",
"      Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/77\">",
"      Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia 2006; 26:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/78\">",
"      Wang YF, Fuh JL, Chen SP, et al. Clinical correlates and diagnostic utility of osmophobia in migraine. Cephalalgia 2012; 32:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/79\">",
"      Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am 2001; 85:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/80\">",
"      Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/81\">",
"      Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology 2006; 66:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/82\">",
"      Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006; 67:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/83\">",
"      Bigal ME, Tsang A, Loder E, et al. Body mass index and episodic headaches: a population-based study. Arch Intern Med 2007; 167:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/84\">",
"      Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/85\">",
"      Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008; 70:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/86\">",
"      Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004; 63:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/87\">",
"      MacGregor EA. \"Menstrual\" migraine: towards a definition. Cephalalgia 1996; 16:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/88\">",
"      Lipton RB, Bigal ME, Steiner TJ, et al. Classification of primary headaches. Neurology 2004; 63:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/89\">",
"      Corbett JJ. Neuro-ophthalmic complications of migraine and cluster headaches. Neurol Clin 1983; 1:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/90\">",
"      Fisher CM. Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci 1980; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/91\">",
"      Grosberg BM, Solomon S, Friedman DI, Lipton RB. Retinal migraine reappraised. Cephalalgia 2006; 26:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/92\">",
"      Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996; 119 ( Pt 2):355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/93\">",
"      Bartleson JD. Transient and persistent neurological manifestations of migraine. Stroke 1984; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/94\">",
"      Choi JY, Jang SH, Park MH, et al. Ophthalmoplegic migraine with alternating unilateral and bilateral internal ophthalmoplegia. Headache 2007; 47:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/95\">",
"      Mark AS, Casselman J, Brown D, et al. Ophthalmoplegic migraine: reversible enhancement and thickening of the cisternal segment of the oculomotor nerve on contrast-enhanced MR images. AJNR Am J Neuroradiol 1998; 19:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/96\">",
"      Lance JW, Zagami AS. Ophthalmoplegic migraine: a recurrent demyelinating neuropathy? Cephalalgia 2001; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/97\">",
"      Friedman DI. The ophthalmoplegic migraines: a proposed classification. Cephalalgia 2010; 30:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/98\">",
"      Lane R, Davies P. Ophthalmoplegic migraine: the case for reclassification. Cephalalgia 2010; 30:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/99\">",
"      Chen PK, Wang SJ. Ophthalmoplegic migraine: migraine variant or cranial neuralgia? Cephalalgia 2012; 32:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/100\">",
"      Margari L, Legrottaglie AR, Craig F, et al. Ophthalmoplegic migraine: migraine or oculomotor neuropathy? Cephalalgia 2012; 32:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/101\">",
"      Smetana GW. The diagnostic value of historical features in primary headache syndromes: a comprehensive review. Arch Intern Med 2000; 160:2729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/102\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/103\">",
"      Kumar KL, Cooney TG. Headaches. Med Clin North Am 1995; 79:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/4/26698/abstract/104\">",
"      Kent DL, Haynor DR, Longstreth WT Jr, Larson EB. The clinical efficacy of magnetic resonance imaging in neuroimaging. Ann Intern Med 1994; 120:856.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3348 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26698=[""].join("\n");
var outline_f26_4_26698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13436872\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21673885\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130649620\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649627\">",
"      Traditional theories of migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649634\">",
"      Cortical spreading depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649641\">",
"      Trigeminovascular system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203274958\">",
"      Sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649648\">",
"      Role of serotonin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649655\">",
"      Role of calcitonin gene-related peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130649662\">",
"      Right-to-left cardiac shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H130650647\">",
"      GENETIC BASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130650973\">",
"      Genetics of the common forms of migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H130650654\">",
"      Familial hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21674074\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21674085\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203275048\">",
"      Migraine prodrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203275055\">",
"      Migraine aura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203275062\">",
"      Migraine headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H203275069\">",
"      Migraine postdrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21674092\">",
"      Precipitating and exacerbating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21674099\">",
"      Cutaneous allodynia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21674106\">",
"      Menstrual migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H222097293\">",
"      MIGRAINE VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222097300\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222097314\">",
"      Retinal (ocular) migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222097321\">",
"      Migraine aura without headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222097328\">",
"      Migraine with acute onset aura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222097335\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13436656\">",
"      Ophthalmoplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203275744\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21674113\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674120\">",
"      - Migraine without aura",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674127\">",
"      - Migraine with aura",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674134\">",
"      - Subforms of aura",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674141\">",
"      - Typical aura",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674148\">",
"      - Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21674155\">",
"      - Complications of migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222096759\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13436872\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3348|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/33/32286\" title=\"figure 1\">",
"      Migraine prevalence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3348|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/28/37323\" title=\"table 1\">",
"      Clinical characteristics basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/60/39883\" title=\"table 2\">",
"      Migrainous vertigo criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10666?source=related_link\">",
"      Amaurosis fugax (transient monocular or binocular visual loss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=related_link\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=related_link\">",
"      Chronic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=related_link\">",
"      Estrogen-associated migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=related_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15496?source=related_link\">",
"      Migrainous vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_4_26699="Causes of metabolic alkalosis";
var content_f26_4_26699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of metabolic alkalosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal hydrogen loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting or nasogastric suction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antacids in advanced renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital chloride diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Renal hydrogen loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary mineralocorticoid excess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop or thiazide diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter or Gitelman syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posthypercapnic alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia and the milk-alkali syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intracellular shift of hydrogen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypokalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alkali administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraction alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive diuresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vomiting or nasogastric suction in achlorhydria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweat losses in cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Villous adenoma or factitious diarrhea (including laxative abuse)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26699=[""].join("\n");
var outline_f26_4_26699=null;
var title_f26_4_26700="DSM-IV-TR diagnostic criteria for dysthymic disorder";
var content_f26_4_26700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F82785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F82785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for dysthymic disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         A. Depressed mood for most of the day, for more days than not, as indicated either by subjective account or observation by others, for at least 2 years.",
"        </p>",
"        <strong>",
"         Note:",
"        </strong>",
"        In children and adolescents, mood can be irritable and duration must be at least 1 year.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        B. Presence, while depressed, of two (or more) of the following:",
"        <ol>",
"         <li>",
"          Poor appetite or overeating",
"         </li>",
"         <li>",
"          Insomnia or hypersomnia",
"         </li>",
"         <li>",
"          Low energy or fatigue",
"         </li>",
"         <li>",
"          Low self-esteem",
"         </li>",
"         <li>",
"          Poor concentration or difficulty making decisions",
"         </li>",
"         <li>",
"          Feelings of hopelessness",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        C. During the 2-year period (1 year for children or adolescents) of the disturbance, the person has never been without the symptoms in criteria A and B for more than 2 months at a time.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         D. No major depressive episode&nbsp;has been present during the first 2 years of the disturbance (1 year for children and adolescents); ie, the disturbance is not better accounted for by chronic major depressive disorder, or major depressive disorder, in partial remission.",
"        </p>",
"        <strong>",
"         Note:",
"        </strong>",
"        There may have been a previous major depressive episode provided there was a full remission (no significant signs or symptoms for 2 months) before development of the dysthymic disorder. In addition, after the initial 2 years (1 year in children or adolescents) of dysthymic disorder, there may be superimposed episodes of major depressive disorder, in which case both diagnoses may be given when the criteria are met for a major depressive episode.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        E. There has never been a manic episode, a mixed episode, or a hypomanic episode, and criteria have never been met for cyclothymic disorder.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        F. The disturbance does not occur exclusively during the course of a chronic psychotic disorder, such as schizophrenia or delusional disorder.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        G. The symptoms are not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition (eg, hypothyroidism).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26700=[""].join("\n");
var outline_f26_4_26700=null;
var title_f26_4_26701="Burns epi mort LIC";
var content_f26_4_26701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estimated global mortality rates from fire-related burn injuries in 2004: Low income countries.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mortality rates are expressed as deaths per 100,000 population. The mortality rate is the highest for the age group 60 years and older. The mortality rates are higher for females in all age groups in low income countries (LIC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     World Health Organization. The Global Burden of Disease: 2004 Update. World Health Organization, Geneva 2008. Available online at: www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.(Accessed on April 2, 2010).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26701=[""].join("\n");
var outline_f26_4_26701=null;
var title_f26_4_26702="Guidelines after polypectomy I";
var content_f26_4_26702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73016%7EGAST%2F51969%7EONC%2F58912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73016%7EGAST%2F51969%7EONC%2F58912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surveillance recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Patients with small rectal hyperplastic polyps should be considered to have normal colonoscopies, and therefore the interval before the subsequent colonoscopy should be 10 years; an exception is patients with a hyperplastic polyposis syndrome; they are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow-up evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Patients with only 1 or 2 small (&lt;1 cm) tubular adenomas with only low-grade dysplasia should have their next follow-up colonoscopy in 5 to 10 years; the precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Patients with 3 to 10 adenomas, or any adenoma &ge;1 cm, or any adenoma with villous features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years providing that piecemeal removal has not been performed and the adenoma(s) are removed completely; if the follow-up colonoscopy is normal or shows only 1 or 2 small tubular adenomas with low-grade dysplasia, then the interval for the subsequent examination should be 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Patients who have more than 10 adenomas at 1 examination should be examined at a shorter (&lt;3 year) interval, established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Patients with sessile adenomas that are removed piecemeal should be considered for follow-up evaluation at short intervals (2 to 6 months) to verify complete removal; once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist's judgment; completeness of removal should be based on both endoscopic and pathologic assessments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. More intensive surveillance is indicated when the family history may indicate HNPCC",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130:1872. Copyright &copy; 2006 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Additional surveillance considerations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. The present recommendations assume that colonoscopy is complete to the cecum and that bowel preparation is adequate; a repeat examination should be performed if the bowel preparation is not adequate before planning a long-term surveillance program",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. There is clear evidence that the quality of examinations is highly variable; continuous quality improvement process is critical to the effective application of colonoscopy in colorectal cancer prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. A repeat examination is warranted if there is a concern that the polyp was removed incompletely, particularly if it shows high grade dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Endoscopists should make clear recommendations to primary care physicians about when the next colonoscopy is indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Given the evolving nature of guidelines, it is important that physicians and patients should remain in contact so that surveillance recommendations reflect changes in guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Pending further investigation, performance of FOBT is discouraged in patients undergoing colonoscopic surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Discontinuation of surveillance colonoscopy should be considered in patients with serious comorbidities with less than 10 years of life expectancy, according to the clinician's judgment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Surveillance guidelines are intended for asymptomatic people; new symptoms may need diagnostic work-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. The application of evolving technologies such as chromoendoscopy, magnification endoscopy, narrow band imaging, and computed tomography colonography are not established for postpolypectomy surveillance at this time",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130:1872. Copyright &copy; 2006 American Gastroenterological Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of updated 2005 colorectal cancer surveillance guidelines from the American Society of Clinical Oncology (ASCO) and from the National Comprehensive Cancer Network (NCCN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        American Society of Clinical Oncology (ASCO)",
"       </td>",
"       <td class=\"subtitle1\">",
"        National Comprehensive Cancer Network (NCCN)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        History and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Every three to six months for the first three years; every six months during years 4 and 5, then annually thereafter.",
"       </td>",
"       <td>",
"        Every three to six months for the first two years; then every six months for a total of five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Carcinoembryonic antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum CEA testing should be performed every three months for at least three years in patients with stage II or III colon or rectal cancer if they would otherwise be candidates for surgery or systemic therapy. Since adjuvant 5-FU-based therapy can falsely elevate the serum CEA, waiting until adjuvant therapy is finished to initiate surveillance is advised.",
"       </td>",
"       <td>",
"        Every three to six months for the first two years, then every six months for a total of five years for T2 or higher stage disease, if patient is a potential candidate for resection of isolated metastases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Liver function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Complete blood cell count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fecal occult blood test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The data are sufficient to recommend against periodic FOBTs in surveillance for colorectal cancer recurrence*.",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not recommended",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Computed tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients with colon or rectal cancer at higher risk of recurrence (stage III or stage II with multiple poor risk features) should undergo annual CT of the chest and abdomen for three years if they would otherwise be eligible for curative intent surgery.",
"       </td>",
"       <td>",
"        Annual CT of the chest, abdomen, and pelvis for three years for patients at high risk of recurrence (lymphatic or venous invasion, or poorly differentiated tumors).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Annual pelvic CT for three years should be considered for rectal cancer surveillance, particularly if the patient has not been treated with pelvic radiation therapy.",
"       </td>",
"       <td>",
"        For resected stage IV disease: CT every three to six months for two years then every six to 12 months for a total of five years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Colonoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All patients with colon or rectal cancer should have a full colonoscopy in the preoperative or perioperative setting to document a cancer-free and polyp-free colon. Patients who present with an obstructing cancer should undergo full colonoscopy within six months of surgery. Repeat colonoscopy is recommended at three years, and if normal, every five years thereafter. For patients with high-risk genetic syndromes, the panel recommended that the screening guidelines of the American Gastroenterology Association be followed",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Colonoscopy in one year. If year one study shows advanced adenoma (villous polyp, any polyp &gt;1 cm, or high-grade dysplasia), repeat in one year. If negative for polyps or not advanced adenoma, repeat in three years then every five years. If no preoperative colonoscopy due to obstructing lesion, colonoscopy in three to six months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Flexible proctosigmoidoscopy, rectal cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For patients who have not received pelvic radiation therapy, direct visualization of the rectum with flexible proctosigmoidoscopy is recommended every six months for five years.",
"       </td>",
"       <td>",
"        Proctosigmoidoscopy every six months for five years if status post low anterior resection for rectal cancer.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Addressed in the year 2000 guidelines (Benson AB, et al. J Clin Oncol 2000; 18:3586).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     American Gastroenterology Association guidelines available from Winawer S, et al. Gastroenterology 2003; 124:544.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Desch, et al. J Clin Oncol 2005; 23:8512.",
"     <br/>",
"     NCCN guidelines available online at www.nccn.org/professionals/physician_gls/default.asp.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26702=[""].join("\n");
var outline_f26_4_26702=null;
var title_f26_4_26703="Duct of Luschka leak";
var content_f26_4_26703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bile leak from duct of Luschka after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 261px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP reveals extravasation in the gallbladder bed (arrow) from a duct of Luschka.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_4_26703=[""].join("\n");
var outline_f26_4_26703=null;
